Original Article
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
N Engl J Med 2005; 353:1673-1684October 20, 2005
- Abstract
Background
We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer.
Methods
The National Surgical Adjuvant Breast and Bowel Project trial B-31 compared doxorubicin and cyclophosphamide followed by paclitaxel every 3 weeks (group 1) with the same regimen plus 52 weeks of trastuzumab beginning with the first dose of paclitaxel (group 2). The North Central Cancer Treatment Group trial N9831 compared three regimens: doxorubicin and cyclophosphamide followed by weekly paclitaxel (group A), the same regimen followed by 52 weeks of trastuzumab after paclitaxel (group B), and the same regimen plus 52 weeks of trastuzumab initiated concomitantly with paclitaxel (group C). The studies were amended to include a joint analysis comparing groups 1 and A (the control group) with groups 2 and C (the trastuzumab group). Group B was excluded because trastuzumab was not given concurrently with paclitaxel.
Results
By March 15, 2005, 394 events (recurrent, second primary cancer, or death before recurrence) had been reported, triggering the first scheduled interim analysis. Of these, 133 were in the trastuzumab group and 261 in the control group (hazard ratio, 0.48; P<0.0001). This result crossed the early stopping boundary. The absolute difference in disease-free survival between the trastuzumab group and the control group was 12 percent at three years. Trastuzumab therapy was associated with a 33 percent reduction in the risk of death (P=0.015). The three-year cumulative incidence of class III or IV congestive heart failure or death from cardiac causes in the trastuzumab group was 4.1 percent in trial B-31 and 2.9 percent in trial N9831.
Conclusions
Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. (ClinicalTrials.gov numbers, NCT00004067 and NCT00005970.)
Media in This Article
Figure 1
Enrollment, Patients, and the Timing of Chemotherapy and Trastuzumab in Trial B-31 and Trial N9831.Figure 2
Kaplan–Meier Estimates of Disease-free Survival (Panel A) and Overall Survival (Panel B).Article Activity
- Article
Trastuzumab, a monoclonal antibody targeting the extracellular domain of the HER2 protein, was approved in 1998 as a first-line treatment in combination with paclitaxel for HER2-positive metastatic breast cancer.1 The benefit of this approach in patients with metastatic disease and the poor prognosis of HER2-positive breast cancer2,3 motivated the National Cancer Institute (NCI) to sponsor two trials of adjuvant treatment with trastuzumab, led by the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the North Central Cancer Treatment Group (NCCTG).
NSABP trial B-31, which began accrual in February 2000, compares four cycles of doxorubicin and cyclophosphamide followed by paclitaxel (group 1) with the same chemotherapy plus 52 weeks of trastuzumab beginning on day 1 of paclitaxel therapy (group 2). NCCTG trial N9831 began enrollment in May 2000 and compares three regimens: four cycles of doxorubicin and cyclophosphamide followed by weekly paclitaxel for 12 weeks (group A), four cycles of doxorubicin and cyclophosphamide followed by 52 weeks of trastuzumab after the completion of paclitaxel therapy (group B), and four cycles of doxorubicin and cyclophosphamide followed by 52 weeks of trastuzumab beginning on day 1 of paclitaxel therapy (group C).
The control groups of the trials, as well as group 2 in trial B-31 and group C in trial N9831, differed in terms of the scheduling of paclitaxel treatment and some aspects of hormonal therapy and radiotherapy but were otherwise identical. For this reason, the NCI and the Food and Drug Administration approved a joint-analysis plan developed by the NSABP and NCCTG to combine data from group 1 and group A (referred to as the control group) for comparison with group 2 and group C (referred to as the trastuzumab group). Group B of trial N9831 was excluded because the protocol required trastuzumab to be administered after the completion of chemotherapy.
The plan required a first interim analysis after the occurrence of 355 events. Before the data were locked, 2043 patients (of a planned total of 2700) were enrolled in trial B-31 and 1633 patients (of a total of 2000 for the comparison of group A with group C) were enrolled in trial N9831. In April 2005, the independent data-monitoring committees of each trial recommended closing enrollment and releasing the results.
Methods
Eligibility and Enrollment
Enrollment required a pathological diagnosis of adenocarcinoma of the breast with immunohistochemical staining for HER2 protein of 3+ intensity or amplification of the HER2 gene on fluorescence in situ hybridization. Initially, both trials required patients to have histologically proven, node-positive disease; as of May 2, 2003, patients with high-risk node-negative disease (defined as a tumor that was more than 2 cm in diameter and positive for estrogen receptors or progesterone receptors or as a tumor that was more than 1 cm in diameter and negative for both estrogen receptors and progesterone receptors) were eligible for trial N9831. Other requirements were adequate hematopoietic, hepatic, and renal function and a left ventricular ejection fraction (LVEF) that met or exceeded the lower limit of normal. Patients with clinical or radiologic evidence of metastatic disease were excluded. Findings suggestive of metastasis were confirmed or refuted by additional radiologic evaluation or biopsy. Complete resection of the primary tumor and axillary-node dissection were required (negative sentinel-node biopsy was allowed in trial N9831). Patients were ineligible if they had angina pectoris requiring antianginal medication, arrhythmia requiring medication, a severe conduction abnormality, clinically significant valvular disease, cardiomegaly on chest radiography, left ventricular hypertrophy on echocardiography (trial B-31 only), poorly controlled hypertension, clinically significant pericardial effusion (trial N9831 only), or a history of myocardial infarction, congestive heart failure, or cardiomyopathy.
Participating institutions obtained the approval of their human investigations committee or institutional review board and filed assurances with the Department of Health and Human Services. Written informed consent was required for enrollment.
In trial B-31, treatment assignments were balanced according to nodal status, the planned hormonal therapy, the type of surgery (lumpectomy vs. mastectomy), the intended radiotherapy, and institution with the use of a biased-coin minimization algorithm.4 Trial N9831 used a dynamic allocation procedure that balanced the marginal distributions of nodal status and hormone-receptor status between groups.5 The procedures used for HER2 testing in the two trials are provided in the Supplementary Appendix (available with the full text of this article at www.nejm.org).
Treatment Regimens
In trial B-31, treatment consisted of 60 mg of doxorubicin per square meter of body-surface area and 600 mg of cyclophosphamide per square meter every 21 days for four cycles, followed by 175 mg of paclitaxel per square meter every 3 weeks for four cycles (group 1), or the same chemotherapy regimen plus trastuzumab, beginning with a loading dose of 4 mg per kilogram of body weight, given with the first dose of paclitaxel, and followed by weekly doses of 2 mg per kilogram for 51 weeks (group 2) (Figure 1Figure 1
Enrollment, Patients, and the Timing of Chemotherapy and Trastuzumab in Trial B-31 and Trial N9831.). Beginning on May 16, 2003, paclitaxel could also be given weekly for 12 weeks at a dose of 80 mg per square meter at the investigator's discretion. Group A in trial N9831 used the same regimen of doxorubicin and cyclophosphamide as in trial B-31, followed by 12 weekly doses of paclitaxel at a dose of 80 mg per square meter. Group B received the same chemotherapy regimen, followed by trastuzumab, beginning with a loading dose of 4 mg per kilogram and followed by weekly doses of 2 mg per kilogram for 51 weeks. Group C received the same chemotherapy regimen plus trastuzumab, beginning with a loading dose of 4 mg per kilogram, given with the first dose of paclitaxel, and followed by weekly doses of 2 mg per kilogram for 51 weeks (Figure 1).In both trials, patients treated with lumpectomy were to receive whole-breast radiotherapy with an optional boost to the tumor bed. Regional radiotherapy after lumpectomy or mastectomy was optional in trial B-31 but required in trial N9831 for patients with at least four positive nodes. In both studies, radiotherapy was initiated after the completion of chemotherapy, and there was no irradiation of the internal-mammary nodes. Trastuzumab treatment was continued during radiotherapy. Women with estrogen-receptor–positive or progesterone-receptor–positive tumors were to receive 20 mg of tamoxifen per day for five years. In trial N9831, hormonal therapy was given after chemotherapy. In trial B-31, tamoxifen was initiated on day 1 of the first cycle of doxorubicin and cyclophosphamide until an amendment on January 14, 2003, required hormonal therapy to be started after chemotherapy, in response to the findings of Southwest Oncology Group trial 8814.6 Following the report of the Arimidex, Tamoxifen Alone or in Combination trial,7 trial N9831 was amended on July 19, 2002, to permit treatment with any aromatase inhibitor in postmenopausal patients with estrogen-receptor–positive or progesterone-receptor–positive tumors. Beginning January 14, 2003, trial B-31 permitted treatment with anastrozole in these patients.
Assessment of Cardiac Function
In both trials, LVEF was assessed before entry, after the completion of doxorubicin and cyclophosphamide therapy, and 6, 9, and 18 months after randomization. Trial B-31 required multiple gated acquisition scanning, whereas trial N9831 allowed multiple gated acquisition scanning or echocardiography. The initiation of trastuzumab required an LVEF after doxorubicin and cyclophosphamide therapy that met or exceeded the lower limit of normal and a decrease of less than 16 percentage points from baseline. Patients in whom clinically significant cardiac symptoms developed while they were receiving doxorubicin and cyclophosphamide were excluded from subsequent trastuzumab therapy. The six- and nine-month cardiac assessments were used to determine whether trastuzumab should be continued in patients without cardiac symptoms. If the LVEF had declined 16 or more percentage points from baseline or 10 to 15 percentage points from baseline to below the lower limit of normal, trastuzumab was withheld for four weeks, at which time the LVEF was reassessed. If the LVEF remained below these levels or if the patient had symptomatic cardiac dysfunction while receiving trastuzumab, administration of the antibody was permanently discontinued.
Role of the Sponsor
Both studies were conducted under a corporate research and development agreement between Genentech and the NCI. Genentech provided trastuzumab and partial funding support but did not participate in the design of the studies or the collection of data. The joint analysis was developed and analyzed by the NSABP and the NCCTG. The lead authors wrote the manuscript, which was reviewed by all authors. A draft was provided to Genentech for comment, but no changes in content or conclusions were requested by Genentech. The authors vouch for the completeness and accuracy of the data.
Statistical Analysis
The primary end point was disease-free survival. Events determining disease-free survival were local, regional, and distant recurrence; contralateral breast cancer, including ductal carcinoma in situ; other second primary cancers; and death before recurrence or a second primary cancer. Comparison of the two groups was based on a log-rank test, stratified according to the study (trial B-31 vs. trial N9831), intended paclitaxel schedule (every three weeks vs. weekly), nodal status (0, 1 to 3, 4 to 9, or 10 or more positive nodes), and hormone-receptor status (estrogen-receptor–positive or progesterone-receptor–positive vs. estrogen-receptor–negative and progesterone-receptor–negative). Disease-free survival was estimated according to the Kaplan–Meier method. The primary cohort included all enrolled patients with follow-up data, analyzed according to the intention-to-treat principle (Figure 1). All reported P values are two-sided.
Other end points were overall survival, time to distant recurrence, death from breast cancer, contralateral breast cancer, and other second primary cancers. The Supplementary Appendix defines these end points. We counted deaths as having been caused by breast cancer if they took place after recurrence or if they were attributed to breast cancer.
Timing of Analyses
Definitive analysis was scheduled after 710 primary end-point events had occurred to provide the study with a statistical power of 90 percent to detect a 25 percent reduction in the event rate, allowing for a number of attenuating factors. The first interim analysis was to take place after 355 events had been reported. Subsequent interim analyses were scheduled to take place semiannually. Consideration was to be given to early reporting if disease-free survival differed at the nominal 0.0001 level. If this boundary was not crossed, alpha spending function was to be applied to the final test so that the overall type I error rate would be 0.05.
Secondary Analyses
Cox models were fitted to adjust for nodal status (0 to 3, 4 to 9, or 10 or more positive nodes), tumor size (2.0 cm or less, 2.1 to 4.0 cm, or 4.1 cm or more), receptor status (estrogen-receptor–positive or progesterone-receptor–positive vs. estrogen-receptor–negative and progesterone-receptor–negative), age (39 years or younger, 40 to 49 years, 50 to 59 years, or 60 years of age or older), grade (poor vs. other), histologic findings (ductal carcinoma vs. other), and trial (B-31 vs. N9831). Forest plots were constructed to show the effects according to the study and subgroups of patients.8 Hazard ratios were computed and compared according to the length of follow-up (one year or less, one to two years, two to three years, or more than three years after randomization).
Sensitivity Analysis
The protocols required a secondary analysis that excluded patients who were ineligible, did not continue therapy after receiving doxorubicin and cyclophosphamide, or were HER2-negative on central review. Also excluded were patients with symptoms of adverse cardiac effects or declines in LVEF during doxorubicin and cyclophosphamide therapy that would preclude the initiation of trastuzumab had they been randomly assigned to the investigational group.
Data Lock
Patients in trial B-31 include those enrolled as of February 15, 2005, with follow-up as of that date. Patients in trial N9831 include those enrolled by November 1, 2004, with follow-up as of March 15, 2005.
Results
Patients
As of February 15, 2005, 2043 patients had been enrolled in trial B-31; 1736 of these women had at least one follow-up evaluation (end-point follow-up was not required for six months after randomization). By November 1, 2004, 1633 patients had been enrolled in groups A and C of trial N9831, 1615 of whom had follow-up data submitted by March 15, 2005 (Figure 1). Table 1Table 1
Characteristics of the Patients. shows the characteristics of patients with follow-up. Except for 191 patients with node-negative breast cancer who were enrolled in trial N9831, the groups from each study were similar.Compliance
Chemotherapy
In the combined trials, 31 of 1843 patients assigned to the control group declined therapy, as did 9 of 1833 women randomly assigned to the trastuzumab group. Of the patients who began chemotherapy with doxorubicin and cyclophosphamide, 97.9 percent received four cycles; 2.7 percent of patients who completed doxorubicin and cyclophosphamide treatment did not begin treatment with paclitaxel; of those who did, 94.7 percent completed all cycles.
Eligibility for Trastuzumab
Of 3497 patients who had an evaluation of LVEF after doxorubicin and cyclophosphamide therapy, 233 (6.7 percent) had an LVEF that declined at least 16 percentage points from baseline or that declined below the lower limit of normal or had cardiac symptoms during such treatment that would preclude the initiation of trastuzumab therapy.
Discontinuation of Trastuzumab
Of 1159 patients with an adequate LVEF after doxorubicin and cyclophosphamide treatment who began treatment with trastuzumab and have completed therapy, 364 (31.4 percent) discontinued the treatment before 52 weeks. Reasons for discontinuation were recurrence in the case of 22 patients (1.9 percent), a confirmed asymptomatic decline in LVEF in 164 (14.2 percent), symptoms of congestive heart failure or other adverse cardiac effect in 54 (4.7 percent), noncardiac adverse effect or death in 27 (2.3 percent), patient-initiated discontinuation in 70 (6.0 percent), and other reasons in 27 (2.3 percent).
Disease-Free Survival, Overall Survival, and Time to Distant Recurrence
The median follow-up was 2.0 years (2.4 years in trial B-31 and 1.5 years in trial N9831). There were 261 events in the control group and 133 events in the trastuzumab group. The hazard ratio for a first event in the trastuzumab group, as compared with the control group, was 0.48 (95 percent confidence interval, 0.39 to 0.59; P <0.0001) (Figure 2AFigure 2
Kaplan–Meier Estimates of Disease-free Survival (Panel A) and Overall Survival (Panel B).). The percentages of patients alive and disease-free at three years were 75.4 percent in the control group and 87.1 percent in the trastuzumab group (absolute difference, 11.8 percentage points; 95 percent confidence interval, 8.1 to 15.4 percentage points). At four years, the respective percentages were 67.1 percent and 85.3 percent (absolute difference, 18.2 percentage points; 95 percent confidence interval, 12.7 to 23.7 percentage points). This difference crossed the early stopping boundary.There were 62 deaths in the trastuzumab group, as compared with 92 deaths in the control group (hazard ratio, 0.67; 95 percent confidence interval, 0.48 to 0.93; P=0.015) (Figure 2B). The absolute survival rate at three years was 94.3 percent in the trastuzumab group and 91.7 percent in the control group (absolute difference, 2.5 percentage points; 95 percent confidence interval, 0.1 to 5.0 percentage points); at four years, the respective rates were 86.6 percent and 91.4 percent (absolute difference, 4.8 percentage points; 95 percent confidence interval, 0.6 to 9.0 percentage points).
Distant metastases were reported in 193 patients in the control group and 96 in the trastuzumab group. The hazard ratio for a first distant recurrence was 0.47 in the trastuzumab group as compared with the control group (95 percent confidence interval, 0.37 to 0.61; P <0.0001) (Figure 3Figure 3
Kaplan–Meier Estimates of Freedom from Distant Recurrence.). At three years, 90.4 percent of women in the trastuzumab group were free of distant recurrence, as compared with 81.5 percent of women in the control group (absolute difference, 8.8 percentage points; 95 percent confidence interval, 5.5 to 12.1 percentage points); the respective rates at four years were 89.7 percent and 73.7 percent (absolute difference, 15.9 percentage points; 95 percent confidence interval, 11.1 to 20.8 percentage points).Sites of First Reported Events
The benefit of trastuzumab was evident at both local–regional and distant sites (Table 2Table 2
Sites of First Events.). The number of contralateral breast cancers was insufficient to evaluate the effect of trastuzumab. There was a reduction in nonbreast second primary cancers in trial B-31 in the trastuzumab group as compared with the control group, but the results of trial N9831 did not confirm (or refute) this trend.Six patients in the control group died without recurrence or second cancers, as did eight patients in the trastuzumab group. These included three treatment-related deaths that occurred in patients who received paclitaxel and trastuzumab, one as a result of cardiomyopathy and two as a result of interstitial pneumonitis.
An increased frequency of brain metastases has been reported among patients with metastatic breast cancer treated with trastuzumab.9-11 In both trials, the incidence of isolated brain metastases as first events was higher in the trastuzumab group than in the control group (21 vs. 11 in trial B-31 and 12 vs. 4 in trial N9831). Since patients in trial B-31 were followed for additional recurrences beyond the first distant event, we could determine whether the imbalance was due to masking of the incidence of brain metastases in the control group as a result of earlier failures in other organs. In trial B-31, brain metastases as a first or subsequent event were diagnosed in 28 patients in the trastuzumab group, as compared with 35 patients in the control group (hazard ratio, 0.79; P=0.35). The imbalance in brain metastases as first events can therefore be attributed to earlier failures at other distant sites among patients in the control group.
Additional Secondary End Points
Table 3Table 3
Summary of Efficacy End-Point Analyses. summarizes additional secondary end points, including the time to recurrence, death from breast cancer, the occurrence of contralateral breast cancer, and the occurrence of other second primary cancers. Sites of second cancers are summarized in Table 4Table 4
Incidence of Second Primary Cancers..Estimated Treatment Benefit after Adjustment for Additional Characteristics
A Cox model was fitted to disease-free survival to control for treatment assignment, nodal status, pathological tumor size, hormone-receptor status, age, tumor grade, histologic appearance of the tumor, and trial. Adjustment for these factors minimally altered the effect of trastuzumab, as compared with that of control therapy (hazard ratio for a first event, 0.46; 95 percent confidence interval, 0.37 to 0.56; P <0.001). The number of positive nodes, pathological tumor size, hormone-receptor status, and tumor grade were significant predictors of disease-free survival. There was no evidence that the benefit of trastuzumab differed significantly between the two studies (P=0.38) (see Figure 1 in the Supplementary Appendix).
Subgroups
A Forest plot of the hazard ratios for first events is shown in Figure 2 in the Supplementary Appendix. Only in subgroups in which there were a negligible number of events (negative nodes and a low tumor grade) did the 95 percent confidence interval fail to exclude 1. Plots of disease-free survival according to nodal and estrogen-receptor status are also shown in Figure 3 in the Supplementary Appendix.
Sensitivity Analysis
A secondary analysis excluded ineligible patients, those who had received only doxorubicin and cyclophosphamide, those found on central testing to be HER2-negative, and those who had symptomatic cardiac dysfunction during therapy with doxorubicin and cyclophosphamide or reductions in LVEF that would preclude treatment with trastuzumab. As compared with the control group, the trastuzumab group had improved disease-free survival (hazard ratio for a first event, 0.45; P<0.0001), a longer time to recurrence (hazard ratio, 0.45; P<0.0001), a longer time to distant recurrence (hazard ratio, 0.46; P<0.0001), and improved overall survival (hazard ratio for death, 0.61; P=0.01).
Variation in Hazard Rates over Time
Figure 4 in the Supplementary Appendix includes plots of the hazard rates for first events, first recurrence, distant recurrence, and death as a function of time since randomization. After the first year, the hazard rate for distant recurrence rose sharply in the control group; in the trastuzumab group, it first rose and then decreased markedly after year 2.
Adverse Cardiac Events
The principal adverse event associated with trastuzumab therapy among patients with prior exposure to anthracycline is cardiac dysfunction.12,13 In trial B-31, of the patients who remained free of cardiac symptoms during doxorubicin and cyclophosphamide therapy and who had LVEF values that met requirements for the initiation of trastuzumab therapy, the cumulative incidence of New York Heart Association class III or IV congestive heart failure or death from cardiac causes at three years was 0.8 percent in the control group (4 patients had congestive heart failure, and 1 died from cardiac causes) and 4.1 percent in the trastuzumab group (31 patients had congestive heart failure). Of the 31 women in the trastuzumab group who had congestive heart failure, 27 have been followed for at least six months after the onset of heart failure, and only 1 reported persistent symptoms of heart failure at the most recent follow-up visit. Details of the cardiac effects of trastuzumab in trial B-31 are reported elsewhere.14 In trial N9831, the three-year cumulative incidence of New York Heart Association class III or IV congestive heart failure or death from cardiac causes was 0 percent in the control group and 2.9 percent in the trastuzumab group (20 patients had congestive heart failure, 1 of whom died of cardiomyopathy).
Other Adverse Events
During treatment with paclitaxel alone or with trastuzumab, there was little imbalance between treatment groups in the incidence of any Common Toxicity Criteria version 2.0 category except for a higher incidence of left ventricular dysfunction in the trastuzumab group. However, rare cases of interstitial pneumonitis were reported that in some cases appeared to be related to trastuzumab therapy. In trial B-31, four patients in the trastuzumab group had interstitial pneumonitis, one of whom died. In the N9831 trial, five patients in the trastuzumab group had grade 3+ pneumonitis or pulmonary infiltrates, one of whom died.
Discussion
The addition of trastuzumab to paclitaxel after a regimen of doxorubicin and cyclophosphamide reduced the rates of recurrence by half among women with HER2-positive breast cancer. The absolute decreases in distant recurrence were 8.8 percentage points after three years and 15.9 percentage points after four years, although the latter value had a wide confidence interval (11.1 to 20.8 percentage points). The reduction was similar among women with hormone-receptor–negative tumors and women with hormone-receptor–positive tumors. No subgroups that did not appear to benefit from trastuzumab therapy were identified. Since only 191 women with node-negative breast cancer were included in these studies and only 3 had had an event at the time of the analysis, we cannot comment on the effect of trastuzumab in this subgroup.
The addition of trastuzumab reduced the mortality rate by one third (P=0.015). Among eligible patients who continued treatment after doxorubicin and cyclophosphamide and who were HER2-positive on central testing, the relative reduction in the mortality rate associated with trastuzumab was 39 percent (P=0.01). Although relatively little follow-up information is available beyond three years, current data rule out a risk of distant recurrence among trastuzumab-treated women of greater than 27 per 1000 women per year, in contrast to a risk of 90 per 1000 women per year in the control group (see Figure 4 in the Supplementary Appendix). Since the risk of distant recurrence should remain appreciable in the control group for some time, a substantial additional survival benefit related to trastuzumab can be anticipated.
The effect of trastuzumab was substantial in both trials (see Figure 1 in the Supplementary Appendix), a finding that is noteworthy given differences in the paclitaxel schedule and the timing of hormonal therapy. The benefit of trastuzumab was evident at local or regional and distant sites. Although isolated brain metastases were more common first events in the trastuzumab group than in the control group, the imbalance can be attributed to the occurrence of earlier failures at other distant sites in the control group.
Data from trial B-31 suggested that trastuzumab reduced the incidence of nonbreast second primary cancers, an unanticipated effect requiring independent verification. There was no obvious pattern of site or histologic type (Table 4).
The primary concern regarding the safety of trastuzumab is the increased risk of cardiac dysfunction associated with past or concurrent anthracycline treatment.12,13 In both studies, the cumulative three-year incidence of congestive heart failure increased by about 3 percentage points with the addition of trastuzumab. Most episodes occurred during trastuzumab treatment, but additional follow-up will be needed to define the long-term cardiotoxicity of trastuzumab. Clearly, appropriate selection and careful cardiac monitoring of patients are essential. Trastuzumab did not increase the overall frequency or severity of noncardiac adverse effects associated with the chemotherapy regimens, but we did see rare cases of interstitial pneumonitis in patients receiving trastuzumab during or shortly after the paclitaxel phase of treatment. Two cases were fatal.
Trial N9831 was also designed to address the efficacy of trastuzumab initiated concurrently with paclitaxel as opposed to sequentially (group C vs. group B), but this comparison requires substantially longer follow-up than was needed for the assessment of concurrent trastuzumab therapy in the joint analysis. However, after reviewing the results of the first joint interim efficacy analysis, the data-monitoring committee overseeing trial N9831 requested an unplanned comparison of groups B and C and subsequently recommended disclosure of the results. Though early, the comparison suggested delayed administration of trastuzumab may be less effective than concurrent administration.15 Recent data from the Herceptin Adjuvant (HERA) Trial showed that treatment with trastuzumab begun after the completion of chemotherapy substantially reduced the rate of recurrence relative to the rate associated with chemotherapy alone.16 Since only 26 percent of patients received taxanes in the HERA trial, comparison of those results with ours may be problematic. Therefore, further follow-up of groups B and C in trial N9831 is necessary for an adequate evaluation of the efficacy of concurrent as compared with sequential administration of trastuzumab.
Supported by Public Health Service grants (U10-CA-12027, U10-CA-69651, U10-CA-37377, and U10-CA-69974 to the NSABP; U10-CA-25224 to the NCCTG; U10-CA-021115 to the Eastern Cooperative Oncology Group; U10-CA-32102 to the Southwest Oncology Group; and U10-CA-31946 to Cancer and Leukemia Group B) from the NCI, Department of Health and Human Services. Genentech, South San Francisco, Calif., provided trastuzumab and partial funding for both trials. The Breast Cancer Research Foundation, New York, provided partial funding to Dr. Perez.
Drs. Romond, Perez, Bryant, Geyer, Tan-Chiu, Paik, Kaufman, and Mamounas report having received compensation for time served on Genentech Breast Cancer Advisory Boards; Drs. Romond, Tan-Chiu, Bryant, Kaufman, and Mamounas, lecture fees from Genentech; and Drs. Perez and Kaufman, grant support from Genentech. Dr. Klein is an employee of Genentech and holds equity stock.
Drs. Romond and Perez contributed equally to the article.
We are indebted to Dr. Barbara C. Good, director of scientific publications for the NSABP, for editorial assistance; to all the women participating in NSABP trial B-31 and NCCTG trial N9831 for their contribution to this research effort; to the investigators of the Eastern Cooperative Oncology Group, the Southwest Oncology Group, Cancer and Leukemia Group B, the NCCTG, and the NSABP for their dedicated efforts in support of these trials; and to Dr. Jeff Abrams, for support in the development and approval of the joint-analysis plan.
Source Information
From the National Surgical Adjuvant Breast and Bowel Project, Pittsburgh (E.H.R., J.B., C.E.G., E.T.-C., S.P., S.M.S., L.F., V.G.V., G.Y., A.M.B., E.P.M., N.W.); University of Kentucky, Lexington (E.H.R.); North Central Cancer Treatment Group, Rochester, Minn. (E.A.P., V.J.S., T.M.P., L.A.K., D.W.V., R.B.J., S.R.D., W.L.L., J.N.I.); Mayo Clinic Jacksonville, Jacksonville, Fla. (E.A.P.); University of Pittsburgh, Pittsburgh (J.B., G.Y.); Mayo Clinic, Rochester, Minn. (V.J.S., T.M.P., D.W.V., R.B.J., W.L.L., J.N.I.); Allegheny General Hospital, Pittsburgh (C.E.G., N.W.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (N.E.D.), the Cancer Research Network, Plantation, Fla. (E.T.-C.); Angeles Clinic and Research Institute, Santa Monica, Calif. (S.M.); Norris Cotton Cancer Center, Dartmouth–Hitchcock Medical Center, Lebanon, N.H. (P.A.K.); Cancer Therapeutics Branch, National Cancer Institute, Bethesda, Md. (S.M.S.); Kaiser Permanente Medical Center Northern California, Vallejo (L.F.); Oncology Associates of Cedar Rapids, Cedar Rapids, Iowa (L.A.K.); University of Pittsburgh Cancer Institute, Pittsburgh (V.G.V.); Wichita Community Clinical Oncology Program, Wichita, Kans. (S.R.D.); Aultman Health Foundation, Canton, Ohio (E.P.M.); and Genentech, South San Francisco, Calif. (P.M.K.).
Address reprint requests to Dr. Geyer at the Allegheny Cancer Center, 5th Fl., 320 E. North Ave., Pittsburgh, PA 15212, or at cgeyer@wpahs.org.
Appendix
The following institutions and principal investigators enrolled at least 25 patients in the B-31 trial or N9831 trial: Trial B-31 — Kaiser Permanente, Northern California Region, Vallejo, Calif., L. Fehrenbacher; University of Pittsburgh, Pittsburgh, V.G. Vogel; Atlanta Regional Community Clinical Oncology Program (CCOP), Atlanta, T.E. Seay; Colorado Cancer Research Program, CCOP, Denver, E.R. Pajon; Metro Minnesota CCOP, St. Louis Park, Minn., P.J. Flynn; Franklin Square Hospital Center, Baltimore, J.L. Zapas; Kaiser Permanente, San Diego, Calif., J. Polikoff; Dayton CCOP, Dayton, Ohio, H.M. Gross; Christiana Care Health Services CCOP, Newark, Del., D.D. Biggs; Southeast Cancer Control Consortium CCOP, Winston-Salem, N.C., J.N. Atkins; Huntsman Cancer Institute, Salt Lake City, Utah, R.D. Noyes; Puget Sound Oncology Consortium, Seattle, R.B. Clarfeld; Columbus CCOP, Columbus, Ohio, J.P. Kuebler; Northwest CCOP, Tacoma, Wash., L.K. Colman; Scripps Clinic, La Jolla, Calif., J.F. Kroener; Illinois Oncology Research Association CCOP, Peoria, J.W. Kugler; Evanston Northwestern Healthcare CCOP/Kellogg Cancer Center, Evanston, Ill., D. Merkel; Kansas City CCOP, Kansas City, Mo., W.T. Stephenson; Montana Cancer Consortium CCOP, Billings, P.W. Cobb; Trial N9831 — Indiana University Cancer Center, Indianapolis, P.J. Loehrer; Johns Hopkins University, Baltimore, A.A. Forastiere; Vanderbilt University, Nashville, D.H. Johnson; Northern New Jersey CCOP, Hackensack, R.J. Rosenbluth; University of Chicago Medical Center, Chicago, G. Fleming; Dana–Farber Cancer Institute, Boston, G.P. Canellos; Duke University Medical Center, Durham, N.C., J. Crawford; Mount Sinai School of Medicine, New York, L.R. Silverman; Memorial Sloan-Kettering Cancer Center, New York, C. Hudis; Loyola University Medical Center, Maywood, Ill., P.J. Stiff; Ohio State University Medical Center, Columbus, C.D. Bloomfield; Georgetown University Medical Center, Washington, D.C., E. Gelmann; Moffitt Cancer Center, Tampa, Fla., J.A. Kish; Mayo Clinic, Rochester, Minn., S.R. Alberts; Toledo CCOP, Toledo, Ohio, P.L. Schaefer; Metro Minnesota CCOP, St. Louis Park, Minn., P.J. Flynn; Wichita CCOP, Wichita, Kans., S. Dakhil; Ann Arbor CCOP, Ann Arbor, Mich., P.J. Stella; Missouri Valley Cancer Consortium CCOP, Omaha, Nebr., J.A. Mailliard.
- References
References
1
Slamon DJ ,Leyland-Jones B ,Shak S , et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792
Full Text | Web of Science | Medline2
Slamon DJ ,Clark GM ,Wong SG ,Levin WJ ,Ullrich A ,McGuire WL . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
CrossRef | Web of Science | Medline3
Paik S ,Bryant J ,Tan-Chiu E , et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:1991-1998
CrossRef | Web of Science | Medline4
White SJ ,Freedman LS . Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 1978;37:849-857
CrossRef | Web of Science | Medline5
Pocock SL ,Simon R . Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115
CrossRef | Web of Science | Medline6
Albain KS ,Green S ,Ravdin P , et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from North American Intergroup Trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 2002;21:37A abstract-37A abstract7
Baum M ,Buzdar AU ,Cuzick J , et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-2139[Erratum, Lancet 2002;360:1520.]
CrossRef | Web of Science | Medline8
Lewis S ,Clarke M . Forest plots: trying to see the wood and the trees. BMJ 2001;322:1479-1480
CrossRef | Web of Science | Medline9
Bendell JC ,Domchek SM ,Burstein HJ , et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-2977
CrossRef | Web of Science | Medline10
Clayton AJ ,Danson S ,Jolly S , et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91:639-643
Web of Science | Medline11
Lin NU ,Bellon JR ,Winer EP . CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-3617
CrossRef | Web of Science | Medline12
Seidman A ,Hudis C ,Pierri MK , et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-1221
CrossRef | Web of Science | Medline13
Ewer MS ,Vooletich M ,Valero V ,Higano CS ,Benjamin RS . Trastuzumab (Herceptin) cardiotoxicity: clinical course and cardiac biopsy correlations. Proc Am Soc Clin Oncol 2002;21:123A-123A abstract.14
Tan Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide (AC) followed by paclitaxel (2AC) followed by paclitaxel plus trastuzumab as adjuvant therapy for patients with node-positive HER2-overexpressing breast cancer. J Clin Oncol (in press).
15
Perez EA, Suman VJ, Davidson N, et al. HER2 testing by local, central and reference laboratories in the NCCTG N9831 trial. Available at http://asco.org/ac/1,1003,_12-002511-00_18-0034-00_19-005815,00.asp.
16
Piccart-Gebhart M. A randomized three-group multi-centre comparison of: 1 year Herceptin, 2 years Herceptin, or no Herceptin, in women with HER-2 positive primary breast cancer who have completed adjuvant chemotherapy. Available at http://asco.org/ac/1,1003,_12-002511-00_18-0034_19-005816,00.asp.
- Citing Articles (1091)
Citing Articles
1
Robert Whitfield, James Kollias, Primali De Silva, Helen Zorbas, Guy Maddern. (2012) Use of trastuzumab in Australia and New Zealand: results from the National Breast Cancer Audit. ANZ Journal of Surgeryno-no
CrossRef2
N. Lynn Henry, Daniel F. Hayes. (2012) Cancer Biomarkers. Molecular Oncology
CrossRef3
Carlos H. Barrios. (2012) The Role of Capecitabine in Early Stage Breast Cancer. Current Breast Cancer Reports
CrossRef4
Sandhya Girish, Manish Gupta, Bei Wang, Dan Lu, Ian E. Krop, Charles L. Vogel, Howard A. Burris III, Patricia M. LoRusso, Joo-Hee Yi, Ola Saad, Barbara Tong, Yu-Waye Chu, Scott Holden, Amita Joshi. (2012) Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemotherapy and Pharmacology
CrossRef5
Paul Cornes. (2012) The economic pressures for biosimilar drug use in cancer medicine. Targeted Oncology
CrossRef6
Stefan A. Lange, Bernd Ebner, Astrid Wess, Matthias Kögel, Mieczyslaw Gajda, Thomas Hitschold, Jens Jung. (2012) Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy. Clinical Research in Cardiology
CrossRef7
J Cohen, A Wilson, K Manzolillo. (2012) Clinical and economic challenges facing pharmacogenomics. The Pharmacogenomics Journal
CrossRef8
Josef Rüschoff, Wedad Hanna, Michael Bilous, Manfred Hofmann, Robert Y Osamura, Frédérique Penault-Llorca, Marc van de Vijver, Giuseppe Viale. (2012) HER2 testing in gastric cancer: a practical approach. Modern Pathology
CrossRef9
Hung-Wen Lai, Su-Yu Chien, Shou-Jen Kuo, Ling-Ming Tseng, Hui-Yi Lin, Chin-Wen Chi, Dar-Ren Chen. (2012) The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin. Evidence-Based Complementary and Alternative Medicine 2012, 1-12
CrossRef10
K.A.B. Goddard, S. Weinmann, K. Richert-Boe, C. Chen, J. Bulkley, C. Wax. (2012) <i>HER2</i> Evaluation and Its Impact on Breast Cancer Treatment Decisions. Public Health Genomics 15:1, 1-10
CrossRef11
István Láng, Zsuzsanna Kahán, Erika Hitre, Magdolna Dank, Gábor Rubovszky, Zsolt Horváth, Miklós Kásler. (2012) Az emlőrák korszerű gyógyszeres kezelése. Orvosi Hetilap 153:2, 56-65
CrossRef12
Andrew Caley, Alpa Kanji, Jake Tanguay. (2012) Adjuvant therapy. Medicine 40:1, 1-4
CrossRef13
José Baselga, Ian Bradbury, Holger Eidtmann, Serena Di Cosimo, Evandro de Azambuja, Claudia Aura, Henry Gómez, Phuong Dinh, Karine Fauria, Veerle Van Dooren, Gursel Aktan, Aron Goldhirsch, Tsai-Wang Chang, Zsolt Horváth, Maria Coccia-Portugal, Julien Domont, Ling-Min Tseng, Georg Kunz, Joo Hyuk Sohn, Vladimir Semiglazov, Guillermo Lerzo, Marketa Palacova, Volodymyr Probachai, Lajos Pusztai, Michael Untch, Richard D Gelber, Martine Piccart-Gebhart. (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet
CrossRef14
Paolo Carli, Elisa Turchet, Daniela Quitadamo, Antonella Spada, Gianmaria Miolo, Elda Lamaj, Simon Spazzapan, Vincenzo Di Lauro, Riccardo Dolcetti, Andrea Veronesi, Diana Crivellari. (2012) Target therapy in elderly breast cancer patients. Critical Reviews in Oncology/Hematology
CrossRef15
Ian Krop, Eric P Winer. (2012) Further progress in HER2-directed therapy. The Lancet Oncology 13:1, 2-3
CrossRef16
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Laslo Roman, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Staroslawska, Juan de la Haba-Rodriguez, Seock-Ah Im, Jose Luiz Pedrini, Brigitte Poirier, Paolo Morandi, Vladimir Semiglazov, Vichien Srimuninnimit, Giulia Bianchi, Tania Szado, Jayantha Ratnayake, Graham Ross, Pinuccia Valagussa. (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet Oncology 13:1, 25-32
CrossRef17
Casey Shuptrine, Rishi Surana, Louis M. Weiner. (2012) Monoclonal antibodies for the treatment of cancer. Seminars in Cancer Biology
CrossRef18
Anna Malicka-Durczak, Konstanty Korski, Matthew Ibbs. (2012) Comparison of in situ hybridization methods for the assessment of HER-2/neu gene amplification status in breast cancer using a tissue microarray. Reports of Practical Oncology & Radiotherapy
CrossRef19
Hope S. Rugo, A. Jo Chien, Sandra X. Franco, Alison T. Stopeck, Alexa Glencer, Soumi Lahiri, Michael C. Arbushites, Janet Scott, John W. Park, Clifford Hudis, Ben Nulsen, Maura N. Dickler. (2011) A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment
CrossRef20
Nadia Harbeck. (2011) Breast cancer: Increasing therapy options for HER2-positive early breast cancer. Nature Reviews Clinical Oncology 9:1, 10-12
CrossRef21
Dorothy M. K. Keefe, Emma H. Bateman. (2011) Tumor control versus adverse events with targeted anticancer therapies. Nature Reviews Clinical Oncology
CrossRef22
Qian Shi, Sumithra J. Mandrekar, Daniel J. Sargent. (2011) Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials. Scandinavian Journal of Gastroenterology1-7
CrossRef23
J. D. Jensen, A. Knoop, A. V. Laenkholm, M. Grauslund, M. B. Jensen, E. Santoni-Rugiu, M. Andersson, M. Ewertz. (2011) PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Annals of Oncology
CrossRef24
Rosa Lerose, Pellegrino Musto, Michele Aieta, Carla Papa, Alfredo Tartarone. (2011) Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. European Journal of Clinical Pharmacology
CrossRef25
Aoife J. Lowery, Malcolm R. Kell, Ronan W. Glynn, Michael J. Kerin, Karl J. Sweeney. (2011) Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Research and Treatment
CrossRef26
Bom Sahn Kim, Sun Hee Sung. (2011) Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Annals of Nuclear Medicine
CrossRef27
E. A. Perez, A. C. Dueck, A. E. McCullough, M. M. Reinholz, K. S. Tenner, N. E. Davidson, J. Gralow, L. N. Harris, L. A. Kutteh, D. W. Hillman, R. B. Jenkins, B. Chen. (2011) Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria. JNCI Journal of the National Cancer Institute
CrossRef28
Stephane Ederhy, Hassan Izzedine, Christophe Massard, Ghislaine Dufaitre, Jean Philippe Spano, Gerard Milano, Catherine Meuleman, Benjamin Besse, Franck Boccara, David Kahyat, Ariel Cohen, Jean Charles Soria. (2011) Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists. Critical Reviews in Oncology/Hematology 80:3, 369-379
CrossRef29
C.B. Moelans, R.A. de Weger, E. Van der Wall, P.J. van Diest. (2011) Current technologies for HER2 testing in breast cancer. Critical Reviews in Oncology/Hematology 80:3, 380-392
CrossRef30
Flora Zagouri, Christos A. Papadimitriou, Meletios-Athanassios Dimopoulos, Dimitrios Pectasides. (2011) Molecularly targeted therapies in unresectable-metastatic gastric cancer. A systematic review. Cancer Treatment Reviews 37:8, 599-610
CrossRef31
Alexandre Cochet, Gaetan Quilichini, Inna Dygai-Cochet, Claude Touzery, Michel Toubeau, Alina Berriolo-Riedinger, Bruno Coudert, Yves Cottin, Pierre Fumoleau, François Brunotte. (2011) Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Research and Treatment 130:3, 845-854
CrossRef32
Gunter Minckwitz, Sibylle Loibl, Andrea Maisch, Michael Untch. (2011) Incorporating Agents that Target HER2 in the Neoadjuvant Setting. Current Breast Cancer Reports 3:4, 190-196
CrossRef33
Fei-fei Zhou, Min Yan, Gui-fang Guo, Fang Wang, Hui-juan Qiu, Fei-meng Zheng, Yan Zhang, Qiang Liu, Xiao-feng Zhu, Liang-ping Xia. (2011) Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells. Medical Oncology 28:4, 1302-1307
CrossRef34
J. Kenneth Burkus, Matthew F. Gornet, Steven D. Glassman, Paul J. Slosar, Michael K. Rosner, Jeffrey E. Deckey, John Nowak, Brian M. Hatcher. (2011) Blood Serum Antibody Analysis and Long-Term Follow-up of Patients Treated With Recombinant Human Bone Morphogenetic Protein-2 in the Lumbar Spine. Spine 36:25, 2158-2167
CrossRef35
Sumithra J Mandrekar, Daniel J Sargent. (2011) Design of clinical trials for biomarker research in oncology. Clinical Investigation 1:12, 1627-1636
CrossRef36
S. P. Bueno Angela, R. M. Viero, C. T. Soares. (2011) Fine needle aspirate cell blocks are reliable for detection of hormone receptors and HER-2 by immunohistochemistry in breast carcinoma. Cytopathologyno-no
CrossRef37
Hye Jin Kim, Hwang-Phill Kim, Young-Kwang Yoon, Maeng-Sup Kim, Gwan-Sun Lee, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Bang. (2011) Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. Anti-Cancer Drugs1
CrossRef38
Luigi Tarantini, Giovanni Cioffi, Stefania Gori, Fausto Tuccia, Lidia Boccardi, Daniella Bovelli, Chiara Lestuzzi, Nicola Maurea, Stefano Oliva, Giulia Russo, Pompilio Faggiano. (2011) Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer. Journal of Cardiac Failure
CrossRef39
M. Pegram, J. Liao. (2011) Trastuzumab Treatment in Multiple Lines: Current Data and Future Directions. Clinical Breast Cancer
CrossRef40
Seigo Nakamura, Masashi Ando, Norikazu Masuda, Kenjiro Aogi, Hiroyo Ino, Hiroji Iwata, Yutaka Tokuda, Naohito Yamamoto, Hiroi Kasai, Masahiko Takeuchi, Hitoshi Tsuda, Futoshi Akiyama, Masafumi Kurosumi, Yasuhiro Fujiwara. (2011) Randomized Phase II Study of Primary Systemic Chemotherapy and Trastuzumab for Operable HER2 Positive Breast Cancer. Clinical Breast Cancer
CrossRef41
Serena Di Cosimo. (2011) Heart to heart with trastuzumab: a review on cardiac toxicity. Targeted Oncology
CrossRef42
Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne, Edith A. Perez, Fabio Puglisi, Luca Gianni. (2011) Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Reviews Clinical Oncology
CrossRef43
Yanan Kong, Shuqin Dai, Xinhua Xie, Xiangsheng Xiao, Ning Lv, Jiaoli Guo, Laisheng Li, Weihua Jia, Yin Zhang, Wanli Liu, Weidong Wei, Xiaoming Xie. (2011) High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. Journal of Cancer Research and Clinical Oncology
CrossRef44
Tatsuo Kanda, Toshirou Nishida, Norihito Wada, Osamu Kobayashi, Masakazu Yamamoto, Akira Sawaki, Narikazu Boku, Masato Koseki, Toshihiko Doi, Yasushi Toh, Yoshihiro Kakeji, Toshiro Sugiyama, Yoshito Komatsu, Shojiro Kikuchi, Kyoji Ogoshi, Hitoshi Katai, Kazuhito Miyachi, Seiichi Hirota, Atsushi Ohtsu. (2011) Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients. International Journal of Clinical Oncology
CrossRef45
Naoki Niikura, Morihiko Kimura, Takayuki Iwamoto, Naoki Hayashi, Junichi Shintoku, Yuki Saito, Yasuhiro Suzuki, Yutaka Tokuda. (2011) Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment. Breast Cancer
CrossRef46
R M Webster, J Abraham, N Palaniappan, A Caley, B Jasani, P Barrett-Lee. (2011) Exploring the use and impact of adjuvant Trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. British Journal of Cancer
CrossRef47
Fuh Yong Wong, Connie Siew Poh Yip, Eu Tiong Chua. (2011) Implications of HER2 Amplification in Small, Node-Negative Breast Cancers: Do Asians Differ?. World Journal of Surgery
CrossRef48
Luc Ceugnart, Bruno Coudert, Florence Dalenc, Jean-Marc Guinebretiere, Philippe Rouanet, Alain Toledano. (2011) Les traitements néoadjuvants (hors cancer du sein inflammatoire). Oncologie
CrossRef49
Seock-Ah Im, Keun Seok Lee, Jungsil Ro, Eun Sook Lee, Youngmee Kwon, Jin-Hee Ahn, Jin Seok Ahn, Jee Hyun Kim, Han Sung Kang, Kyung Hwan Shin, Dong-Young Noh, In-Ae Park, Sung-Bae Kim, Young Hyuck Im, Sung Whan Ha. (2011) Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01. Breast Cancer Research and Treatment
CrossRef50
Katsuya Nakai, Hiroyuki Mitomi, Yimit Alkam, Atsushi Arakawa, Takashi Yao, Emi Tokuda, Mitsue Saito, Fujio Kasumi. (2011) Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients. Cancer Chemotherapy and Pharmacology
CrossRef51
Jin Cheon Kim, Jong Han Yu, Yoon Kyung Cho, Choon Sik Jung, Sei Hyun Ahn, Gyungyub Gong, Yong Sung Kim, Dong-Hyung Cho. (2011) Expression of SPRR3 is associated with tumor cell proliferation in less advanced stages of breast cancer. Breast Cancer Research and Treatment
CrossRef52
Giampietro Gasparini, Raffaele Longo. (2011) The paradigm of personalized therapy in oncology. Expert Opinion on Therapeutic Targets1-10
CrossRef53
Nicholas A. Barber, Apar Kishor Ganti. (2011) Pulmonary toxicities from targeted therapies: a review. Targeted Oncology
CrossRef54
Gabrielle Rocque, Adedayo Onitilo, Jessica Engel, Erica Pettke, Alice Boshoven, KyungMann Kim, Shailly Rishi, Bonnie Waack, Kari B. Wisinski, Amye Tevaarwerk, Mark E. Burkard. (2011) Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. Breast Cancer Research and Treatment
CrossRef55
Agustí Barnadas, Laura G. Estévez, Ana Lluch-Hernández, Álvaro Rodriguez-Lescure, César Rodriguez-Sanchez, Pedro Sanchez-Rovira. (2011) An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer. Advances in Therapy
CrossRef56
D. M. Collins, N. O'Donovan, P. M. McGowan, F. O'Sullivan, M. J. Duffy, J. Crown. (2011) Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Annals of Oncology
CrossRef57
D. Rayson, T. M. Suter, C. Jackisch, S. van der Vegt, B. Bermejo, J. van den Bosch, G. L. Vivanco, A. M. van Gent, H. Wildiers, A. Torres, L. Provencher, M. Temizkan, J. Chirgwin, J. L. Canon, G. Ferrandina, S. Srinivasan, L. Zhang, D. J. Richel. (2011) Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Annals of Oncology
CrossRef58
Umut Demirci, Suleyman Buyukberber, Guldal Yılmaz, Mustafa Kerem, Ugur Coskun, Aytug Uner, Meltem Baykara, Hatice Pasali, Mustafa Benekli. (2011) Hepatotoxicity associated with lapatinib in an experimental rat model. European Journal of Cancer
CrossRef59
K. Tanaka, H. Kawaguchi, Y. Nakamura, K. Taguchi, K. Nishiyama, S. Ohno. (2011) Effect of HER2 status on risk of recurrence in women with small, node-negative breast tumours. British Journal of Surgery 98:11, 1561-1565
CrossRef60
Alan K Sears, Sonia A Perez, Guy T Clifton, Linda C Benavides, Jeremy D Gates, Kevin S Clive, Jarrod P Holmes, Nathan M Shumway, David C Van Echo, Mark G Carmichael, Sathibalan Ponniah, Constantin N Baxevanis, Elizabeth A Mittendorf, Michael Papamichail, George E Peoples. (2011) AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opinion on Biological Therapy 11:11, 1543-1550
CrossRef61
Cyrus Chargari, Hind Riahi Idrissi, Jean-Yves Pierga, Marc A. Bollet, Véronique Diéras, François Campana, Paul Cottu, Alain Fourquet, Youlia M. Kirova. (2011) Preliminary Results of Whole Brain Radiotherapy With Concurrent Trastuzumab for Treatment of Brain Metastases in Breast Cancer Patients. International Journal of Radiation Oncology*Biology*Physics 81:3, 631-636
CrossRef62
Jacob Mathew, Edith A. Perez. (2011) Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer. Current Opinion in Oncology 23:6, 594-600
CrossRef63
Hee Jeong Kim, Wonshik Han, On Vox Yi, Hee Chul Shin, Soo-Kyung Ahn, Beom Seok Koh, Hyeong-Gon Moon, Jong Han You, Byung Ho Son, Sei Hyun Ahn, Dong-Young Noh. (2011) Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype. Breast Cancer Research and Treatment 130:2, 499-505
CrossRef64
Giorgio Valabrega, Sonia Capellero, Giuliana Cavalloni, Gianluca Zaccarello, Annalisa Petrelli, Giorgia Migliardi, Andrea Milani, Caterina Peraldo-Neia, Loretta Gammaitoni, Anna Sapino, Carla Pecchioni, Aldo Moggio, Silvia Giordano, Massimo Aglietta, Filippo Montemurro. (2011) HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Research and Treatment 130:1, 29-40
CrossRef65
Sarah Barton, Charles Swanton. (2011) Recent Developments in Treatment Stratification for Metastatic Breast Cancer. Drugs 71:16, 2099-2113
CrossRef66
Jung-min Lee, Jasmine J. Han, Gary Altwerger, Elise C. Kohn. (2011) Proteomics and biomarkers in clinical trials for drug development. Journal of Proteomics 74:12, 2632-2641
CrossRef67
C. M. Kelly, K. I. Pritchard, M. Trudeau, E. Andreopoulou, K. Hess, L. Pusztai. (2011) Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?. Annals of Oncology 22:11, 2387-2393
CrossRef68
Thomas A Buchholz. (2011) Radiotherapy and survival in breast cancer. The Lancet 378:9804, 1680-1682
CrossRef69
Min A Kim, Hyuk-Joon Lee, Han-Kwang Yang, Yung-Jue Bang, Woo Ho Kim. (2011) Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 59:5, 822-831
CrossRef70
Aditya Bardia, Erin T. Arieas, Zhe Zhang, Andrew DeFilippis, Karineh Tarpinian, Stacie Jeter, Anne Nguyen, N. Lynn Henry, David A. Flockhart, Daniel F. Hayes, Jill Hayden, Anna Maria Storniolo, Deborah K. Armstrong, Nancy E. Davidson, John Fetting, Pamela Ouyang, Antonio C. Wolff, Roger S. Blumenthal, M. Dominique Ashen, Vered Stearns. (2011) Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Research and Treatment
CrossRef71
G. Somlo, C. L. Martel, S. K. Lau, P. Frankel, C. Ruel, L. Gu, A. Hurria, C. Chung, T. Luu, R. Morgan, L. Leong, M. Koczywas, M. McNamara, C. A. Russell, S. E. Kane. (2011) A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer. Breast Cancer Research and Treatment
CrossRef72
Michael L. Maitland, Richard L. Schilsky. (2011) Clinical trials in the era of personalized oncology. CA: A Cancer Journal for Clinicians 61:6, 365-381
CrossRef73
Mark R. Trusheim, Breon Burgess, Sean Xinghua Hu, Theresa Long, Steven D. Averbuch, Aiden A. Flynn, Alfons Lieftucht, Abhijit Mazumder, Judy Milloy, Peter M. Shaw, David Swank, Jian Wang, Ernst R. Berndt, Federico Goodsaid, Michael C. Palmer. (2011) Quantifying factors for the success of stratified medicine. Nature Reviews Drug Discovery 10:11, 817-833
CrossRef74
Rebecca L. Hirsh, Angela DeMichele. (2011) The Role of Lapatinib in the Preoperative Therapy of Breast Cancer. Current Oncology Reports
CrossRef75
T Shiroiwa, T Fukuda, K Shimozuma. (2011) Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. British Journal of Cancer 105:9, 1273-1278
CrossRef76
Kunal S. Taskar, Vinay Rudraraju, Rajendar K. Mittapalli, Ramakrishna Samala, Helen R. Thorsheim, Julie Lockman, Brunilde Gril, Emily Hua, Diane Palmieri, Joseph W. Polli, Stephen Castellino, Stephen D. Rubin, Paul R. Lockman, Patricia S. Steeg, Quentin R. Smith. (2011) Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer. Pharmaceutical Research
CrossRef77
Lakshmi Nayak, Eudocia Quant Lee, Patrick Y. Wen. (2011) Epidemiology of Brain Metastases. Current Oncology Reports
CrossRef78
T Nguyen-Hoai, G Baldenhofer, M S Sayed Ahmed, M Pham-Duc, M D Vu, M Lipp, B Dörken, A Pezzutto, J Westermann. (2011) CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model. Cancer Gene Therapy
CrossRef79
Slamon, Dennis, Eiermann, Wolfgang, Robert, Nicholas, Pienkowski, Tadeusz, Martin, Miguel, Press, Michael, Mackey, John, Glaspy, John, Chan, Arlene, Pawlicki, Marek, Pinter, Tamas, Valero, Vicente, Liu, Mei-Ching, Sauter, Guido, von Minckwitz, Gunter, Visco, Frances, Bee, Valerie, Buyse, Marc, Bendahmane, Belguendouz, Tabah-Fisch, Isabelle, Lindsay, Mary-Ann, Riva, Alessandro, Crown, John, . (2011) Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine 365:14, 1273-1283
Full Text80
Daniel F. Hayes. (2011) Clinical trials: The silent minority—unpublished data on cancer care. Nature Reviews Clinical Oncology 8:11, 631-632
CrossRef81
Michaela J. Higgins, José Baselga. (2011) Targeted therapies for breast cancer. Journal of Clinical Investigation 121:10, 3797-3803
CrossRef82
Hajime Sunagozaka, Masao Honda, Taro Yamashita, Ryuhei Nishino, Hajime Takatori, Kuniaki Arai, Tatsuya Yamashita, Yoshio Sakai, Shuichi Kaneko. (2011) Identification of a secretory protein c19orf10 activated in hepatocellular carcinoma. International Journal of Cancer 129:7, 1576-1585
CrossRef83
Rachel L. Theriault, Jennifer K. Litton, Elizabeth A. Mittendorf, Huiqin Chen, Funda Meric-Bernstam, Mariana Chavez-MacGregor, Phuong K. Morrow, Wendy A. Woodward, Aysegul Sahin, Gabriel N. Hortobagyi, Ana M. Gonzalez-Angulo. (2011) Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. Clinical Breast Cancer 11:5, 325-331
CrossRef84
Scott A. Waldman, Andre Terzic. (2011) Widening the Path to Personalized Medicine. Clinical and Translational Science 4:5, 392-394
CrossRef85
Sarah J. Storr, Caroline M. Woolston, Fabricio F.T. Barros, Andrew R. Green, Mohamed Shehata, Stephen Y. Chan, Ian O. Ellis, Stewart G. Martin. (2011) Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. International Journal of Cancer 129:7, 1773-1780
CrossRef86
Nehmat Houssami, Petra Macaskill, Rosemary L. Balleine, Michael Bilous, Mark D. Pegram. (2011) HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Research and Treatment 129:3, 659-674
CrossRef87
Robert C. Seeger. (2011) Immunology and immunotherapy of neuroblastoma. Seminars in Cancer Biology 21:4, 229-237
CrossRef88
Elena B. Elkin, Deborah A. Marshall, Nathalie A. Kulin, Ilia L. Ferrusi, Michael J. Hassett, Uri Ladabaum, Kathryn A. Phillips. (2011) Economic evaluation of targeted cancer interventions: Critical review and recommendations. Genetics in Medicine 13:10, 853-860
CrossRef89
Jiannan Wu, Shunrong Li, Weijuan Jia, Fengxi Su. (2011) Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology 137:10, 1505-1510
CrossRef90
C. Hennequin, D. Azria. (2011) L’avenir de la radiothérapie du cancer du sein : de la taille unique au sur-mesure. Cancer/Radiothérapie 15:6-7, 455-459
CrossRef91
Howard A. Burris, Jay Tibbitts, Scott N. Holden, Mark X. Sliwkowski, Gail D. Lewis Phillips. (2011) Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer. Clinical Breast Cancer 11:5, 275-282
CrossRef92
Masakazu Toi, Eric P. Winer, Takashi Inamoto, John R. Benson, John F. Forbes, Michihide Mitsumori, John F. R. Robertson, Hironobu Sasano, Gunter Minckwitz, Akira Yamauchi, V. Suzanne Klimberg. (2011) Identifying Gaps in the Locoregional Management of Early Breast Cancer: Highlights from the Kyoto Consensus Conference. Annals of Surgical Oncology 18:10, 2885-2892
CrossRef93
M. Valentini, A. Milesi, A. Bettini, C. Tondini, A. Nicolucci. (2011) Type and trends in outcomes research in breast cancer between 2000 and 2007. Annals of Oncology 22:10, 2160-2165
CrossRef94
V. Semiglazov, W. Eiermann, M. Zambetti, A. Manikhas, A. Bozhok, A. Lluch, S. Tjulandin, M.D. Sabadell, A. Caballero, P. Valagussa, J. Baselga, L. Gianni. (2011) Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. European Journal of Surgical Oncology (EJSO) 37:10, 856-863
CrossRef95
Monica Morrow. (2011) Prophylactic mastectomy of the contralateral breast. The Breast 20, S108-S110
CrossRef96
Anastasia Constantinidou, Ian Smith. (2011) Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?. The Breast 20, S158-S161
CrossRef97
Kamal S. Saini, Hatem A. Azim Jr, Otto Metzger-Filho, Sherene Loi, Christos Sotiriou, Evandro de Azambuja, Martine Piccart. (2011) Beyond trastuzumab: New treatment options for HER2-positive breast cancer. The Breast 20, S20-S27
CrossRef98
Bohuslav Melichar, Mario Plebani. (2011) Targeted therapy for HER-2: personalized medicine for her, too. Clinical Chemistry and Laboratory Medicine---
CrossRef99
Eugene R. Ahn, Charles L. Vogel. (2011) Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Research and Treatment
CrossRef100
Thomas I. Peng Soh, Wei Peng Yong, Federico Innocenti. (2011) Review: Recent progress and clinical importance on pharmacogenetics in cancer therapy. Clinical Chemistry and Laboratory Medicine---
CrossRef101
Carmine Fedele, Gennaro Riccio, Carmela Coppola, Antonio Barbieri, Maria Gaia Monti, Claudio Arra, Carlo G. Tocchetti, Giuseppe D’Alessio, Nicola Maurea, Claudia De Lorenzo. (2011) Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Research and Treatment
CrossRef102
Marieke A. Vollebergh, Jos Jonkers, Sabine C. Linn. (2011) Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cellular and Molecular Life Sciences
CrossRef103
Laura J. Tafe, Gregory J. Tsongalis. (2011) The human epidermal growth factor receptor 2 (HER2). Clinical Chemistry and Laboratory Medicine---
CrossRef104
Barbara Bernasconi, Anna Maria Chiaravalli, Giovanna Finzi, Katia Milani, Maria Grazia Tibiletti. (2011) Genetic heterogeneity in HER2 testing may influence therapy eligibility. Breast Cancer Research and Treatment
CrossRef105
Jennifer R. Bellon, Eleanor E. R. Harris, Douglas W. Arthur, Lisa Bailey, Lisa Carey, Sharad Goyal, Michele Y. Halyard, Kathleen C. Horst, Meena S. Moran, Shannon M. MacDonald, Bruce G. Haffty. (2011) ACR Appropriateness Criteria® Conservative surgery and Radiation - Stage I and II Breast Carcinoma. The Breast Journal 17:5, 448-455
CrossRef106
Jonathan W. Uhr, Michael L. Huebschman, Eugene P. Frenkel, Nancy L. Lane, Raheela Ashfaq, Huaying Liu, Dipen R. Rana, Lawrence Cheng, Alice T. Lin, Gareth A. Hughes, Xiaojing J. Zhang, Harold R. Garner. (2011) Molecular profiling of individual tumor cells by hyperspectral microscopic imaging. Translational Research
CrossRef107
Olivia Pagani, Ann Partridge, Larissa Korde, Sunil Badve, John Bartlett, Kathy Albain, Richard Gelber, Aron Goldhirsch. (2011) Pregnancy after breast cancer: if you wish, ma’am. Breast Cancer Research and Treatment 129:2, 309-317
CrossRef108
M. Bates, J. Sperinde, W. J. Kostler, S. M. Ali, K. Leitzel, E. M. Fuchs, A. Paquet, Y. Lie, T. Sherwood, R. Horvat, C. F. Singer, J. Winslow, J. M. Weidler, W. Huang, A. Lipton. (2011) Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Annals of Oncology 22:9, 2014-2020
CrossRef109
Abigail S. Caudle, Kelly K. Hunt, Henry M. Kuerer, Funda Meric-Bernstam, Anthony Lucci, Isabelle Bedrosian, Gildy V. Babiera, Rosa F. Hwang, Merrick I. Ross, Barry W. Feig, Karen Hoffman, Jennifer K. Litton, Aysegul A. Sahin, Wei Yang, Gabriel N. Hortobagyi, Thomas A. Buchholz, Elizabeth A. Mittendorf. (2011) Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial. Annals of Surgical Oncology 18:9, 2407-2412
CrossRef110
Katharina Pachmann, O. Camara, T. Kroll, M. Gajda, A. K. Gellner, J. Wotschadlo, I. B. Runnebaum. (2011) Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinoma. Journal of Cancer Research and Clinical Oncology 137:9, 1317-1327
CrossRef111
H. Joensuu, J. Sperinde, M. Leinonen, W. Huang, J. Weidler, P. Bono, V. Kataja, R. Kokko, T. Turpeenniemi-Hujanen, S. Jyrkkio, J. Isola, P.- L. Kellokumpu-Lehtinen, A. Paquet, Y. Lie, M. Bates. (2011) Very high quantitative tumor HER2 content and outcome in early breast cancer. Annals of Oncology 22:9, 2007-2013
CrossRef112
Gretchen Kimmick. (2011) Adjuvant Chemotherapy for Breast Cancer in Older Women: Emerging Evidence to Aid in Decision Making. Current Treatment Options in Oncology 12:3, 286-301
CrossRef113
Radoslaw Zagozdzon, William M. Gallagher, John Crown. (2011) Truncated HER2: implications for HER2-targeted therapeutics. Drug Discovery Today 16:17-18, 810-816
CrossRef114
Ulas Darda Bayraktar, Tae Kon Kim, Katherine Drews-Elger, Cara Benjamin, Dorraya El-Ashry, Eric Wieder, Krishna V. Komanduri. (2011) Simultaneous measurement of ERα, HER2, and PhosphoERK1/2 in breast cancer cell lines by flow cytometry. Breast Cancer Research and Treatment 129:2, 623-628
CrossRef115
Monica Morrow, Armando E. Giuliano. (2011) To Cut Is to Cure: Can We Really Apply Z11 in Practice?. Annals of Surgical Oncology 18:9, 2413-2415
CrossRef116
S. Aebi, T. Davidson, G. Gruber, F. Cardoso, . (2011) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 22:Supplement 6, vi12-vi24
CrossRef117
Vinochani Pillay, Hui K. Gan, Andrew M. Scott. (2011) Antibodies in oncology. New Biotechnology 28:5, 518-529
CrossRef118
Joshua Cohen. (2011) Dearth of clinically useful diagnostics limits growth of personalized medicine. Expert Review of Clinical Pharmacology 4:5, 527-529
CrossRef119
Mohamed B Satti. (2011) Oestrogen receptor/progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer: a 9-year study at Princess Noorah Oncology Center, Saudi Arabia. Histopathology 59:3, 537-542
CrossRef120
J. Huober, P.A. Fasching, M. Barsoum, L. Petruzelka, D. Wallwiener, C. Thomssen, T. Reimer, S. Paepke, H.A. Azim, V. Ragosch, E. Kubista, A.K. Baumgärtner, M.W. Beckmann, C. May, I. Nimmrich, N. Harbeck. (2011) Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial. The Breast
CrossRef121
Sanjay P. Bagaria, Partha S. Ray, Jinhua Wang, Luisa Kropcho, Alice Chung, Myung-Shin Sim, Jaime M. Shamonki, Silvana Martino, Xiaojiang Cui, Armando E. Giuliano. (2011) Prognostic Value of Basal Phenotype in HER2-overexpressing Breast Cancer. Annals of Surgical Oncology
CrossRef122
Kazuhiro Araki, Shigehira Saji, Michelle Gallas, Mark Pegram, Yasutsuna Sasaki. (2011) Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer. Breast Cancer
CrossRef123
Nicholas B. La Thangue, David J. Kerr. (2011) Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nature Reviews Clinical Oncology 8:10, 587-596
CrossRef124
Sara Abu-Ghanem, Anat Rabinovich, Bertha Delgado, Daniel Benharroch, Samuel Ariad, Itai Levi, David B. Geffen. (2011) Chronic myelogenous leukemia diagnosed in two patients with breast cancer. Leukemia & Lymphoma1-3
CrossRef125
Y. A. Lussier, J. L. Chen. (2011) The Emergence of Genome-Based Drug Repositioning. Science Translational Medicine 3:96, 96ps35-96ps35
CrossRef126
C. Serrano, J. Cortes, L. De Mattos-Arruda, M. Bellet, P. Gomez, C. Saura, J. Perez, M. Vidal, E. Munoz-Couselo, M. J. Carreras, G. Sanchez-Olle, J. Tabernero, J. Baselga, S. Di Cosimo. (2011) Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Annals of Oncology
CrossRef127
G Sala, S Traini, M D'Egidio, G Vianale, C Rossi, E Piccolo, R Lattanzio, M Piantelli, N Tinari, P G Natali, R Muraro, S Iacobelli. (2011) An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. Oncogene
CrossRef128
Yasuaki Sagara, Yoshihiko Kamada, Yutaka Yamamoto, Maki Tanaka, Makoto Kubo, Rin Yamaguchi, Reiki Nishimura, Shoshu Mitsuyama. (2011) Study on the state of implementation of HER2 testing and positive ratios in patients with breast cancer in the Kyushu-Okinawa region of Japan. Breast Cancer
CrossRef129
K. D. Miller, A. O'Neill, E. A. Perez, A. D. Seidman, G. W. Sledge. (2011) A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. Annals of Oncology
CrossRef130
A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thurlimann, H.- J. Senn, . (2011) Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology 22:8, 1736-1747
CrossRef131
Roscoe Atkinson, Jens Mollerup, Anne-Vibeke Lænkholm, Mark Verardo, Debra Hawes, Deborah Commins, Birte Engvad, Adrian Correa, Charlotte Cort Ehlers, Kirsten Vang Nielsen. (2011) Effects of the Change in Cutoff Values for Human Epidermal Growth Factor Receptor 2 Status by Immunohistochemistry and Fluorescence In Situ Hybridization: A Study Comparing Conventional Brightfield Microscopy, Image Analysis-Assisted Microscopy, and Interobserver Variation. Archives of Pathology & Laboratory Medicine 135:8, 1010-1016
CrossRef132
Zoe Kemp, Alison Jones. (2011) A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer. Advances in Therapy 28:8, 603-614
CrossRef133
Paromita Raha, Scott Thomas, Pamela N Munster. (2011) Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Epigenomics 3:4, 451-470
CrossRef134
Till Sebastian Clauditz, Maren Reiff, Linn Gravert, Alexander Gnoss, Maria-Christina Tsourlakis, Adrian Münscher, Guido Sauter, Carsten Bokemeyer, Rainald Knecht, Waldemar Wilczak. (2011) Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas. Pathology 43:5, 459-464
CrossRef135
F. Charles Brunicardi, Richard A. Gibbs, David A. Wheeler, John Nemunaitis, William Fisher, John Goss, Changyi Chen. (2011) Overview of the Development of Personalized Genomic Medicine and Surgery. World Journal of Surgery 35:8, 1693-1699
CrossRef136
L. Munck, M. Schaapveld, S. Siesling, J. Wesseling, A. C. Voogd, V. C. G. Tjan-Heijnen, R. Otter, P. H. B. Willemse. (2011) Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands. Breast Cancer Research and Treatment 129:1, 229-233
CrossRef137
J. E. Panoff, J. Hurley, C. Takita, I. M. Reis, W. Zhao, V. Sujoy, C. R. Gomez, M. Jorda, L. Koniaris, J. L. Wright. (2011) Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Research and Treatment 128:3, 899-906
CrossRef138
J.- C. Soria, J. Y. Blay, J. P. Spano, X. Pivot, Y. Coscas, D. Khayat. (2011) Added value of molecular targeted agents in oncology. Annals of Oncology 22:8, 1703-1716
CrossRef139
M. Tahir, T. Robinson, A. Stotter. (2011) How not to neglect the care of elderly breast cancer patients?. The Breast 20:4, 293-296
CrossRef140
Shinya Toyokuni. (2011) Iron as a target of chemoprevention for longevity in humans. Free Radical Research 45:8, 906-917
CrossRef141
Ryohei Adachi, Shota Horiuchi, Yoshiyuki Sakurazawa, Takuya Hasegawa, Koji Sato, Toshiyuki Sakamaki. (2011) ErbB2 down-regulates microRNA-205 in breast cancer. Biochemical and Biophysical Research Communications 411:4, 804-808
CrossRef142
Meng Sun, Yan-min Zhang, Jie Zhang, Si-cen Wang, Lang-chong He. (2011) A high expression EGFR/cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening EGFR antagonists from Rhizoma Polygoni Cuspidati. Acta Pharmaceutica Sinica B 1:2, 115-120
CrossRef143
Y. Belkacémi, A. Fourquet, B. Cutuli, C. Bourgier, M. Hery, G. Ganem, H. Marsiglia, M. Namer, J. Gligorov, D. Azria. (2011) Radiotherapy for invasive breast cancer: Guidelines for clinical practice from the French expert review board of Nice/Saint-Paul de Vence. Critical Reviews in Oncology/Hematology 79:2, 91-102
CrossRef144
S Ladoire, L Arnould, G Mignot, L Apetoh, C Rébé, F Martin, P Fumoleau, B Coudert, F Ghiringhelli. (2011) T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. British Journal of Cancer 105:3, 366-371
CrossRef145
H. K. Chew, G. Somlo, P. C. Mack, B. Gitlitz, R. Gandour-Edwards, S. Christensen, H. Linden, L. J. Solis, X. Yang, A. M. Davies. (2011) Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Annals of Oncology
CrossRef146
A Ring, M Reed, R Leonard, I Kunkler, H Muss, H Wildiers, L Fallowfield, A Jones, R Coleman. (2011) The treatment of early breast cancer in women over the age of 70. British Journal of Cancer 105:2, 189-193
CrossRef147
Ronald M. Witteles, Michael B. Fowler, Melinda L. Telli. (2011) Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?. Heart Failure Clinics 7:3, 333-344
CrossRef148
Sylvain Ladoire, Grégoire Mignot, Sandrine Dabakuyo, Laurent Arnould, Lionel Apetoh, Cedric Rébé, Bruno Coudert, Francois Martin, Marie Hélène Bizollon, André Vanoli, Charles Coutant, Pierre Fumoleau, Franck Bonnetain, François Ghiringhelli. (2011) In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. The Journal of Pathology 224:3, 389-400
CrossRef149
Viviana Barbieri, Pietro Sanpaolo, Domenico Genovesi. (2011) Prognostic Impact of Triple Negative Phenotype in Conservatively Treated Breast Cancer. The Breast Journal 17:4, 377-382
CrossRef150
S. John Weroha, Ann L. Oberg, Katie L. Allen Ziegler, Shaker R. Dakhilm, Kendrith M. Rowland, Lynn C. Hartmann, Dennis F. Moore, Gary L. Keeney, Prema P. Peethambaram, Paul Haluska. (2011) Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecologic Oncology 122:1, 116-120
CrossRef151
Heloisa Sawaya, Juan Carlos Plana, Marielle Scherrer-Crosbie. (2011) Newest Echocardiographic Techniques for the Detection of Cardiotoxicity and Heart Failure During Chemotherapy. Heart Failure Clinics 7:3, 313-321
CrossRef152
Yabing Cao, Yongsheng Lan, Jianfei Qian, Yuhuan Zheng, Sungyoul Hong, Haiyan Li, Michael Wang, Larry W. Kwak, Dongyu Lin, Jing Yang, Qing Yi. (2011) Targeting cell surface β2-microglobulin by pentameric IgM antibodies. British Journal of Haematology 154:1, 111-121
CrossRef153
Giuseppe Bogina, Laura Bortesi, Marcella Marconi, Marco Venturini, Gianluigi Lunardi, Francesca Coati, Alberto Massocco, Erminia Manfrin, Cristina Pegoraro, Giuseppe Zamboni. (2011) Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Archiv 459:1, 1-10
CrossRef154
J G C van Hasselt, A H Boekhout, J H Beijnen, J H M Schellens, A D R Huitema. (2011) Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity. Clinical Pharmacology & Therapeutics 90:1, 126-132
CrossRef155
Shu-Lian Wang, Ye-Xiong Li, Yong-Wen Song, Wei-Hu Wang, Jing Jin, Yue-Ping Liu, Xin-Fan Liu, Zi-Hao Yu. (2011) Triple-Negative or HER2-Positive Status Predicts Higher Rates of Locoregional Recurrence in Node-Positive Breast Cancer Patients After Mastectomy. International Journal of Radiation Oncology*Biology*Physics 80:4, 1095-1101
CrossRef156
Teemu T. Junttila, Guangmin Li, Kathryn Parsons, Gail Lewis Phillips, Mark X. Sliwkowski. (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Research and Treatment 128:2, 347-356
CrossRef157
Simona F. Shaitelman, Leonard H. Kim, Di Yan, Alvaro A. Martinez, Frank A. Vicini, Inga S. Grills. (2011) Continuous Arc Rotation of the Couch Therapy for the Delivery of Accelerated Partial Breast Irradiation: A Treatment Planning Analysis. International Journal of Radiation Oncology*Biology*Physics 80:3, 771-778
CrossRef158
Milayna Subar, WenLong Lin, William Chen, Donald G. Pittman. (2011) Lack of Uniformity in Cardiac Assessment during Trastuzumab Therapy. The Breast Journal 17:4, 383-390
CrossRef159
Patrizia Paterlini-Bréchot. (2011) Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis-capable malignancy. Future Oncology 7:7, 849-871
CrossRef160
Sylvie Lorenzen, Florian Lordick. (2011) How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?. Current Opinion in Oncology 23:4, 396-402
CrossRef161
Krishna K. Singh, Praphulla C. Shukla, Adrian Quan, Fina Lovren, Yi Pan, Jesse I. Wolfstadt, Milan Gupta, Mohammed Al-Omran, Howard Leong-Poi, Hwee Teoh, Subodh Verma. (2011) Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death. Biochemical and Biophysical Research Communications 411:2, 421-426
CrossRef162
Jaclyn Yoong, Michael Michael, Trevor Leong. (2011) Targeted Therapies for Gastric Cancer. Drugs 71:11, 1367-1384
CrossRef163
Yoomi Choi, Eun Joo Kim, Hyesil Seol, Hee Eun Lee, Mi Jung Jang, Sun Mi Kim, Jee Hyun Kim, Sung-Won Kim, Gheeyoung Choe, So Yeon Park. (2011) The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast. Human Pathology
CrossRef164
Su Wei Wong, Kai Hung Tiong, Weng Yip Kong, Yuen Chee Yue, Choon Hooi Chua, Jae Ying Lim, Chai Yuin Lee, Sean I. Quah, Cindy Fow, Cyril Chung, Irene So, Boon Shing Tan, Heng Lungh Choo, Rozita Rosli, Soon-Keng Cheong, Chee-Onn Leong. (2011) Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. Breast Cancer Research and Treatment 128:2, 301-313
CrossRef165
Janneke P.C. Grutters, Shanly C. Seferina, Vivianne C.G. Tjan-Heijnen, Roel J.W. van Kampen, Wim G. Goettsch, Manuela A. Joore. (2011) Bridging Trial and Decision: A Checklist to Frame Health Technology Assessments for Resource Allocation Decisions. Value in Health 14:5, 777-784
CrossRef166
Brigitte Rack, Julia Jückstock, Maria Günthner-Biller, Ulrich Andergassen, Julia Neugebauer, Philip Hepp, Alexandra Schoberth, Doris Mayr, Thomas Zwingers, Christian Schindlbeck, Klaus Friese, Wolfgang Janni. (2011) Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Archives of Gynecology and Obstetrics
CrossRef167
Steven M. Sorscher. (2011) Marked Response to Single Agent Trastuzumab in a Patient with Metastatic HER-2 Gene Amplified Rectal Cancer. Cancer Investigation110622111845059
CrossRef168
Akiyo Horio, Takashi Fujita, Hironori Hayashi, Masaya Hattori, Naoto Kondou, Mai Yamada, Eri Adachi, Aya Ushio, Naomi Gondou, Aiko Sueta, Yasushi Yatabe, Hiroji Iwata. (2011) High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers. International Journal of Clinical Oncology
CrossRef169
Kathryn C. Amirikia, Paul Mills, Jason Bush, Lisa A Newman. (2011) Higher population-based incidence rates of triple-negative breast cancer among young African-American women. Cancer 117:12, 2747-2753
CrossRef170
Eun-Kyung Lim, Yong-Min Huh, Jaemoon Yang, Kwangyeol Lee, Jin-Suck Suh, Seungjoo Haam. (2011) pH-Triggered Drug-Releasing Magnetic Nanoparticles for Cancer Therapy Guided by Molecular Imaging by MRI. Advanced Materials 23:21, 2436-2442
CrossRef171
Rosalba Amodio, Maurizio Zarcone, Rosanna Cusimano, Ildegarda Campisi, Cecilia Dolcemascolo, Adele Traina, Biagio Agostara, Nino Romano. (2011) Target Therapy in HER2-Overexpressing Breast Cancer Patients. OMICS: A Journal of Integrative Biology 15:6, 363-367
CrossRef172
Elżbieta Senkus, Jacek Jassem. (2011) Cardiovascular effects of systemic cancer treatment. Cancer Treatment Reviews 37:4, 300-311
CrossRef173
Elizabeth A Mittendorf, Gheath Alatrash, Haile Xiao, G Travis Clifton, James L Murray, George E Peoples. (2011) Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. Expert Review of Vaccines 10:6, 755-774
CrossRef174
Jonathan Krell, Colin R. James, Deep Shah, Ondrej Gojis, Adrian Lim, Pippa Riddle, Riz Ahmad, Andreas Makris, Andrew Cowdray, Angela Chow, Tamerlan Babayev, Peter Madden, Robert Leonard, Susan Cleator, Carlo Palmieri. (2011) Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Relapsing Post-Adjuvant Trastuzumab: Pattern of Recurrence, Treatment and Outcome. Clinical Breast Cancer 11:3, 153-160
CrossRef175
Cathy A. Andorfer, Brian M. Necela, E. Aubrey Thompson, Edith A. Perez. (2011) MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends in Molecular Medicine 17:6, 313-319
CrossRef176
L. Yao, Y. Liu, Z. Li, T. Ouyang, J. Li, T. Wang, Z. Fan, T. Fan, B. Lin, Y. Xie. (2011) HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Annals of Oncology 22:6, 1326-1331
CrossRef177
Rexxi D. Prasasya, Dan Tian, Pamela K. Kreeger. (2011) Analysis of cancer signaling networks by systems biology to develop therapies. Seminars in Cancer Biology 21:3, 200-206
CrossRef178
Cyrus Chargari, Krassen M. Kirov, Marc A. Bollet, Nicolas Magné, Lionel Védrine, Serge Cremades, Philippe Beuzeboc, Alain Fourquet, Youlia M. Kirova. (2011) Cardiac toxicity in breast cancer patients: From a fractional point of view to a global assessment. Cancer Treatment Reviews 37:4, 321-330
CrossRef179
N. Harbeck, M. S. Ewer, M. De Laurentiis, T. M. Suter, S. M. Ewer. (2011) Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Annals of Oncology 22:6, 1250-1258
CrossRef180
François Bertucci, Nathalie Borie, Henri Roche, Thomas Bachelot, Jean-Marc Doussal, Gaëtan Macgrogan, Stéphane Debono, Agnès Martinec, Isabelle Treilleux, Pascal Finetti, Benjamin Esterni, Jean-Marc Extra, Jean Geneve, Fabienne Hermitte, Christian Chabannon, Jocelyne Jacquemier, Anne-Laure Martin, Michel Longy, Dominique Maraninchi, Vincent Fert, Daniel Birnbaum, Patrice Viens. (2011) Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Research and Treatment 127:2, 363-373
CrossRef181
Shinji Ohno, Kimihiro Tanaka, Chinami Koga, Sumiko Nishimura, Hiroshi Yamaguchi, Hidetoshi Kawaguchi, Tomoyuki Yoshiyama, Yoshiaki Nakamura. (2011) Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?. Breast Cancer
CrossRef182
Jonathan R. Walker, Anita Sharma, Matthew Lytwyn, Sheena Bohonis, James Thliveris, Pawan K. Singal, Davinder S. Jassal. (2011) The Cardioprotective Role of Probucol Against Anthracycline and Trastuzumab-Mediated Cardiotoxicity. Journal of the American Society of Echocardiography 24:6, 699-705
CrossRef183
Wilson Gonsalves, Apar Kishor Ganti. (2011) Targeted anti-cancer therapy in the elderly. Critical Reviews in Oncology/Hematology 78:3, 227-242
CrossRef184
Soo-Kie Kim, Xiaohong Wu, Govind Ragupathi, John Gathuru, Fusataka Koide, Nai-Kong Cheung, Katherine Panageas, Philip O. Livingston. (2011) Impact of minimal tumor burden on antibody response to vaccination. Cancer Immunology, Immunotherapy 60:5, 621-627
CrossRef185
H. J. Chang, S.-W. Han, D.-Y. Oh, S.-A. Im, Y. K. Jeon, I. A. Park, W. Han, D.-Y. Noh, Y.-J. Bang, T.-Y. Kim. (2011) Discordant Human Epidermal Growth Factor Receptor 2 and Hormone Receptor Status in Primary and Metastatic Breast Cancer and Response to Trastuzumab. Japanese Journal of Clinical Oncology 41:5, 593-599
CrossRef186
Roger Y. Tsang, Richard S. Finn. (2011) HER2-positive breast cancer: trastuzumab, lapatinib and emerging therapies. Drug Discovery Today: Therapeutic Strategies
CrossRef187
G. Yavas, F. Yildiz, S. Guler, M. F. Sargon, D. Yildiz, T. Yolcu, M. Tuncer, F. H. Akyol. (2011) Concomitant trastuzumab with thoracic radiotherapy: a morphological and functional study. Annals of Oncology 22:5, 1120-1126
CrossRef188
Frederick L. Baehner, Mark Lee, Michael J. Demeure, Kimberly J. Bussey, Jeffrey A. Kiefer, Michael T. Barrett. (2011) Genomic signatures of cancer: Basis for individualized risk assessment, selective staging and therapy. Journal of Surgical Oncology 103:6, 563-573
CrossRef189
Peter S. Hall, Claire Hulme, Christopher McCabe, Yemi Oluboyede, Jeff Round, David A. Cameron. (2011) Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer. PharmacoEconomics 29:5, 415-432
CrossRef190
P. Cornes. (2011) The economic pressures for biosimilar drug use in cancer medicine. Oncologie 13:5, 222-233
CrossRef191
Joshua P Cohen. (2011) Personalized medicine: are payers the weak link?. Personalized Medicine 8:3, 293-296
CrossRef192
M. Sawaki, N. Tokudome, T. Mizuno, T. Nakayama, N. Taira, H. Bando, S. Murakami, Y. Yamamoto, M. Kashiwaba, H. Iwata, Y. Uemura, Y. Ohashi. (2011) Evaluation of Trastuzumab Without Chemotherapy as a Post-operative Adjuvant Therapy in HER2-positive Elderly Breast Cancer Patients: Randomized Controlled Trial [RESPECT (N-SAS BC07)]. Japanese Journal of Clinical Oncology 41:5, 709-712
CrossRef193
Sally Greenberg, Alison Stopeck, Hope S. Rugo. (2011) Systemic treatment of early breast cancer-a biological perspective. Journal of Surgical Oncology 103:6, 619-626
CrossRef194
Javier Cortés, Cristina Saura, Meritxell Bellet, Eva Muñoz-Couselo, Natalia Ramírez-Merino, Virginia Calvo, Jose Pérez, María Vidal. (2011) HER2 and hormone receptor-positive breast cancer—blocking the right target. Nature Reviews Clinical Oncology 8:5, 307-311
CrossRef195
Thor Edvardsen. (2011) Can Modern Echocardiographic Techniques Predict Drug-Induced Cardiotoxicity?
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 57:22, 2271-2272
CrossRef196
Maurice J. C. Sangen, Fenneke M. M. Wiel, Philip M. P. Poortmans, Vivianne C. G. Tjan-Heijnen, Grard A. P. Nieuwenhuijzen, Rudi M. H. Roumen, Miranda F. Ernst, M. Cathelijne B. J. E. Tutein Nolthenius-Puylaert, Adri C. Voogd. (2011) Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged ≤40 years. Breast Cancer Research and Treatment 127:1, 207-215
CrossRef197
S. Guiu, I. Adoubi, J. C. Kouassi Comoe, P. Fumoleau, B. Coudert. (2011) Trastuzumab et lapatinib dans la prise en charge du cancer du sein HER2 positif. Journal Africain du Cancer / African Journal of Cancer 3:2, 128-140
CrossRef198
Nazanin Fallah-Rad, Jonathan R. Walker, Anthony Wassef, Matthew Lytwyn, Sheena Bohonis, Tielan Fang, Ganhong Tian, Iain D.C. Kirkpatrick, Pawan K. Singal, Marianne Krahn, Debjani Grenier, Davinder S. Jassal. (2011) The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Imaging, and Cardiac Magnetic Resonance Imaging in Predicting Early Left Ventricular Dysfunction in Patients With Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Treated With Adjuvant Trastuzumab Therapy. Journal of the American College of Cardiology 57:22, 2263-2270
CrossRef199
Jona A. Hattangadi-Gluth, Jennifer Y. Wo, Paul L. Nguyen, Rita F. Abi Raad, Meera Sreedhara, Andrzej Niemierko, Phoebe E. Freer, Dianne Georgian-Smith, Jennifer R. Bellon, Julia S. Wong, Barbara L. Smith, Jay R. Harris, Alphonse G. Taghian. (2011) Basal Subtype of Invasive Breast Cancer is Associated with a Higher Risk of True Recurrence After Conventional Breast-Conserving Therapy. International Journal of Radiation Oncology*Biology*Physics
CrossRef200
Masataka Sawaki, Hirofumi Mukai, Nahomi Tokudome, Takahiro Nakayama, Naruto Taira, Toshiro Mizuno, Yutaka Yamamoto, Akiyo Horio, Toru Watanabe, Yukari Uemura, Yasuo Ohashi. (2011) Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study. Breast Cancer
CrossRef201
Elizabeth A Guancial, Dipanjan Chowdhury, Jonathan E Rosenberg. (2011) Personalized therapy for urothelial cancer: review of the clinical evidence. Clinical Investigation 1:4, 543-555
CrossRef202
Alessandra Buja, Egle Perissinotto, Antonio Compostella, Andrea Tramarin, Vincenzo Rebba, Davide Pastorelli, Francesco Grigoletto, Costantino Gallo, Giuseppe Rausa, Dario Gregori. (2011) Taking decisions on expenditure for high-cost drugs at the regional level: a model for evaluating the overall impact of Trastuzumab in the Veneto Region of Italy. Journal of Evaluation in Clinical Practice 17:2, 298-303
CrossRef203
Carlo Palmieri, Deep Shah, Jonathan Krell, Ondrej Gojis, Katy Hogben, Pippa Riddle, Riz Ahmad, Tri Tat, Kevin Fox, Andrew Porter, Sarah Mahmoud, Stephanie Kirschke, Sami Shousha, Mihir Gudi, R. Charles Coombes, Robert Leonard, Susan Cleator. (2011) Management and Outcome of HER2-Positive Early Breast Cancer Treated With or Without Trastuzumab in the Adjuvant Trastuzumab Era. Clinical Breast Cancer 11:2, 93-102
CrossRef204
D H Roukos. (2011) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. The Pharmacogenomics Journal 11:2, 81-92
CrossRef205
Simon Spazzapan, Diana Crivellari, Philippe Bedard, Davide Lombardi, Gianmaria Miolo, Simona Scalone, Andrea Veronesi. (2011) Therapeutic management of breast cancer in the elderly. Expert Opinion on Pharmacotherapy 12:6, 945-960
CrossRef206
Nagi S. El Saghir, Clement A. Adebamowo, Benjamin O. Anderson, Robert W. Carlson, Peter A. Bird, Marilys Corbex, Rajendra A. Badwe, Mohammad A. Bushnaq, Alexandru Eniu, Julie R. Gralow, Jay K. Harness, Riccardo Masetti, Fernando Perry, Massoud Samiei, David B. Thomas, Beatrice Wiafe-Addai, Eduardo Cazap. (2011) Breast cancer management in low resource countries (LRCs): Consensus statement from the Breast Health Global Initiative. The Breast 20, S3-S11
CrossRef207
Timo T. Purmonen, Emma Pänkäläinen, Juha H. O. Turunen, Christian Asseburg, Janne A. Martikainen. (2011) Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncologica 50:3, 344-352
CrossRef208
R. Tanz, T. Mahfoud, A. Bazine, R. Khmamouch, Y. Bensouda, N. Ismaili, N. Benjaafar, B.K. El Gueddari, M. Ichou, H. Errihani. (2011) Tolérance cardiaque du trastuzumab en adjuvant : revue à travers 53 observations. Journal de Gynécologie Obstétrique et Biologie de la Reproduction 40:2, 144-148
CrossRef209
Ronald M. Witteles, Geoffrey Yoon, Melinda Telli, David P. Kao, Kelly Y. Matsuda, Robert W. Carlson. (2011) Reply. Journal of the American College of Cardiology 57:17, 1790-1791
CrossRef210
Siyuan Zhang, Wen-Chien Huang, Ping Li, Hua Guo, Say-Bee Poh, Samuel W Brady, Yan Xiong, Ling-Ming Tseng, Shau-Hsuan Li, Zhaoxi Ding, Aysegul A Sahin, Francisco J Esteva, Gabriel N Hortobagyi, Dihua Yu. (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Medicine 17:4, 461-469
CrossRef211
Paul W. Sperduto, Norbert Kased, David Roberge, Zhiyuan Xu, Ryan Shanley, Xianghua Luo, Penny K. Sneed, Samuel T. Chao, Robert J. Weil, John Suh, Amit Bhatt, Ashley W. Jensen, Paul D. Brown, Helen A. Shih, John Kirkpatrick, Laurie E. Gaspar, John B. Fiveash, Veronica Chiang, Jonathan P.S. Knisely, Christina Maria Sperduto, Nancy Lin, Minesh Mehta. (2011) Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases. International Journal of Radiation Oncology*Biology*Physics
CrossRef212
Christopher M. Booth, Pavlo Ohorodnyk, Liting Zhu, Dongsheng Tu, Ralph M. Meyer. (2011) Randomised controlled trials in oncology closed early for benefit: Trends in methodology, results, and interpretation. European Journal of Cancer 47:6, 854-863
CrossRef213
William C. Wood. (2011) Cooperation in Clinical Trials. Journal of the American College of Surgeons 212:4, 431-439
CrossRef214
Vaishali Bagalkot, Mi Kyung YU, Sangyong Jon. 2011. Nanoparticles for Combined Cancer Imaging and Therapy. , 565-592.
CrossRef215
M. Martin, P. Sanchez-Rovira, M. Munoz, J. M. Baena-Canada, J. R. Mel, M. Margeli, M. Ramos, E. Martinez, J. A. Garcia-Saenz, A. Casado, A. M. Jaen, X. Gonzalez-Farre, M. J. Escudero, C. Rodriguez-Martin, E. Carrasco, . (2011) Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Annals of Oncology
CrossRef216
Tari A. King. (2011) Selecting local therapy in the young breast cancer patient. Journal of Surgical Oncology 103:4, 330-336
CrossRef217
Richard H DE BOER, Arlene CHAN, Ben TRAN, Nicholas WILCKEN. (2011) Use of non-anthracycline regimens in early stage breast cancer in Australia. Asia-Pacific Journal of Clinical Oncology 7:1, 4-10
CrossRef218
Ivana Bozovic-Spasojevic, Hatem A Azim, Marianne Paesmans, Thomas Suter, Martine J Piccart, Evandro de Azambuja. (2011) Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?. The Lancet Oncology 12:3, 209-211
CrossRef219
George Dranitsaris, Ilse Truter, Martie S. Lubbe, Eitan Amir, William Evans. (2011) Advances in Cancer Therapeutics and Patient Access to New Drugs. PharmacoEconomics 29:3, 213-224
CrossRef220
Dennis A. Wigle. (2011) Personalized Therapy for Non–Small Cell Lung Cancer: Hype or Clinical Reality?. Seminars in Thoracic and Cardiovascular Surgery 23:1, 30-35
CrossRef221
Roshawn G. Watson, Howard L. McLeod. (2011) Pharmacogenomic Contribution to Drug Response. The Cancer Journal 17:2, 80-88
CrossRef222
Vishal Rana, Ramona F. Swaby. (2011) Targeted Therapies for HER2 Breast Cancer: A View of the Landscape. Current Breast Cancer Reports 3:1, 55-62
CrossRef223
Elena Geuna, Andrea Milani, Stefania Redana, Valentina Rossi, Giorgio Valabrega, Massimo Aglietta, Filippo Montemurro. (2011) Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. Expert Opinion on Pharmacotherapy 12:4, 549-565
CrossRef224
J. -P. Spano, J. -C. Thery. (2011) Place des thérapies ciblées chez la patiente âgée atteinte de cancer du sein. Oncologie 13:2-3, 97-101
CrossRef225
Luca Gianni, Urania Dafni, Richard D Gelber, Evandro Azambuja, Susanne Muehlbauer, Aron Goldhirsch, Michael Untch, Ian Smith, José Baselga, Christian Jackisch, David Cameron, Max Mano, José Luiz Pedrini, Andrea Veronesi, Cesar Mendiola, Anna Pluzanska, Vladimir Semiglazov, Eduard Vrdoljak, Michael J Eckart, Zhenzhou Shen, George Skiadopoulos, Marion Procter, Kathleen I Pritchard, Martine J Piccart-Gebhart, Richard Bell. (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. The Lancet Oncology 12:3, 236-244
CrossRef226
Marc Buyse, Stefan Michiels, Daniel J Sargent, Axel Grothey, Alastair Matheson, Aimery de Gramont. (2011) Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics 11:2, 171-182
CrossRef227
Daniel Hind, Allan J. Wailoo, Paul Sutcliffe. (2011) Demands for ‘off-licence’ access to trastuzumab (Herceptin): content analysis of UK newspaper articles. Health Expectations 14:1, 38-47
CrossRef228
Paul C. Boutros, Cindy Q. Yao, John D. Watson, Alexander H. Wu, Ivy D. Moffat, Stephenie D. Prokopec, Ashley B. Smith, Allan B. Okey, Raimo Pohjanvirta. (2011) Hepatic transcriptomic responses to TCDD in dioxin-sensitive and dioxin-resistant rats during the onset of toxicity. Toxicology and Applied Pharmacology 251:2, 119-129
CrossRef229
Valentina Rossi, Stefania Redana, Andrea Milani, Elena Geuna, Giorgio Valabrega, Massimo Aglietta, Filippo Montemurro. (2011) Trastuzumab in the adjuvant setting: a practical review. Therapy 8:2, 161-177
CrossRef230
Natalie Galanina, Veerle Bossuyt, Lyndsay N. Harris. (2011) Molecular Predictors of Response to Therapy for Breast Cancer. The Cancer Journal 17:2, 96-103
CrossRef231
Pietro Sanpaolo, Viviana Barbieri, Piernicola Pedicini, Vincenzo Fusco. (2011) Her-2 prognostic value in very early-stage breast cancer: a single-institution retrospective analysis. Medical Oncology
CrossRef232
Hideya Onishi, Takashi Morisaki, Yuji Nakafusa, Yutaka Nakashima, Kazunori Yokohata, Mitsuo Katano. (2011) Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. International Journal of Clinical Oncology
CrossRef233
Yan-Xia Shi, Yu-Ting Tan, Zhong-Yu Yuan, Shu-Sen Wang, Rou-Jun Peng, Xin An, Ye Cao, Ying Jin, Xiu-Yu Cai, Yue-Li Sun, Xiao-Yu Teng, Dong-Geng Liu. (2011) Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer. Medical Oncology
CrossRef234
T. Iwamoto, G. Bianchini, D. Booser, Y. Qi, C. Coutant, C. Ya-Hui Shiang, L. Santarpia, J. Matsuoka, G. N. Hortobagyi, W. F. Symmans, F. A. Holmes, J. O'Shaughnessy, B. Hellerstedt, J. Pippen, F. Andre, R. Simon, L. Pusztai. (2011) Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. JNCI Journal of the National Cancer Institute 103:3, 264-272
CrossRef235
Shaheenah Dawood, Rong Hu, Michelle D. Homes, Laura C. Collins, Stuart J. Schnitt, James Connolly, Graham A. Colditz, Rulla M. Tamimi. (2011) Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Research and Treatment 126:1, 185-192
CrossRef236
Abigail S Caudle, Kelly K Hunt. (2011) The neoadjuvant approach in breast cancer treatment: it is not just about chemotherapy anymore. Current Opinion in Obstetrics and Gynecology 23:1, 31-36
CrossRef237
S. Guiu, M. Liegard, L. Favier, I. van Praagh, R. Largillier, B. Weber, D. Coeffic, L. Moreau, F. Priou, M. Campone, J. Gligorov, L. Vanlemmens, V. Trillet-Lenoir, L. Arnould, B. Coudert. (2011) Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. Annals of Oncology 22:2, 321-328
CrossRef238
Sandra A OʼToole, Christina I Selinger, Ewan K A Millar, Trina Lum, Jane M Beith. (2011) Molecular assays in breast cancer pathology. Pathology 43:2, 116-127
CrossRef239
Aleix Prat, Charles M. Perou. (2011) Deconstructing the molecular portraits of breast cancer. Molecular Oncology 5:1, 5-23
CrossRef240
Robert O. Dillman. (2011) Cancer Immunotherapy. Cancer Biotherapy & Radiopharmaceuticals 26:1, 1-64
CrossRef241
Devika Gajria, Sarat Chandarlapaty. (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Review of Anticancer Therapy 11:2, 263-275
CrossRef242
Rena Callahan, Sara Hurvitz. (2011) Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease. Current Opinion in Obstetrics and Gynecology 23:1, 37-43
CrossRef243
Sabine Riethdorf, Bernhard Hoegel, Birgit John, German Ott, Peter Fritz, Susanne Thon, Thomas Loening, Klaus Pantel. (2011) Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients. Journal of Cancer Research and Clinical Oncology 137:2, 261-269
CrossRef244
M. Aapro, C. Bernard-Marty, E. G. C. Brain, G. Batist, F. Erdkamp, K. Krzemieniecki, R. Leonard, A. Lluch, S. Monfardini, M. Ryberg, P. Soubeyran, U. Wedding. (2011) Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Annals of Oncology 22:2, 257-267
CrossRef245
Florian Lordick. (2011) Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncology 7:2, 187-199
CrossRef246
Takayuki Iwamoto, Giampaolo Bianchini, Yuan Qi, Massimo Cristofanilli, Anthony Lucci, Wendy A. Woodward, James M. Reuben, Junji Matsuoka, Yun Gong, Savitri Krishnamurthy, Vicente Valero, Gabriel N. Hortobagyi, Fredika Robertson, W. Fraser Symmans, Lajos Pusztai, Naoto T. Ueno. (2011) Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Research and Treatment 125:3, 785-795
CrossRef247
Stephen H. Settle, Erik P. Sulman. (2011) Tumor Profiling: Development of Prognostic and Predictive Factors to Guide Brain Tumor Treatment. Current Oncology Reports 13:1, 26-36
CrossRef248
Omid Farokhzad, Robert S. Langer. (2011) Nanoparticle Delivery of Cancer Drugs. Annual Review of Medicine 63:1, 110301100719093
CrossRef249
Montserrat Solá, Mireia Margelí, Eva Castellá, Juan F Julian, Miquel Rull, Josep M Gubern, Antonio Mariscal, Agustí Barnadas, Manuel Fraile. (2011) Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study. BMC Cancer 11:1, 252
CrossRef250
Sarah Lee, Woohee Jung, Soon-Won Hong, Ja Seung Koo. (2011) Evaluation of Intratumoral HER-2 Heterogeneity by Fluorescence In Situ Hybridization in Invasive Breast Cancer: A Single Institution Study. Journal of Korean Medical Science 26:8, 1001
CrossRef251
Toru Mukohara. (2011) Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Science 102:1, 1-8
CrossRef252
Ashley Davidson, Karen Gelmon. (2011) Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?. Future Oncology 7:1, 37-55
CrossRef253
T. Eschenhagen, T. Force, M. S. Ewer, G. W. de Keulenaer, T. M. Suter, S. D. Anker, M. Avkiran, E. de Azambuja, J.-L. Balligand, D. L. Brutsaert, G. Condorelli, A. Hansen, S. Heymans, J. A. Hill, E. Hirsch, D. Hilfiker-Kleiner, S. Janssens, S. de Jong, G. Neubauer, B. Pieske, P. Ponikowski, M. Pirmohamed, M. Rauchhaus, D. Sawyer, P. H. Sugden, J. Wojta, F. Zannad, A. M. Shah. (2011) Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure 13:1, 1-10
CrossRef254
Kanwal P. S. Raghav, Leonel F. Hernandez-Aya, Xiudong Lei, Marianan Chavez-Mac Gregor, Funda Meric-Bernstam, Thomas A. Buchholz, Aysegul Sahin, Kim-Anh Do, Gabriel N. Hortobagyi, Ana M. Gonzalez-Angulo. (2011) Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancern/a-n/a
CrossRef255
Toru Mukohara. (2011) Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer. Chemotherapy Research and Practice 2011, 1-12
CrossRef256
David Khayat. (2011) Innovative cancer therapies. Cancern/a-n/a
CrossRef257
Leiping Wang, Qunling Zhang, Jian Zhang, Si Sun, Haiyi Guo, Zhen Jia, Biyun Wang, Zhimin Shao, Zhonghua Wang, Xichun Hu. (2011) PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 11:1, 248
CrossRef258
Elizabeth A. Mittendorf, Guy T. Clifton, Jarrod P. Holmes, Kevin S. Clive, Ritesh Patil, Linda C. Benavides, Jeremy D. Gates, Alan K. Sears, Alexander Stojadinovic, Sathibalan Ponniah, George E. Peoples. (2011) Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients. Cancern/a-n/a
CrossRef259
Gilberto de Lima Lopes. (2011) Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore. BMC Cancer 11:1, 178
CrossRef260
Erik P. Sulman, Ken Aldape. (2011) The Use of Global Profiling in Biomarker Development for Gliomas. Brain Pathology 21:1, 88-95
CrossRef261
Jiyoung Rhee, Sae-Won Han, Yongjun Cha, Hye Seon Ham, Hwang-phill Kim, Do-Youn Oh, Seock-Ah Im, Jong-Wan Park, Jungsil Ro, Keun Seok Lee, In Hae Park, Young-Hyuck Im, Yung-Jue Bang, Tae-You Kim. (2011) High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. Breast Cancer Research and Treatment 125:1, 107-114
CrossRef262
Mariana Varna, Guilhem Bousquet, Louis-François Plassa, Philippe Bertheau, Anne Janin. (2011) TP53 Status and Response to Treatment in Breast Cancers. Journal of Biomedicine and Biotechnology 2011, 1-9
CrossRef263
Anthony S.-Y. Leong, Zhengping Zhuang. (2011) The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment. Pathobiology 78:2, 99-114
CrossRef264
Wataru Onozato, Keishi Yamashita, Kazuya Yamashita, Tatsuru Kuba, Hiroshi Katoh, Takatoshi Nakamura, Takeo Sato, Atsushi Ihara, Isao Okayasu, Masahiko Watanabe. (2011) Genetic alterations of K-ras may reflect prognosis in stage III colon cancer patients below 60 years of age. Journal of Surgical Oncology 103:1, 25-33
CrossRef265
Günter Mayer, Jens Müller, Christina E. Lünse. (2011) RNA diagnostics: real-time RT-PCR strategies and promising novel target RNAs. Wiley Interdisciplinary Reviews: RNA 2:1, 32-41
CrossRef266
K.P.S. Raghav, A.M. Gonzalez-Angulo. (2011) Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Breast Diseases: A Year Book Quarterly 22:2, 156-158
CrossRef267
Karim S. ElSahwi, Alessandro D. Santin. (2011) erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy. Obstetrics and Gynecology International 2011, 1-5
CrossRef268
Edith Pituskin, Mark Haykowsky, John R Mackey, Richard B Thompson, Justin Ezekowitz, Sheri Koshman, Gavin Oudit, Kelvin Chow, Joseph J Pagano, Ian Paterson. (2011) Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 11:1, 318
CrossRef269
Ana P. Kiess, Heather L. McArthur, Kathleen Mahoney, Sujata Patil, Patrick G. Morris, Alice Ho, Clifford A. Hudis, Beryl McCormick. (2011) Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancern/a-n/a
CrossRef270
Sejal Shah, Beiyun Chen. (2011) Testing for HER2 in Breast Cancer: A Continuing Evolution. Pathology Research International 2011, 1-16
CrossRef271
Yulan Ren, Huaying Wang, Xiaoyan Zhou, Wentao Yang, Xiaowei Huang, Yongming Lu, Daren Shi. (2011) Clinicopathological Characteristics and Her-2/neu Status in Chinese Patients with Uterine Papillary Serous Carcinoma. ISRN Obstetrics and Gynecology 2011, 1-8
CrossRef272
Masahiro Takada, Hiroshi Terunuma, Xuewen Deng, Md. Zahidunnabi Dewan, Shigehira Saji, Katsumasa Kuroi, Naoki Yamamoto, Masakazu Toi. (2011) Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer 18:1, 64-67
CrossRef273
Jeffrey J Barry, Brian J Jian, Michael E Sughrue, Ari J Kane, Steven A Mills, Tarik Tihan, Andrew T Parsa. (2011) The Next Step: Innovative Molecular Targeted Therapies for Treatment of Intracranial Chordoma Patients. Neurosurgery 68:1, 231-241
CrossRef274
Dok Hyun Yoon, Yoon-Koo Kang. (2011) Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial. Clinical Investigation 1:1, 87-95
CrossRef275
Gabriel L. Fiszman, María A. Jasnis. (2011) Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer. International Journal of Breast Cancer 2011, 1-11
CrossRef276
Lorenzo Livi, Icro Meattini, Calogero Saieva, Ciro Franzese, Vanessa Di Cataldo, Daniela Greto, Davide Franceschini, Vieri Scotti, Pierluigi Bonomo, Jacopo Nori, Luis Sanchez, Vania Vezzosi, Simonetta Bianchi, Luigi Cataliotti, Giampaolo Biti. (2011) Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. Cancern/a-n/a
CrossRef277
Elmar Stickeler. (2011) Prognostic and Predictive Markers for Treatment Decisions in Early Breast Cancer. Breast Care 6:3, 193-198
CrossRef278
Anthony Jarkowski, Ashley E Glode, Edward J Spangenthal, Michael K. K Wong. (2011) Heart Failure Caused by Molecularly Targeted Therapies for Cancer. Pharmacotherapy 31:1, 62-75
CrossRef279
M. Joerger, B. Thurlimann, J. Huober. (2011) Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?. Annals of Oncology 22:1, 17-23
CrossRef280
Michael L Gatza, Hsiu-Ni Kung, Kimberly L Blackwell, Mark W Dewhirst, Jeffrey R Marks, Jen-Tsan Chi. (2011) Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Research 13:3, R62
CrossRef281
Hideo Shigematsu, Hidetoshi Kawaguchi, Yoshiaki Nakamura, Kimihiro Tanaka, Satoko Shiotani, Chinami Koga, Sumiko Nishimura, Kenichi Taguchi, Kenichi Nishiyama, Shinji Ohno. (2011) Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000. BMC Cancer 11:1, 118
CrossRef282
Rohit Bhargava, Nicole N. Esposito, David J. Dabbs. 2011. Immunohistology of the Breast. , 763-819.
CrossRef283
Jae Myoung Noh, Doo Ho Choi, Seung Jae Huh, Won Park, Jung Hyun Yang, Seok Jin Nam, Young Hyuck Im, Jin Seok Ahn. (2011) Patterns of Recurrence after Breast-Conserving Treatment for Early Stage Breast Cancer by Molecular Subtype. Journal of Breast Cancer 14:1, 46
CrossRef284
Alfonso Sánchez-Muñoz, Elisabeth Pérez-Ruiz, Jose Manuel Jurado, Nuria Ribelles, Antonia Márquez, Jose Miramón, Maria Maíz, Bella Pajares, Elena Gallego, Victoria Scholtz, Begona Jiménez, Concepcion Soler, Manuel Molina, Isabel García-Ríos, Emilio Alba. (2011) Outcome of Small Invasive Breast Cancer with No Axillary Lymph Node Involvement. The Breast Journal 17:1, 32-38
CrossRef285
Soley Bayraktar, Ana M. Gonzalez-Angulo, Xiudong Lei, Aman U. Buzdar, Vicente Valero, Amal Melhem-Bertrandt, Henry M. Kuerer, Gabriel N. Hortobagyi, Aysegul A. Sahin, Funda Meric-Bernstam. (2011) Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancern/a-n/a
CrossRef286
John A. Vargo, Sushil Beriwal, Gretchen M. Ahrendt, Atilla Soran, Ronald R. Johnson, Kandace McGuire, Rohit Bhargava. (2011) Molecular Class as a Predictor of Locoregional and Distant Recurrence in the Neoadjuvant Setting for Breast Cancer. Oncology 80:5-6, 341-349
CrossRef287
Jan Hysing, Erik Wist. (2011) Kardiotoksiske effekter av trastuzumab. Tidsskrift for Den norske legeforening 131:22, 2239-2241
CrossRef288
Henry Lin, Marija Balic, Siyang Zheng, Ram Datar, Richard J. Cote. (2011) Disseminated and circulating tumor cells: Role in effective cancer management. Critical Reviews in Oncology/Hematology 77:1, 1-11
CrossRef289
Heather L. McArthur, Kathleen M. Mahoney, Patrick G. Morris, Sujata Patil, Lindsay M. Jacks, Jane Howard, Larry Norton, Clifford A. Hudis. (2011) Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancern/a-n/a
CrossRef290
Jean-Paul Guastalla, Olivier Tredan, Isabelle Ray-Coquard, Sana Intidhar Labidi-Galy, Aude Duret, Philippe Cassier, Thomas Bachelot. 2011. Traitements adjuvants du cancer du sein. , 93-105.
CrossRef291
Amedeo Amedei, Marisa Benagiano, Chiara della Bella, Elena Niccolai, Mario M. D'Elios. (2011) Novel Immunotherapeutic Strategies of Gastric Cancer Treatment. Journal of Biomedicine and Biotechnology 2011, 1-17
CrossRef292
Katsutoshi Ando, Norio Masumoto, Masaaki Sakamoto, Kou Teraoka, Takako Suzuki, Terumasa Kurihara, Satoko Abe, Mitsuhiro Tozaki, Eisuke Fukuma, Kazuei Hoshi. (2011) Parotid Gland Metastasis of Breast Cancer: Case Report and Review of the Literature. Breast Care 6:6, 471-473
CrossRef293
Kyeongmee Park, Sehwan Han, Jung-Yeon Kim, Hyun-Jung Kim, Ji Eun Kwon, Geumhee Gwak. (2011) Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer. Journal of Breast Cancer 14:4, 276
CrossRef294
Jeffrey L Nordstrom, Sergey Gorlatov, Wenjun Zhang, Yinhua Yang, Ling Huang, Steve Burke, Hua Li, Valentina Ciccarone, Tengfei Zhang, Jeffrey Stavenhagen, Scott Koenig, Stanford J Stewart, Paul A Moore, Syd Johnson, Ezio Bonvini. (2011) Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc-gamma receptor binding properties. Breast Cancer Research 13:6, R123
CrossRef295
Irene Karam, Alan Nichol, Ryan Woods, Scott Tyldesley. (2011) Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era. Radiation Oncology 6:1, 181
CrossRef296
Mark D. Danese, Deepa Lalla, Melissa Brammer, Quan Doan, Kevin Knopf. (2010) Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States. Cancer 116:24, 5575-5583
CrossRef297
L. Tookman, R. Roylance. (2010) New drugs for breast cancer. British Medical Bulletin 96:1, 111-129
CrossRef298
Hideo Shigematsu, Yoshiaki Nakamura, Kimihiro Tanaka, Satoko Shiotani, Chinami Koga, Hidetoshi Kawaguchi, Sumiko Nishimura, Kenichi Taguchi, Kenichi Nishiyama, Shinji Ohno. (2010) A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment. International Journal of Clinical Oncology 15:6, 615-620
CrossRef299
Nehmat Houssami, Petra Macaskill, M. Luke Marinovich, J. Michael Dixon, Les Irwig, Meagan E. Brennan, Lawrence J. Solin. (2010) Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. European Journal of Cancer 46:18, 3219-3232
CrossRef300
Debora Fumagalli, Christine Desmedt, Martine Piccart, Christos Sotiriou. (2010) Strategies to Incorporate Translational Research Science into Clinical Trials in Breast Cancer. Current Breast Cancer Reports 2:4, 208-213
CrossRef301
Pablo Sanchez-Soria, Todd D. Camenisch. (2010) ErbB signaling in cardiac development and disease. Seminars in Cell & Developmental Biology 21:9, 929-935
CrossRef302
Sallie-Anne Pearson, Melvin Chin, Margaret Faedo, Robyn Ward. (2010) Rationale for treatment durations of targeted cancer agents. The Lancet Oncology 11:12, 1113-1115
CrossRef303
Nobuyoshi Kittaka, Ichiro Takemasa, Shigeto Seno, Yutaka Takeda, Shogo Kobayashi, Shigeru Marubashi, Keizo Dono, Koji Umeshita, Hiroaki Nagano, Hideo Matsuda, Morito Monden, Masaki Mori, Yuichiro Doki. (2010) Exploration of Potential Genomic Portraits Associated with Intrahepatic Recurrence in Human Hepatocellular Carcinoma. Annals of Surgical Oncology 17:12, 3145-3154
CrossRef304
D. Herr, I. Bekes, R. Kreienberg. (2010) Antikörper und Tyrosinkinaseinhibitoren. Der Gynäkologe 43:12, 996-1001
CrossRef305
Gelareh Farshid, Jane E. Armes, Richard Bell, Margaret Cummings, Stephen Fox, Glenn Francis, Martin Haswell, Adrienne Morey, Glenda McCue, Wendy Raymond, Peter Robbins, Michael Bilous. (2010) Establishment of the Australian In Situ Hybridization Program for the Assessment of HER2 Amplification in Breast Cancer. Diagnostic Molecular Pathology 19:4, 187-193
CrossRef306
Nicolas Magné, Cyrus Chargari, Dhara MacDermed, Rosa Conforti, Lionel Védrine, Jean-Philippe Spano, David Khayat. (2010) Tomorrow's targeted therapies in breast cancer patients: What is the risk for increased radiation-induced cardiac toxicity?. Critical Reviews in Oncology/Hematology 76:3, 186-195
CrossRef307
N. S. Bese, C. Umay, S. Serdengecti, N. Kepil, N. Sut, T. Altug, A. Ober. (2010) The impact of trastuzumab on radiation-induced pulmonary fibrosis: results of an experimental study. Medical Oncology 27:4, 1415-1419
CrossRef308
Susana Banerjee, Ian E Smith. (2010) Management of small HER2-positive breast cancers. The Lancet Oncology 11:12, 1193-1199
CrossRef309
Xi-ru Li, Mei Liu, Yan-jun Zhang, Jian-dong Wang, Yi-qiong Zheng, Jie Li, Bing Ma, Xin Song. (2010) CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Medical Oncology
CrossRef310
Allan Lipton, Wolfgang J. Köstler, Kim Leitzel, Suhail M. Ali, Jeff Sperinde, Jodi Weidler, Agnes Paquet, Thomas Sherwood, Weidong Huang, Michael Bates. (2010) Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 116:22, 5168-5178
CrossRef311
Melissa L James, Margot Lehman, Phil N Hider, Mark Jeffery, Brigid E Hickey, Daniel P Francis, Brigid E Hickey. 2010. Fraction size in radiation treatment for breast conservation in early breast cancer. .
CrossRef312
Huguette Albrecht. (2010) Trastuzumab (Herceptin ® ): overcoming resistance in HER2 -overexpressing breast cancer models. Immunotherapy 2:6, 795-798
CrossRef313
Ke Liang, Francisco J. Esteva, Constance Albarracin, Katherine Stemke-Hale, Yang Lu, Giampaolo Bianchini, Ching-Yi Yang, Yong Li, Xinqun Li, Chun-Te Chen, Gordon B. Mills, Gabriel N. Hortobagyi, John Mendelsohn, Mien-Chie Hung, Zhen Fan. (2010) Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation. Cancer Cell 18:5, 423-435
CrossRef314
Baohui Liu, Daofeng Tian, Wei Yi, Liquan Wu, Qiang Cai, Huimin Dong, Heng Shen, Baowei Ji, Long Wang, Shenqi Zhang, Dong Ruan, Qianxue Chen. (2010) Effect of Bone Morphogenetic Protein 4 in the Human Brain Glioma Cell Line U251. Cell Biochemistry and Biophysics 58:2, 91-96
CrossRef315
Geoffrey J. Yoon, Melinda L. Telli, David P. Kao, Kelly Y. Matsuda, Robert W. Carlson, Ronald M. Witteles. (2010) Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies. Journal of the American College of Cardiology 56:20, 1644-1650
CrossRef316
Rebecca A. Burrell, Nicolai Juul, Stephen R. Johnston, Jorge S. Reis-Filho, Zoltan Szallasi, Charles Swanton. (2010) Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer. Journal of Cellular Biochemistry 111:4, 782-790
CrossRef317
R. B. Costa, G. Kurra, L. Greenberg, C. E. Geyer. (2010) Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Annals of Oncology 21:11, 2153-2160
CrossRef318
Yvonne Kienast, Frank Winkler. (2010) Therapy and prophylaxis of brain metastases. Expert Review of Anticancer Therapy 10:11, 1763-1777
CrossRef319
Fredika M. Robertson, Melissa Bondy, Wei Yang, Hideko Yamauchi, Shannon Wiggins, Samira Kamrudin, Savitri Krishnamurthy, Huong Le-Petross, Luc Bidaut, Audrey N. Player, Sanford H. Barsky, Wendy A. Woodward, Thomas Buchholz, Anthony Lucci, Naoto Ueno, Massimo Cristofanilli. (2010) Inflammatory Breast Cancer: The Disease, the Biology, the Treatment. CA: A Cancer Journal for Clinicians 60:6, 351-375
CrossRef320
Zsolt Gabos, John Thoms, Sunita Ghosh, John Hanson, Jean Deschênes, Siham Sabri, Bassam Abdulkarim. (2010) The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Research and Treatment 124:1, 187-194
CrossRef321
Stacy Moulder. (2010) Intrinsic resistance to chemotherapy in breast cancer. Women's Health 6:6, 821-830
CrossRef322
Rita Nahta, Ruth M. O'Regan. (2010) Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway. Clinical Breast Cancer 10:0, S72-S78
CrossRef323
Patricia R. Blank, Matthias Schwenkglenks, Holger Moch, Thomas D. Szucs. (2010) Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost–effectiveness analysis of different predictive assay strategies. Breast Cancer Research and Treatment 124:2, 497-507
CrossRef324
V. Guarneri, E. Barbieri, M.V. Dieci, F. Piacentini, P. Conte. (2010) Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treatment Reviews 36, S62-S66
CrossRef325
S Guiu, M Gauthier, B Coudert, F Bonnetain, L Favier, S Ladoire, H Tixier, B Guiu, F Penault-Llorca, F Ettore, P Fumoleau, L Arnould. (2010) Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer. British Journal of Cancer 103:9, 1335-1342
CrossRef326
Xianglin L. Du, Rui Xia, Keith Burau, Chih-Chin Liu. (2010) Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. Medical Oncology
CrossRef327
Stephane Ederhy, Christophe Massard, Ghislaine Dufaitre, Ratio Balheda, Catherine Meuleman, Carlos Gomez Rocca, Hassane Izzedine, Ariel Cohen, Jean-Charles Soria. (2010) Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. Investigational New Drugs
CrossRef328
Shu-Xia Li, Ashley Sjolund, Lyndsay Harris, Joann B. Sweasy. (2010) DNA repair and personalized breast cancer therapy. Environmental and Molecular Mutagenesis 51:8-9, 897-908
CrossRef329
L.J. Murray, S. Ramakrishnan, L. O'Toole, I.H. Manifold, O.P. Purohit, R.E. Coleman. (2010) Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery. The Breast 19:5, 339-344
CrossRef330
Jason A. Wilken, Nita J. Maihle. (2010) Primary trastuzumab resistance: new tricks for an old drug. Annals of the New York Academy of Sciences 1210:1, 53-65
CrossRef331
Masataka Sawaki, Hiroji Iwata, Yasuyuki Sato, Masaki Wada, Tatsuya Toyama, Eiichi Sasaki, Yasushi Yatabe, Tsuneo Imai, Yasuo Ohashi. (2010) Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer. The Breast 19:5, 370-376
CrossRef332
Julie A. Y. Billar, Amylou C. Dueck, Chee-Chee H. Stucky, Richard J. Gray, Nabil Wasif, Donald W. Northfelt, Ann E. McCullough, Barbara A. Pockaj. (2010) Triple-Negative Breast Cancers: Unique Clinical Presentations and Outcomes. Annals of Surgical Oncology 17:S3, 384-390
CrossRef333
Francisco J. Esteva, Hua Guo, Siyuan Zhang, Cesar Santa-Maria, Steven Stone, Jerry S. Lanchbury, Aysegul A. Sahin, Gabriel N. Hortobagyi, Dihua Yu. (2010) PTEN, PIK3CA, p-AKT, and p-p70S6K Status. The American Journal of Pathology 177:4, 1647-1656
CrossRef334
Lori M. Minasian, William R. Carpenter, Bryan J. Weiner, Darrell E. Anderson, Worta McCaskill-Stevens, Stefanie Nelson, Cynthia Whitman, Joseph Kelaghan, Ann M. O'Mara, Arnold D. Kaluzny. (2010) Translating research into evidence-based practice. Cancer 116:19, 4440-4449
CrossRef335
J. Baselga. (2010) Treatment of HER2-overexpressing breast cancer. Annals of Oncology 21:Supplement 7, vii36-vii40
CrossRef336
Archontoula Stoffel. (2010) Targeted Therapies for Solid Tumors. BioDrugs 24:5, 303-316
CrossRef337
Kathleen A. Cronin, Linda C. Harlan, Kevin W. Dodd, Jeffrey S. Abrams, Rachel Ballard-Barbash. (2010) Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US. Cancer Investigation 28:9, 963-968
CrossRef338
C. Oakman, A. Sapino, C. Marchio, M. Pestrin, L. Biganzoli, A. Di Leo. (2010) Chemotherapy with or without trastuzumab. Annals of Oncology 21:Supplement 7, vii112-vii119
CrossRef339
P. Maroun, J. Gligorov, J. Ohnona, C. Murariu, Y. Belkacémi. (2010) Détermination de HER2 dans les adénocarcinomes pour établir le pronostic et prédire la réponse aux traitements. Bio tribune magazine 36:1, 30-35
CrossRef340
Thaer Khoury, Kazunori Kanehira, Dan Wang, Foluso Ademuyiwa, Wilfrido Mojica, Richard Cheney, Carl Morrison, Jeffrey Conroy, Norma Nowak, Song Liu. (2010) Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis. Modern Pathology 23:10, 1364-1378
CrossRef341
Elisabetta Munzone, Franco Nolé, Aron Goldhirsch, Edoardo Botteri, Angela Esposito, Laura Zorzino, Giuseppe Curigliano, Ida Minchella, Laura Adamoli, Maria Cristina Cassatella, Chiara Casadio, Maria Teresa Sandri. (2010) Changes of HER2 Status in Circulating Tumor Cells Compared With the Primary Tumor During Treatment for Advanced Breast Cancer. Clinical Breast Cancer 10:5, 392-397
CrossRef342
Joseph R. Carver. (2010) Management of Trastuzumab-Related Cardiac Dysfunction. Progress in Cardiovascular Diseases 53:2, 130-139
CrossRef343
Giuseppe Curigliano, Erica L. Mayer, Harold J. Burstein, Eric P. Winer, Aron Goldhirsch. (2010) Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Progress in Cardiovascular Diseases 53:2, 94-104
CrossRef344
Josef Rüschoff, Manfred Dietel, Gustavo Baretton, Susanne Arbogast, Axel Walch, Geneviéve Monges, Marie-Pierre Chenard, Frédérique Penault-Llorca, Iris Nagelmeier, Werner Schlake, H. Höfler, H. H. Kreipe. (2010) HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing. Virchows Archiv 457:3, 299-307
CrossRef345
C. Hofer, B. Schmalfeldt, J.E. Gschwend, K. Herkommer. (2010) Das Mammakarzinom beim Mann. Der Urologe 49:9, 1142-1148
CrossRef346
Denise Yardley, Howard Burris, Nancy Peacock, Eric Raefsky, Marianne Melnik, Roger Inhorn, Dianna Shipley, John Hainsworth. (2010) A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. Breast Cancer Research and Treatment 123:2, 471-475
CrossRef347
Gerald M Higa, Vikramjit Singh, Jame Abraham. (2010) Biological considerations and clinical applications of new HER2-targeted agents. Expert Review of Anticancer Therapy 10:9, 1497-1509
CrossRef348
Michael R. Mallmann, Andrea Staratschek-Jox, Christian Rudlowski, Michael Braun, Andrea Gaarz, Matthias Wolfgarten, Walther Kuhn, Joachim L. Schultze. (2010) Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients. The EPMA Journal 1:3, 421-437
CrossRef349
Monica Morrow. (2010) Trends in the Surgical Treatment of Breast Cancer. The Breast Journal 16, S17-S19
CrossRef350
Jean-Philippe Theurillat, Birgit Dreier, Gabriela Nagy-Davidescu, Burkhardt Seifert, Silvia Behnke, Ursina Zürrer-Härdi, Fabienne Ingold, Andreas Plückthun, Holger Moch. (2010) Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer. Modern Pathology 23:9, 1289-1297
CrossRef351
Otto Metzger Filho, Kamal S. Saini, Hatem A. Azim, Ahmad Awada. (2010) Prevention and management of major side effects of targeted agents in breast cancer. Critical Reviews in Oncology/Hematology
CrossRef352
Stacy L. Moulder. (2010) Novel Cytotoxic Backbones and Targeted Therapies: Recent Data and Ongoing Clinical Trials. Clinical Breast Cancer 10:0, S30-S40
CrossRef353
TS Kristedja, RJ Morgan, M Cristea. (2010) Targeted agents in ovarian cancer. Women's Health 6:5, 679-694
CrossRef354
C A Purdie, L Baker, A Ashfield, S Chatterjee, L B Jordan, P Quinlan, D J A Adamson, J A Dewar, A M Thompson. (2010) Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. British Journal of Cancer 103:4, 475-481
CrossRef355
Sophie Otter, Alistair Ring. (2010) Outcomes following adjuvant therapy for HER2-positive early breast cancer in the elderly. Expert Review of Anticancer Therapy 10:8, 1265-1272
CrossRef356
Cynthia Moreira, Virginia Kaklamani. (2010) Lapatinib and breast cancer: current indications and outlook for the future. Expert Review of Anticancer Therapy 10:8, 1171-1182
CrossRef357
SaeGwang Park, Zhujun Jiang, Eric D. Mortenson, Liufu Deng, Olga Radkevich-Brown, Xuanming Yang, Husain Sattar, Yang Wang, Nicholas K. Brown, Mark Greene, Yang Liu, Jie Tang, Shengdian Wang, Yang-Xin Fu. (2010) The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity. Cancer Cell 18:2, 160-170
CrossRef358
Nicole Schneiderhan-Marra, Georg Sauer, Cornelia Kazmaier, Hsin-Yun Hsu, Karin Koretz, Helmut Deissler, Thomas O. Joos. (2010) Multiplexed immunoassays for the analysis of breast cancer biopsies. Analytical and Bioanalytical Chemistry 397:8, 3329-3338
CrossRef359
Hirofumi Mukai. (2010) Treatment strategy for HER2-positive breast cancer. International Journal of Clinical Oncology 15:4, 335-340
CrossRef360
Gianluca Tomasello, Philippe L. Bedard, Evandro de Azambuja, Dominique Lossignol, Daniel Devriendt, Martine J. Piccart-Gebhart. (2010) Brain metastases in HER2-positive breast cancer: The evolving role of lapatinib. Critical Reviews in Oncology/Hematology 75:2, 110-121
CrossRef361
Bruce G. Haffty, Sharad Goyal. (2010) Molecular Subtyping of Early-Stage Breast Cancer: Implications for Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics 77:5, 1293-1295
CrossRef362
Guillermo Gervasini, Julio Benítez, Juan Antonio Carrillo. (2010) Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. European Journal of Clinical Pharmacology 66:8, 755-774
CrossRef363
Catherine C. Parker, Fred Ampil, Gary Burton, Benjamin D.L. Li, Quyen D. Chu. (2010) Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?. Surgery 148:2, 386-391
CrossRef364
Rajiv Dua, Jianhuan Zhang, Phets Nhonthachit, Elicia Penuel, Chris Petropoulos, Gordon Parry. (2010) EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Research and Treatment 122:3, 685-697
CrossRef365
Jeffrey M. Albert, Ana M. Gonzalez-Angulo, Merih Guray, Aysegul Sahin, Eric A. Strom, Welela Tereffe, Wendy A. Woodward, Susan L. Tucker, Kelly K. Hunt, Gabriel N. Hortobagyi, Thomas A. Buchholz. (2010) Estrogen/Progesterone Receptor Negativity and HER2 Positivity Predict Locoregional Recurrence in Patients With T1a,bN0 Breast Cancer. International Journal of Radiation Oncology*Biology*Physics 77:5, 1296-1302
CrossRef366
Marc A Bollet, Youlia M Kirova, Alain Fourquet, Patricia de Cremoux, Fabien Reyal. (2010) Prognostic factors for local recurrence following breast-conserving treatment in young women. Expert Review of Anticancer Therapy 10:8, 1215-1227
CrossRef367
H. Mukai. (2010) Targeted Therapy in Breast Cancer: Current Status and Future Directions. Japanese Journal of Clinical Oncology 40:8, 711-716
CrossRef368
Alastair J Munro, Paddy G Niblock. (2010) Cancer research in the global village. The Lancet 376:9742, 659-660
CrossRef369
Miguel Martín, Álvaro Rodríguez-Lescure, Amparo Ruiz, Emilio Alba, Lourdes Calvo, Manuel Ruiz-Borrego, Ana Santaballa, César A. Rodríguez, Carmen Crespo, Mar Abad, Severina Domínguez, Jesús Florián, Cristina Llorca, Miguel Méndez, María Godes, Ricardo Cubedo, Adolfo Murias, Norberto Batista, María José García, Rosalía Caballero, Enrique Álava. (2010) Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment 123:1, 149-157
CrossRef370
Ulla Wilking, Bengt Jönsson, Nils Wilking, Jonas Bergh. (2010) Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden. Acta Oncologica 49:6, 844-850
CrossRef371
Alicia F.C. Okines, David Cunningham. (2010) Trastuzumab in gastric cancer. European Journal of Cancer 46:11, 1949-1959
CrossRef372
Xin-Xin Zhou, Feng Ji, Jing-Li Zhao, Lin-Fang Cheng, Cheng-Fu Xu. (2010) Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells. Journal of Gastroenterology and Hepatology 25:7, 1266-1275
CrossRef373
Catherine M. Kelly, Gabriel N. Hortobagyi. (2010) Adjuvant Chemotherapy in Early-Stage Breast Cancer: What, When, and for Whom?. Surgical Oncology Clinics of North America 19:3, 649-668
CrossRef374
Patricia S Kho, Wei Chua, Melissa M Moore, Stephen J Clarke. (2010) Is it prime time for personalized medicine in cancer treatment?. Personalized Medicine 7:4, 387-397
CrossRef375
Andreana L Rivera, Christopher E Pelloski. (2010) Diagnostic and prognostic molecular markers in common adult gliomas. Expert Review of Molecular Diagnostics 10:5, 637-649
CrossRef376
George W. Sledge, Aparna C. Jotwani, Lida Mina. (2010) Targeted Therapies in Early-Stage Breast Cancer: Achievements and Promises. Surgical Oncology Clinics of North America 19:3, 669-679
CrossRef377
Aislyn D. W. Boran, Ravi Iyengar. (2010) Systems Pharmacology. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:4, 333-344
CrossRef378
Britta Weigelt, Alvin T. Lo, Catherine C. Park, Joe W. Gray, Mina J. Bissell. (2010) HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Research and Treatment 122:1, 35-43
CrossRef379
Valentina Macrinici, Edward Romond. (2010) Clinical Updates on EGFR/HER Targeted Agents in Early-Stage Breast Cancer. Clinical Breast Cancer 10:0, E38-E46
CrossRef380
W. Chris Taylor, Hyman B. Muss. (2010) Recent Advances. The Cancer Journal 16:4, 289-293
CrossRef381
Heather L. McArthur, Clifford A. Hudis. (2010) Chemotherapy: Neoadjuvant trial design: time for a brave new world?. Nature Reviews Clinical Oncology 7:7, 359-360
CrossRef382
Shaheenah Dawood. (2010) Novel biomarkers of metastatic cancer. Expert Review of Molecular Diagnostics 10:5, 581-590
CrossRef383
Heidrun Karlic, Harald Herrmann, Axel Schulenburg, Thomas W. Grunt, Sylvia Laffer, Irina Mirkina, Rainer Hubmann, Medhat Shehata, Brigitte Marian, Edgar Selzer, Michael Pfeilstöcker, Elisabeth Pittermann, Ulrich Jäger, Hubert Pehamberger, Christoph Zielinski, Peter Valent. (2010) Tumor-Stammzellforschung – Basis und Herausforderung für Diagnostik und Therapie. Wiener klinische Wochenschrift 122:13-14, 423-436
CrossRef384
Efrat Dotan, Lori J. Goldstein. (2010) Optimizing Chemotherapy Regimens for Patients With Early-Stage Breast Cancer. Clinical Breast Cancer 10:0, E8-E15
CrossRef385
E. Fenton. (2010) Making Fair Funding Decisions for High Cost Cancer Care: The Case of Herceptin in New Zealand. Public Health Ethics 3:2, 137-146
CrossRef386
P. Maroun, J. Gligorov, J. Ohnona, C. Murariu, Y. Belkacémi. (2010) Détermination de HER2 dans les adénocarcinomes pour établir le pronostic et prédire la réponse aux traitements. Oncologie 12:7, 416-421
CrossRef387
Karen E. Hoffman, Thomas A. Buchholz. (2010) How Improved Local-Regional Therapy Impacts Survival. Current Breast Cancer Reports 2:2, 83-89
CrossRef388
Laura S. Dominici, Elizabeth A. Mittendorf, Tse-Kuan Yu, Isabelle Bedrosian. (2010) Impact of Breast Cancer Subtypes on Local-Regional Outcomes. Current Breast Cancer Reports 2:2, 107-113
CrossRef389
F. Grudé, M. Campone, A. Lortholary, R. Delva, P. Soulie, P. Kerbrat, G. Ganem, H. Bourgeois, S. Hulst, E. Vuillemin, A.-C. Hardy-Bessard, M.-J. Goudier, H. Simon, B. Lucas, F. Priou, C. Riché, E. Gamelin. (2010) Étude de phase IV de pharmacovigilance portant sur la toxicité cardiaque du trastuzumab en néoadjuvant et adjuvant dans le cancer du sein. Analyse conduite par l’Observatoire des Médicaments et des Innovations Thérapeutiques de Bretagne et des Pays de la Loire (OMIT B PL). Oncologie 12:5-6, 362-368
CrossRef390
Patrice Viens, Carole Tarpin, Henri Roche, François Bertucci. (2010) Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies. Cancer 116:S11, 2829-2836
CrossRef391
Kai-Keen Shiu, Rachael Natrajan, Felipe C Geyer, Alan Ashworth, Jorge S Reis-Filho. (2010) DNA amplifications in breast cancer: genotypic–phenotypic correlations. Future Oncology 6:6, 967-984
CrossRef392
Marc Buyse, Daniel J. Sargent, Axel Grothey, Alastair Matheson, Aimery de Gramont. (2010) Biomarkers and surrogate end points—the challenge of statistical validation. Nature Reviews Clinical Oncology 7:6, 309-317
CrossRef393
Christina A. Saurel, Tejal A. Patel, Edith A. Perez. (2010) Changes to Adjuvant Systemic Therapy in Breast Cancer: A Decade in Review. Clinical Breast Cancer 10:3, 196-208
CrossRef394
Frances M. Palmieri, Charlyn V. Myatt, Edith A. Perez. (2010) Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer. Clinical Journal of Oncology Nursing 14:3, 326-336
CrossRef395
Karly P. Garnock-Jones, Gillian M. Keating, Lesley J. Scott. (2010) Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer†. BioDrugs 24:3, 207-209
CrossRef396
Cristina Oliveras-Ferraros, Alejandro Vazquez-Martin, Begoña Martin-Castillo, Silvia Cufí, Sonia Del Barco, Eugeni Lopez-Bonet, Joan Brunet, Javier A. Menendez. (2010) Dynamic emergence of the mesenchymal CD44posCD24neg/low phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochemical and Biophysical Research Communications 397:1, 27-33
CrossRef397
Connie G. Chiu, Hamid Masoudi, Samuel Leung, David K. Voduc, Blake Gilks, David G. Huntsman, Sam M. Wiseman. (2010) HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival. Annals of Surgery 251:6, 1107-1116
CrossRef398
Per E. Lønning. (2010) Molecular basis for therapy resistance. Molecular Oncology 4:3, 284-300
CrossRef399
Alejandro Forner, Carlos Rodríguez De Lope, María Reig, Jordi Bruix. (2010) Tratamiento del carcinoma hepatocelular avanzado. Gastroenterología y Hepatología 33:6, 461-468
CrossRef400
Patrick G Morris, Heather L McArthur, Clifford Hudis, Larry Norton. (2010) Dose-dense chemotherapy for breast cancer: what does the future hold?. Future Oncology 6:6, 951-965
CrossRef401
Massimo Cristofanilli. (2010) Novel targeted therapies in inflammatory breast cancer. Cancer 116:S11, 2837-2839
CrossRef402
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Muss, Hyman B., D'Alessandro, Helen Anne, Brachtel, Elena F., . (2010) Case 15-2010. New England Journal of Medicine 362:20, 1921-1928
Full Text403
Geoffrey Y. Ku, David H. Ilson. (2010) Esophagogastric cancer: Targeted agents. Cancer Treatment Reviews 36:3, 235-248
CrossRef404
R.W. Glynn, N. Miller, M.J. Kerin. (2010) 17q12-21 – The pursuit of targeted therapy in breast cancer. Cancer Treatment Reviews 36:3, 224-229
CrossRef405
S. Aebi, T. Davidson, G. Gruber, M. Castiglione, . (2010) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v9-v14
CrossRef406
W. Kwan, A. J. Al-Tourah, C. Speers, R. Woods, H. Kennecke, I. A. Olivotto. (2010) Does HER2 status influence locoregional failure rates in breast cancer patients treated with mastectomy for pT1-2pN0 disease?. Annals of Oncology 21:5, 988-993
CrossRef407
Volkmar Müller, Catherine Alix-Panabières, Klaus Pantel. (2010) Insights into minimal residual disease in cancer patients: Implications for anti-cancer therapies. European Journal of Cancer 46:7, 1189-1197
CrossRef408
Noha Gerges, Nada Jabado. (2010) Biomarkers in cancer micrometastasis: where are we at?. Bioanalysis 2:5, 881-899
CrossRef409
S.G. Coulson, V.S. Kumar, I.M. Manifold, M.Q. Hatton, S. Ramakrishnan, K.S. Dunn, O.P. Purohit, C. Bridgewater, R.E. Coleman. (2010) Review of Testing and Use of Adjuvant Trastuzumab across a Cancer Network — Are We Treating the Right Patients?. Clinical Oncology 22:4, 289-293
CrossRef410
T. Pienkowski, C. C. Zielinski. (2010) Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. Annals of Oncology 21:5, 917-924
CrossRef411
Colin A Purdie, Lee B Jordan, Jean B McCullough, Sharon L Edwards, Joan Cunningham, Miriam Walsh, Andrew Grant, Norman Pratt, Alastair M Thompson. (2010) HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma. Histopathology 56:6, 702-707
CrossRef412
Jennifer Y. Wo, Alphonse G. Taghian, Paul L. Nguyen, Rita Abi Raad, Meera Sreedhara, Jennifer R. Bellon, Julia S. Wong, Michele A. Gadd, Barbara L. Smith, Jay R. Harris. (2010) The Association Between Biological Subtype and Isolated Regional Nodal Failure After Breast-Conserving Therapy. International Journal of Radiation Oncology*Biology*Physics 77:1, 188-196
CrossRef413
Jan Jørgensen. 2010. Pharmacodiagnostics and Personalized Medicine in Cancer. , 325-344.
CrossRef414
Rebecca Scully, Steven E. Lipshultz. 2010. Cardiovascular Toxicity of Antitumor Drugs: Dimensions of the Problem in Children. , 97-126.
CrossRef415
Sabino Ciavarella, Annalisa Milano, Franco Dammacco, Franco Silvestris. (2010) Targeted Therapies in Cancer. BioDrugs 24:2, 77-88
CrossRef416
Li Ma, Ferenc Reinhardt, Elizabeth Pan, Jürgen Soutschek, Balkrishen Bhat, Eric G Marcusson, Julie Teruya-Feldstein, George W Bell, Robert A Weinberg. (2010) Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nature Biotechnology 28:4, 341-347
CrossRef417
Timo T. Purmonen, Päivi K. Auvinen, Janne A. Martikainen. (2010) Budget impact analysis of trastuzumab in early breast cancer: A hospital district perspective. International Journal of Technology Assessment in Health Care 26:02, 163
CrossRef418
Yoshinari Asaoka, Motohisa Tada, Tsuneo Ikenoue, Motoko Seto, Mitsuho Imai, Koji Miyabayashi, Keisuke Yamamoto, Shinzo Yamamoto, Yotaro Kudo, Dai Mohri, Yoshihiro Isomura, Hideaki Ijichi, Keisuke Tateishi, Fumihiko Kanai, Seishi Ogawa, Masao Omata, Kazuhiko Koike. (2010) Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochemical and Biophysical Research Communications 394:4, 1042-1046
CrossRef419
Tim J. Kruser, Deric L. Wheeler. (2010) Mechanisms of resistance to HER family targeting antibodies. Experimental Cell Research 316:7, 1083-1100
CrossRef420
Richard A Morgan, James C Yang, Mio Kitano, Mark E Dudley, Carolyn M Laurencot, Steven A Rosenberg. (2010) Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. Molecular Therapy 18:4, 843-851
CrossRef421
Denise A. Yardley. (2010) Integrating Bevacizumab Into the Treatment of Patients With Early-Stage Breast Cancer: Focus on Cardiac Safety. Clinical Breast Cancer 10:2, 119-129
CrossRef422
M. Lae, J. Couturier, S. Oudard, F. Radvanyi, P. Beuzeboc, A. Vieillefond. (2010) Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Annals of Oncology 21:4, 815-819
CrossRef423
Fabrício F T Barros, Desmond G Powe, Ian O Ellis, Andrew R Green. (2010) Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology 56:5, 560-572
CrossRef424
Marc C Chamberlain. (2010) Anticancer therapies and CNS relapse: overcoming blood–brain and blood–cerebrospinal fluid barrier impermeability. Expert Review of Neurotherapeutics 10:4, 547-561
CrossRef425
Arpad Z. Barabas, Chad D. Cole, Arpad D. Barabas, Richard M. Graeff, Rene Lafreniere, Donald M. Weir. (2010) Modified Vaccination Technique for Prophylactic and Therapeutic Applications to Combat Endogenous Antigen-Induced Disorders. Scandinavian Journal of Immunology 71:3, 125-133
CrossRef426
N. Patani, K. Mokbel. (2010) Herceptin and breast cancer: An overview for surgeons. Surgical Oncology 19:1, e11-e21
CrossRef427
Windy Dean-Colomb, Francisco J. Esteva. (2010) Treatment of Her2-Positive Breast Cancer: What’s on the Horizon. Current Breast Cancer Reports 2:1, 42-52
CrossRef428
Chitta Ranjan Patra, Resham Bhattacharya, Debabrata Mukhopadhyay, Priyabrata Mukherjee. (2010) Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Advanced Drug Delivery Reviews 62:3, 346-361
CrossRef429
Tomás García-Caballero, Dorthe Grabau, Andrew R Green, John Gregory, Arno Schad, Elke Kohlwes, Ian O Ellis, Sarah Watts, Jens Mollerup. (2010) Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology 56:4, 472-480
CrossRef430
Ashwani K. Sood. (2010) PDEF and PDEF-induced proteins as candidate tumor antigens for T cell and antibody-mediated immunotherapy of breast cancer. Immunologic Research 46:1-3, 206-215
CrossRef431
Janet K. Horton, Jan Halle, Madlyn Ferraro, Lisa Carey, Dominic T. Moore, David Ollila, Carolyn I. Sartor. (2010) Radiosensitization of Chemotherapy-Refractory, Locally Advanced or Locally Recurrent Breast Cancer With Trastuzumab: A Phase II Trial. International Journal of Radiation Oncology*Biology*Physics 76:4, 998-1004
CrossRef432
Anil Bagri, Hosein Kouros-Mehr, Kevin G. Leong, Greg D. Plowman. (2010) Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. Trends in Molecular Medicine 16:3, 122-132
CrossRef433
Serena T. Wong, Deborah Toppmeyer. (2010) Adjuvant Chemotherapy for Early Stage Breast Cancer: Current Trends and Future Directions. Current Breast Cancer Reports 2:1, 16-24
CrossRef434
Anne Katrin Berger, Thomas Herrmann. (2010) „Targeted therapies“ in der Behandlung solider Tumoren. Onkopipeline 3:1, 48-51
CrossRef435
Mary E. Abusief, Stacey A. Missmer, Elizabeth S. Ginsburg, Jane C. Weeks, Ann H. Partridge. (2010) The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 116:4, 791-798
CrossRef436
Shaheenah Dawood. (2010) Biology and management of inflammatory breast cancer. Expert Review of Anticancer Therapy 10:2, 209-220
CrossRef437
Dimitrios H Roukos, Dimosthenis Ziogas. (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Review of Anticancer Therapy 10:2, 123-128
CrossRef438
, Paula Manchon, Josep M. Borràs, Tàrsila Ferro, Josep Alfons Espinàs. (2010) Breast cancer OncoGuia. Clinical and Translational Oncology 12:2, 113-137
CrossRef439
James C. Coyne, Howard Tennen, Adelita V. Ranchor. (2010) Positive Psychology in Cancer Care: A Story Line Resistant to Evidence. Annals of Behavioral Medicine 39:1, 35-42
CrossRef440
Nikolas H. Stoecklein, Christoph A. Klein. (2010) Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. International Journal of Cancer 126:3, 589-598
CrossRef441
Maajid Mumtaz Peerzada, Timothy P. Spiro, Hamed A. Daw. (2010) Pulmonary toxicities of biologics: a review. Anti-Cancer Drugs 21:2, 131-139
CrossRef442
Laura Ottini, Domenico Palli, Sergio Rizzo, Mario Federico, Viviana Bazan, Antonio Russo. (2010) Male breast cancer. Critical Reviews in Oncology/Hematology 73:2, 141-155
CrossRef443
Sophie Hamel, Amélie Bouchard, Cristiano Ferrario, Saima Hassan, Adriana Aguilar-Mahecha, Marguerite Buchanan, Louise Quenneville, Wilson Miller, Mark Basik. (2010) Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers. Breast Cancer Research and Treatment 120:1, 47-57
CrossRef444
Amanda Nickles Fader, David Boruta, Alexander B Olawaiye, Paola A Gehrig. (2010) Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Current Opinion in Obstetrics and Gynecology 22:1, 21-29
CrossRef445
Saranya Chumsri, Stacie Jeter, Lisa K. Jacobs, Hind Nassar, Deborah K. Armstrong, Leisha A. Emens, John H. Fetting, Julie R. Lange, Carol Riley, Theodore N. Tsangaris, Antonio C. Wolff, Richard Zellars, Zhe Zhang, Vered Stearns. (2010) Pathologic Complete Response to Preoperative Sequential Doxorubicin/Cyclophosphamide and Single-Agent Taxane With or Without Trastuzumab in Stage II/III HER2-Positive Breast Cancer. Clinical Breast Cancer 10:1, 40-45
CrossRef446
Y. Kataoka, T. Mukohara, H. Shimada, N. Saijo, M. Hirai, H. Minami. (2010) Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Annals of Oncology 21:2, 255-262
CrossRef447
Francisco J. Esteva, Dihua Yu, Mien-Chie Hung, Gabriel N. Hortobagyi. (2010) Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nature Reviews Clinical Oncology 7:2, 98-107
CrossRef448
Yeon Hee Park, Seung Tae Kim, Eun Yoon Cho, Yoon La Choi, Oh-Nam Ok, Hae Jin Baek, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang, Won Park, Doo Ho Choi, Seung Jae Huh, Jin Seok Ahn, Young-Hyuck Im. (2010) A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?. Breast Cancer Research and Treatment 119:3, 653-661
CrossRef449
Joseph A. Sparano, Gabriel N. Hortobagyi, Julie R. Gralow, Edith A. Perez, Robert L. Comis. (2010) Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization. Breast Cancer Research and Treatment 119:3, 511-527
CrossRef450
Emanuel Raschi, Valentina Vasina, Maria Grazia Ursino, Giuseppe Boriani, Andrea Martoni, Fabrizio De Ponti. (2010) Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacology & Therapeutics 125:2, 196-218
CrossRef451
Alba A Brandes, Enrico Franceschi, Alicia Tosoni, Roberta Degli Esposti. (2010) Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. Expert Review of Anticancer Therapy 10:2, 179-184
CrossRef452
Corinne Renier, Hannes Vogel, Onyinye Offor, Chen Yao, Irene Wapnir. (2010) Breast cancer brain metastases express the sodium iodide symporter. Journal of Neuro-Oncology 96:3, 331-336
CrossRef453
Tommaso Susini, Cecilia Bussani, Giulia Marini, Jacopo Nori, Simone Olivieri, Cecilia Molino, Simonetta Bianchi, Vania Vezzosi, Milena Paglierani, Massimo Giachi, Elena Borrani, Gianfranco Scarselli. (2010) Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens. Gynecologic Oncology 116:2, 234-239
CrossRef454
Kan Yonemori, Koji Tsuta, Makiko Ono, Chikako Shimizu, Akihiro Hirakawa, Tadashi Hasegawa, Yutaka Hatanaka, Yoshitaka Narita, Soichiro Shibui, Yasuhiro Fujiwara. (2010) Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu -positive breast cancer. Cancer 116:2, 302-308
CrossRef455
A V Lucs, W J Muller, S K Muthuswamy. (2010) Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity. Oncogene 29:2, 174-187
CrossRef456
Hoenil Jo. (2010) A general perspective on breast disease and training system for breast cancer specialists in Europe. Korean Journal of Obstetrics and Gynecology 53:7, 565
CrossRef457
Aimee M. Crago, Michelle Azu, Shannon Tierney, Monica Morrow. (2010) Randomized Clinical Trials in Breast Cancer. Surgical Oncology Clinics of North America 19:1, 33-58
CrossRef458
Dimitrios H Roukos, Dimosthenis E Ziogas, Christos Katsios. (2010) Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks. Expert Review of Anticancer Therapy 10:8, 1187
CrossRef459
Ana M. Gonzalez-Angulo. (2010) Defining the Lower Limit of Risk, Stage, or Tumor Size for Trastuzumab-Based Adjuvant Chemotherapy for HER2-Positive Breast Cancer. Breast Diseases: A Year Book Quarterly 21:2, 112-115
CrossRef460
Brian Thiessen, Clinton Stewart, Ming Tsao, Suzanne Kamel-Reid, Paula Schaiquevich, Warren Mason, Jacob Easaw, Karl Belanger, Peter Forsyth, Lynn McIntosh, Elizabeth Eisenhauer. (2010) A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemotherapy and Pharmacology 65:2, 353-361
CrossRef461
Sumanta K. Pal, Barrett H. Childs, Mark Pegram. (2010) Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer. Breast Cancer Research and Treatment 119:1, 25-32
CrossRef462
Aristides Polyzos, Nikolaos Malamos, Ioannis Boukovinas, Adamos Adamou, Nikolaos Ziras, Kostas Kalbakis, Stylianos Kakolyris, Kostas Syrigos, Pavlos Papakotoulas, Charalambos Kouroussis, Nikolaos Karvounis, Lambros Vamvakas, Charalambos Christophyllakis, Athanasios Athanasiadis, Ioannis Varthalitis, Vassilis Georgoulias, Dimitris Mavroudis. (2010) FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment 119:1, 95-104
CrossRef463
Melanie D. Seal, Stephen K. Chia. (2010) What Is the Difference Between Triple-Negative and Basal Breast Cancers?. The Cancer Journal 16:1, 12-16
CrossRef464
J.R. Bellon. (2010) Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. Breast Diseases: A Year Book Quarterly 21:4, 373-375
CrossRef465
Sebastian Szmit, Marcin Kurzyna, Renata Glówczynska, Marcin Grabowski, Jaroslaw Kober, Justyna Czerniawska, Krzysztof J Filipiak, Grzegorz Opolski, Cezary Szczylik. (2010) Manageability of Acute Severe Heart Failure Complicated With Left Ventricular Thrombosis During Therapy for Breast Cancer. International Heart Journal 51:2, 141-145
CrossRef466
S.B. Motwani, B.G. Haffty. (2010) Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer. Breast Diseases: A Year Book Quarterly 21:3, 269-270
CrossRef467
Kenji Shibuta, Hiroaki Ueo, Hidemi Furusawa, Kansei Komaki, Yoshiaki Rai, Yoshiatsu Sagara, Yoshihiko Kamada, Nobumitsu Tamaki. (2010) The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer. Breast Cancer 18:4, 292
CrossRef468
Eunyoung Kang, Sang Ah Han, Sairhee Kim, Sun Mi Kim, Mijung Jang, Hee Eun Lee, So Yeon Park, Jae-Young Lim, Eun Joo Yang, In Ah Kim, Yu Kyeong Kim, Chan Yeong Heo, Yu Jung Kim, Jee-Hyun Kim, Jeong-Hyun Kim, Sung-Won Kim. (2010) Five-years of Breast Cancer Management in a New Hospital: Analysis Using Clinical Data Warehouse. Journal of Breast Cancer 13:1, 96
CrossRef469
Cinzia Giordano, Yukun Cui, Ines Barone, Sebastiano Ando, Michael A. Mancini, Valeria Berno, Suzanne A. W. Fuqua. (2010) Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor α and its phosphorylation at serine 305. Breast Cancer Research and Treatment 119:1, 71-85
CrossRef470
Agnieszka M. Rygiel, Francesca Milano, Fiebo J. ten Kate, Jacques J. G. H. M. Bergman, Kausillia K. Krishnadath. (2010) Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus. Journal of Oncology 2010, 1-8
CrossRef471
Major Kenneth Lee IV, Anupama Sharma, Brian J Czerniecki. (2010) It’s all in for the HER family in tumorigenesis. Expert Review of Vaccines 9:1, 29-34
CrossRef472
Yazid Belkacémi, Joseph Gligorov. (2010) Concurrent trastuzumab – Internal mammary irradiation for HER2 positive breast cancer: “It hurts to be on the cutting edge”. Radiotherapy and Oncology 94:1, 119-120
CrossRef473
Karly P. Garnock-Jones, Gillian M. Keating, Lesley J. Scott. (2010) Trastuzumab. Drugs 70:2, 215-239
CrossRef474
Mary Jo Lund, Ebonee N. Butler, Brionna Y. Hair, Kevin C. Ward, Judy H. Andrews, Gabriella Oprea-Ilies, A. Rana Bayakly, Ruth M. O'Regan, Paula M. Vertino, J. William Eley. (2010) Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes. CancerNA-NA
CrossRef475
Sejal S. Shah, Rhett P. Ketterling, Matthew P. Goetz, James N. Ingle, Carol A. Reynolds, Edith A. Perez, Beiyun Chen. (2010) Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Human Pathology 41:1, 103-106
CrossRef476
Cathy B Moelans, Roel A de Weger, Marja TM van Blokland, Elsken van der Wall, Paul J van Diest. (2010) Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Modern Pathology 23:1, 62-70
CrossRef477
Ruchi Saxena, Anila Dwivedi. (2010) ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Medicinal Research Reviewsn/a-n/a
CrossRef478
Tatjana Ivkovic-Kapicl, Slavica Knezevic-Usaj. (2010) Human epidermal growth factor receptor 2 testing in breast cancer. Medicinski pregled 63:1-2, 69-74
CrossRef479
Michael E. Stefanek, Steven C. Palmer, Brett D. Thombs, James C. Coyne. (2009) Finding what is not there. Cancer 115:24, 5612-5616
CrossRef480
Peter G. Kaufmann. (2009) Psychosocial interventions in breast cancer. Cancer 115:24, 5617-5619
CrossRef481
Thomas R. Geiger, Daniel S. Peeper. (2009) Metastasis mechanisms. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1796:2, 293-308
CrossRef482
Yi Wang, Xinrong Liu, Ling Chen, Dengfeng Cheng, Mary Rusckowski, Donald J. Hnatowich. (2009) Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle. European Journal of Nuclear Medicine and Molecular Imaging 36:12, 1977-1986
CrossRef483
Austin Duffy, Shivaani Kummar. (2009) Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. Targeted Oncology 4:4, 267-273
CrossRef484
Julia Aigner, Andreas Schneeweiss. (2009) Systemtherapie des Mammakarzinoms. Onkopipeline 2:4, 171-184
CrossRef485
Thoralf Christoffersen, Tormod K. Guren, Karen-Lise Garm Spindler, Olav Dahl, Per Eystein Lønning, Bjørn Tore Gjertsen. (2009) Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology 625:1-3, 6-22
CrossRef486
Anna Bergamaschi, Geir Olav Hjortland, Tiziana Triulzi, Therese Sørlie, Hilde Johnsen, Anne Hansen Ree, Hege Giercksky Russnes, Sigurd Tronnes, Gunhild M. Mælandsmo, Oystein Fodstad, Anne-Lise Borresen-Dale, Olav Engebraaten. (2009) Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Molecular Oncology 3:5-6, 469-482
CrossRef487
Alberto Ocaña, Eitan Amir. (2009) Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions. Cancer Treatment Reviews 35:8, 685-691
CrossRef488
Kathryn M. Kash, Smiriti Sharma, Neil I. Goldfarb. (2009) Is Disease Management Right for Oncology?. Population Health Management 12:6, 337-343
CrossRef489
Hossein Borghaei, Mitchell R. Smith, Kerry S. Campbell. (2009) Immunotherapy of cancer. European Journal of Pharmacology 625:1-3, 41-54
CrossRef490
Cynthia Owusu. (2009) Clinical Management Update: Evaluation and Management of Older Patients with Breast Cancer. Journal of the American Geriatrics Society 57, 250-252
CrossRef491
O. Gluz, C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz, N. Harbeck. (2009) Triple-negative breast cancer--current status and future directions. Annals of Oncology 20:12, 1913-1927
CrossRef492
Hwee Tong Tan, Jiayi Low, Seng Gee Lim, Maxey C. M. Chung. (2009) Serum autoantibodies as biomarkers for early cancer detection. FEBS Journal 276:23, 6880-6904
CrossRef493
S. E. Taube, G. M. Clark, J. E. Dancey, L. M. McShane, C. C. Sigman, S. I. Gutman. (2009) A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment. JNCI Journal of the National Cancer Institute 101:21, 1453-1463
CrossRef494
Nan Soon Wong, Benjamin O Anderson, Kei Siong Khoo, Peng Tiam Ang, Cheng Har Yip, Yen-Shen Lu, Narind Voravud, Zhi-Ming Shao, Kathleen I Pritchard. (2009) Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. The Lancet Oncology 10:11, 1077-1085
CrossRef495
A. Schneeweiss. (2009) Mammakarzinom. Der Gynäkologe 42:11, 841-846
CrossRef496
Karen Y. Wonders, David S. Hydock, Stephanie Greufe, Carole M. Schneider, Reid Hayward. (2009) Endurance exercise training preserves cardiac function in rats receiving doxorubicin and the HER-2 inhibitor GW2974. Cancer Chemotherapy and Pharmacology 64:6, 1105-1113
CrossRef497
Hamdy Azim, Hatem A. Azim, Bernard Escudier. (2009) Trastuzumab versus lapatinib: The cardiac side of the story. Cancer Treatment Reviews 35:7, 633-638
CrossRef498
Amanda Nickles Fader, David Boruta, Alexander B Olawaiye, Paola A Gehrig. (2009) Updates on uterine papillary serous carcinoma. Expert Review of Obstetrics & Gynecology 4:6, 647-657
CrossRef499
Shawn P. Fessler, Mark T. Wotkowicz, Sanjeev K. Mahanta, Cynthia Bamdad. (2009) MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Research and Treatment 118:1, 113-124
CrossRef500
M. D. Green, P. A. Francis, V. Gebski, V. Harvey, C. Karapetis, A. Chan, R. Snyder, A. Fong, R. Basser, J. F. Forbes, . (2009) Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Annals of Oncology 20:11, 1813-1817
CrossRef501
J-S Frenel, E Bourbouloux, D Berton-Rigaud, S Sadot-Lebouvier, A Zanetti, M Campone. (2009) Lapatinib in metastatic breast cancer. Women's Health 5:6, 603-612
CrossRef502
Louis P. Garrison, David L. Veenstra. (2009) The Economic Value of Innovative Treatments over the Product Life Cycle: The Case of Targeted Trastuzumab Therapy for Breast Cancer. Value in Health 12:8, 1118-1123
CrossRef503
Giovanna Damia, Maurizio D’Incalci. (2009) Contemporary pre-clinical development of anticancer agents – What are the optimal preclinical models?. European Journal of Cancer 45:16, 2768-2781
CrossRef504
(2009) Le cancer du sein chez la femme âgée (hors situation métastatique). Oncologie 11:11, 533-551
CrossRef505
D. Collins, A.D.K. Hill, L. Young. (2009) Lapatinib: A competitor or companion to trastuzumab?. Cancer Treatment Reviews 35:7, 574-581
CrossRef506
M E Montañez-Wiscovich, D D Seachrist, M D Landis, J Visvader, B Andersen, R A Keri. (2009) LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression. Oncogene 28:41, 3608-3618
CrossRef507
Xiaolei Zhou, David Cella, David Cameron, Mayur M. Amonkar, Anthony Segreti, Steven Stein, Mel Walker, Charles E. Geyer. (2009) Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Research and Treatment 117:3, 577-589
CrossRef508
Susan Bahl, Robert E. Roses, Anupama Sharma, Ursula Koldovsky, Shuwen Xu, Susan Weinstein, Harvey Nisenbaum, Kevin Fox, Theresa Pasha, Paul Zhang, Louis Araujo, Joseph Carver, Brian J. Czerniecki. (2009) Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu–pulsed dendritic cell vaccines. The American Journal of Surgery 198:4, 488-494
CrossRef509
Mikiya Ishihara, Hirofumi Mukai, Shunji Nagai, Toru Mukohara. (2009) Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer. International Journal of Clinical Oncology 14:5, 431-435
CrossRef510
Wendy A. Woodward, Massimo Cristofanilli. (2009) Inflammatory Breast Cancer. Seminars in Radiation Oncology 19:4, 256-265
CrossRef511
Carole Perez-Ellis, Anthony Goncalves, Jocelyne Jacquemier, Michel Marty, Véronique Girre, Henri Roché, Etienne Brain, Jean-Paul Moatti, Patrice Viens, Anne-Gaëlle Le Corroller-Soriano. (2009) Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer. American Journal of Clinical Oncology 32:5, 492-498
CrossRef512
Larissa J. Lee, Jay R. Harris. (2009) Innovations in radiation therapy (RT) for breast cancer. The Breast 18, S103-S111
CrossRef513
Philippe L. Bedard, Phuong Dinh, Christos Sotiriou, Martine J. Piccart-Gebhart. (2009) Aiming at the target: improved adjuvant medical therapy. The Breast 18, S25-S30
CrossRef514
Nathan M. Shumway, Nuhad Ibrahim, Sathibalan Ponniah, George E. Peoples, James L. Murray. (2009) Therapeutic Breast Cancer Vaccines. BioDrugs 23:5, 277-287
CrossRef515
Shani Paluch-Shimon, Noa Ben-Baruch, Ido Wolf, Lior Zach, Juri Kopolovic, Anna Kruglikova, Tami Modiano, Ady Yosepovich, Raphael Catane, Bella Kaufman. (2009) Hormone Receptor Expression Is Associated With a Unique Pattern of Metastatic Spread and Increased Survival Among HER2-Overexpressing Breast Cancer Patients. American Journal of Clinical Oncology 32:5, 504-508
CrossRef516
Kathryn E. Huber, Lisa A. Carey, David E. Wazer. (2009) Breast Cancer Molecular Subtypes in Patients With Locally Advanced Disease: Impact on Prognosis, Patterns of Recurrence, and Response to Therapy. Seminars in Radiation Oncology 19:4, 204-210
CrossRef517
Alfonso Sánchez-Muñoz, Elisabeth Pérez-Ruiz, Begoña Jiménez, Nuria Ribelles, Antonia Márquez, Isabel García-Ríos, Emilio Alba Conejo. (2009) Targeted therapy of metastatic breast cancer. Clinical and Translational Oncology 11:10, 643-650
CrossRef518
M. Morrow. (2009) Breast conservation and negative margins: how much is enough?. The Breast 18, S84-S86
CrossRef519
Felipe C. Geyer, Maria A. Lopez-Garcia, Maryou B. Lambros, Jorge S. Reis-Filho. (2009) Genetic characterization of breast cancer and implications for clinical management. Journal of Cellular and Molecular Medicine 13:10, 4090-4103
CrossRef520
Lisa Wiechmann, Michelle Sampson, Michelle Stempel, Lindsay M. Jacks, Sujata M. Patil, Tari King, Monica Morrow. (2009) Presenting Features of Breast Cancer Differ by Molecular Subtype. Annals of Surgical Oncology 16:10, 2705-2710
CrossRef521
Maya Guglin, Gregory Hartlage, Christopher Reynolds, Ren Chen, Vinod Patel. (2009) Trastuzumab-Induced Cardiomyopathy: Not as Benign as it Looks? A Retrospective Study. Journal of Cardiac Failure 15:8, 651-657
CrossRef522
Deepa Wadhwa, Nazanin Fallah-Rad, Debjani Grenier, Marianne Krahn, Tielan Fang, Roien Ahmadie, Jonathan R. Walker, Danica Lister, Rakesh C. Arora, Ivan Barac, Andrew Morris, Davinder S. Jassal. (2009) Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Research and Treatment 117:2, 357-364
CrossRef523
J. Boone, R. van Hillegersberg, G. J. A. Offerhaus, P. J. van Diest, I. H. M. Borel Rinkes, F. J. W. ten Kate. (2009) Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Diseases of the Esophagus 22:6, 496-504
CrossRef524
Irfan Cicin, Hakan Karagol, Ufuk Usta, Atakan Sezer, Sernaz Uzunoglu, Rusen Alas-Cosar, Tarkan Yetisyigit, Kazim Uygun. (2009) Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer. Medical Oncology 26:3, 335-343
CrossRef525
Giuseppe Viale. (2009) Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. The Journal of Pathology 219:1, 1-2
CrossRef526
Toru Mukohara, Hiroyuki Shimada, Naomi Ogasawara, Ryoko Wanikawa, Manami Shimomura, Tetsuya Nakatsura, Genichiro Ishii, Joon Oh Park, Pasi A. Jänne, Nagahiro Saijo, Hironobu Minami. (2009) Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. Cancer Letters 282:1, 14-24
CrossRef527
Chung-Ming Tu, Kai-Ming Chu, Shin-Ping Yang, Shu-Mung Cheng, Wen-been Wang. (2009) Trastuzumab (Herceptin)–associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: a case report and literature review. The American Journal of Emergency Medicine 27:7, 903.e1-903.e3
CrossRef528
Elizabeth L. Strevel, Lillian L. Siu. (2009) Cardiovascular toxicity of molecularly targeted agents. European Journal of Cancer 45, 318-331
CrossRef529
Sabine C. Linn, Laura J. Van 't Veer. (2009) Clinical relevance of the triple-negative breast cancer concept: Genetic basis and clinical utility of the concept. European Journal of Cancer 45, 11-26
CrossRef530
T. Fojo, C. Grady. (2009) How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. JNCI Journal of the National Cancer Institute 101:15, 1044-1048
CrossRef531
Jaclyn A. Freudenberg, Qiang Wang, Makoto Katsumata, Jeffrey Drebin, Izumi Nagatomo, Mark I. Greene. (2009) The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Experimental and Molecular Pathology 87:1, 1-11
CrossRef532
Ana Maria López, Anna R. Graham, Gail P. Barker, Lynne C. Richter, Elizabeth A. Krupinski, Fangru Lian, Lauren L. Grasso, Ashley Miller, Lindsay N. Kreykes, Jeffrey T. Henderson, Achyut K. Bhattacharyya, Ronald S. Weinstein. (2009) Virtual slide telepathology enables an innovative telehealth rapid breast care clinic. Human Pathology 40:8, 1082-1091
CrossRef533
Meng-Lay Lin, Chikako Fukukawa, Jae-Hyun Park, Kie Naito, Kyoko Kijima, Arata Shimo, Masahiko Ajiro, Toshihiko Nishidate, Yusuke Nakamura, Toyomasa Katagiri. (2009) Involvement of G-patch domain containing 2 overexpression in breast carcinogenesis. Cancer Science 100:8, 1443-1450
CrossRef534
R.C.F. Leonard, S. Williams, A. Tulpule, A.M. Levine, S. Oliveros. (2009) Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet™). The Breast 18:4, 218-224
CrossRef535
Eliyaz Ahamed, Francesco A Mauri, Grant Pakter, Adrian Lim, Justin Stebbing. (2009) Trastuzumab: unusual responses and toxicities. Future Oncology 5:6, 779-784
CrossRef536
Geeta Lal, Samad Hashimi, Brian J. Smith, Charles F. Lynch, Lurong Zhang, Robert A. Robinson, Ronald J. Weigel. (2009) Extracellular Matrix 1 (ECM1) Expression Is a Novel Prognostic Marker for Poor Long-Term Survival in Breast Cancer: A Hospital-Based Cohort Study in Iowa. Annals of Surgical Oncology 16:8, 2280-2287
CrossRef537
Adam Brufsky. (2009) Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer. American Journal of Clinical Oncology1
CrossRef538
Y. H. Choi, J. H. Ahn, S.-B. Kim, K.-H. Jung, G.-Y. Gong, M.-J. Kim, B.-H. Son, S.-H. Ahn, W. K. Kim. (2009) Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Annals of Oncology 20:8, 1337-1343
CrossRef539
A. Goldhirsch, J. N. Ingle, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, . (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Annals of Oncology 20:8, 1319-1329
CrossRef540
James L. Hare, Joseph K. Brown, Rodel Leano, Carly Jenkins, Natasha Woodward, Thomas H. Marwick. (2009) Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. American Heart Journal 158:2, 294-301
CrossRef541
Pelagia G. Tsoutsou, Michael I. Koukourakis, David Azria, Yazid Belkacémi. (2009) Optimal timing for adjuvant radiation therapy in breast cancerA comprehensive review and perspectives. Critical Reviews in Oncology/Hematology 71:2, 102-116
CrossRef542
Kristopher C. Carver, Lisa M. Arendt, Linda A. Schuler. (2009) Complex prolactin crosstalk in breast cancer: New therapeutic implications. Molecular and Cellular Endocrinology 307:1-2, 1-7
CrossRef543
D. Takabatake, N. Taira, F. Hara, T. Sien, S. Kiyoto, S. Takashima, K. Aogi, S. Ohsumi, H. Doihara, S. Takashima. (2009) Feasibility Study of Docetaxel with Cyclophosphamide as Adjuvant Chemotherapy for Japanese Breast Cancer Patients. Japanese Journal of Clinical Oncology 39:8, 478-483
CrossRef544
Alberto Patriti, Graziano Ceccarelli, Luciano Casciola. (2009) Author reply to the letter to the Editor “Robotic D2 surgery for gastric cancer”. Surgical Endoscopy 23:8, 1922-1923
CrossRef545
Mary Leung, Iulianna Shapira, Thomas Bradley, Daniel R. Budman. (2009) Adjuvant Chemotherapy for Early Breast Cancer in the Elderly. Current Treatment Options in Oncology 10:3-4, 144-158
CrossRef546
C. Shimizu, N. Masuda, K. Yoshimura, H. Tsuda, M. Mano, M. Ando, K. Tamura, Y. Fujiwara. (2009) Long-term Outcome and Pattern of Relapse after Neoadjuvant Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 2-positive Primary Breast Cancer. Japanese Journal of Clinical Oncology 39:8, 484-490
CrossRef547
Chris Skedgel, Daniel Rayson, Tallal Younis. (2009) The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial. Value in Health 12:5, 641-648
CrossRef548
Shelby D. Reed, Kevin A. Schulman. (2009) Cost Utility of Sequential Adjuvant Trastuzumab for HER2/Neu-Positive Breast Cancer. Value in Health 12:5, 637-640
CrossRef549
Fernando Schmitt. (2009) HER2+ breast cancer: How to evaluate?. Advances in Therapy 26:S1, 1-8
CrossRef550
Hideko Yamauchi, Massimo Cristofanilli, Seigo Nakamura, Gabriel N. Hortobagyi, Naoto T. Ueno. (2009) Molecular targets for treatment of inflammatory breast cancer. Nature Reviews Clinical Oncology 6:7, 387-394
CrossRef551
Tyler Lahusen, Ralf T. Henke, Benjamin L. Kagan, Anton Wellstein, Anna T. Riegel. (2009) The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Research and Treatment 116:2, 225-237
CrossRef552
Dimosthenis Ziogas, Dimitrios H. Roukos. (2009) Genetics and Personal Genomics for Personalized Breast Cancer Surgery: Progress and Challenges in Research and Clinical Practice. Annals of Surgical Oncology 16:7, 1771-1782
CrossRef553
Bert van der Vegt, Geertruida H de Bock, Joost Bart, Nick G Zwartjes, Jelle Wesseling. (2009) Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer. Modern Pathology 22:7, 879-886
CrossRef554
José Baselga, Sandra M. Swain. (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer 9:7, 463-475
CrossRef555
D. R. Rhodes, B. Ateeq, Q. Cao, S. A. Tomlins, R. Mehra, B. Laxman, S. Kalyana-Sundaram, R. J. Lonigro, B. E. Helgeson, M. S. Bhojani, A. Rehemtulla, C. G. Kleer, D. F. Hayes, P. C. Lucas, S. Varambally, A. M. Chinnaiyan. (2009) AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proceedings of the National Academy of Sciences 106:25, 10284-10289
CrossRef556
Evandro Azambuja, Philippe L. Bedard, Thomas Suter, Martine Piccart-Gebhart. (2009) Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?. Targeted Oncology 4:2, 77-88
CrossRef557
David Jamieson, Nicola Cresti, Mark W Verrill, Alan V. Boddy. (2009) Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma. Journal of Immunological Methods 345:1-2, 106-111
CrossRef558
Takashi Oshima, Xuefei Cao, Fedora Grande, Roppei Yamada, Antonio Garofalo, Stan Louie, Nouri Neamati. (2009) Combination effects of SC144 and cytotoxic anticancer agents. Anti-Cancer Drugs 20:5, 312-320
CrossRef559
Bingfeng Sun, Si-Shen Feng. (2009) Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel. Nanomedicine 4:4, 431-445
CrossRef560
Tsz-Kok YAU, Ting-Ying NG, Inda Sung SOONG, Chi-Wai CHOI, ka-On LAM, Alice Wan-Ying NG, Anne Wing-Mui LEE, Yuk TUNG. (2009) Toxicity of docetaxel plus cyclophosphamide as adjuvant therapy for breast cancer in Chinese patients - the Hong Kong experience. Asia-Pacific Journal of Clinical Oncology 5:2, 123-128
CrossRef561
Thomas W. Flaig, Lih-Jen Su, Caroline McCoach, Yuan Li, David Raben, Marileila Varella-Garcia, Lynne T. Bemis. (2009) Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU International 103:12, 1729-1737
CrossRef562
Edward T.H. Yeh, Courtney L. Bickford. (2009) Cardiovascular Complications of Cancer Therapy. Journal of the American College of Cardiology 53:24, 2231-2247
CrossRef563
H. Masmoudi, S.M. Hewitt, N. Petrick, K.J. Myers, M.A. Gavrielides. (2009) Automated Quantitative Assessment of HER-2/neu Immunohistochemical Expression in Breast Cancer. IEEE Transactions on Medical Imaging 28:6, 916-925
CrossRef564
Aman U. Buzdar. (2009) Medical oncology: Endocrine-therapy-related symptoms and breast cancer. Nature Reviews Clinical Oncology 6:6, 309-310
CrossRef565
Ilana Kadmon, Frida Barak. (2009) Multidisciplinary approach to breast cancer: A new outlook on nursing care. Clinical Oncology and Cancer Research 6:3, 157-161
CrossRef566
A. U. Buzdar. (2009) Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Annals of Oncology 20:6, 993-999
CrossRef567
I. Pauporté, C. Faure, X. Pivot. (2009) Impulser la recherche clinique française dans le cancer du sein: l’exemple de l’essai PHARE. Oncologie 11:6, 348-352
CrossRef568
Joan Albanell, Xavier Andreu, María José Calasanz, Ángel Concha, José María Corominas, Tomás García-Caballero, José Antonio López, Fernando López-Ríos, Santiago Ramón y Cajal, Francisco J. Vera-Sempere, Ramón Colomer, Miguel Martín, Emilio Alba, Antonio González-Martín, Antonio Llombart, Ana Lluch, José Palacios. (2009) Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clinical and Translational Oncology 11:6, 363-375
CrossRef569
Yu Shen, Wenli Dong, Barry W. Feig, Peter Ravdin, Richard L. Theriault, Sharon H. Giordano. (2009) Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004. Cancer 115:10, 2041-2051
CrossRef570
L. Quaye, D. Dafou, S. J. Ramus, H. Song, A. G. Maharaj, M. Notaridou, E. Hogdall, S. K. Kjaer, L. Christensen, C. Hogdall, D. F. Easton, I. Jacobs, U. Menon, P. D.P. Pharoah, S. A. Gayther. (2009) Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Human Molecular Genetics 18:10, 1869-1878
CrossRef571
BM Fine, L Amler. (2009) Predictive Biomarkers in the Development of Oncology Drugs: A Therapeutic Industry Perspective. Clinical Pharmacology & Therapeutics 85:5, 535-538
CrossRef572
Paula J. Whittington, Olga Radkevich-Brown, Jennifer B. Jacob, Richard F. Jones, Amy M. Weise, Wei-Zen Wei. (2009) Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity. Cancer Immunology, Immunotherapy 58:5, 759-767
CrossRef573
P. J. Barrett-Lee, J. M. Dixon, C. Farrell, A. Jones, R. Leonard, N. Murray, C. Palmieri, C. J. Plummer, A. Stanley, M. W. Verrill. (2009) Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Annals of Oncology 20:5, 816-827
CrossRef574
C. Dreyer, E. Raymond, S. Faivre. (2009) Les thérapies ciblées et leurs indications dans les tumeurs solides. La Revue de Médecine Interne 30:5, 416-424
CrossRef575
Christina Justenhoven, Christiane B. Pierl, Susanne Haas, Hans-Peter Fischer, Ute Hamann, Christian Baisch, Volker Harth, Anne Spickenheuer, Sylvia Rabstein, Caren Vollmert, Thomas Illig, Beate Pesch, Thomas Brüning, Jürgen Dippon, Yon-Dschun Ko, Hiltrud Brauch. (2009) Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors. International Journal of Cancer 124:9, 2077-2081
CrossRef576
Maura N. Dickler, Melody A. Cobleigh, Kathy D. Miller, Pamela M. Klein, Eric P. Winer. (2009) Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Research and Treatment 115:1, 115-121
CrossRef577
Miklós Kásler, Csaba Polgár, János Fodor. (2009) A korai emlőrák kezelésének aktuális helyzete. Orvosi Hetilap 150:22, 1013-1021
CrossRef578
V. Kataja, M. Castiglione, . (2009) Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv10-iv14
CrossRef579
Wen-Jin Yin, Jin-Song Lu, Gen-Hong Di, Yan-Ping Lin, Li-Heng Zhou, Guang-Yu Liu, Jiong Wu, Kun-Wei Shen, Qi-Xia Han, Zhen-Zhou Shen, Zhi-Ming Shao. (2009) Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Research and Treatment 115:2, 325-333
CrossRef580
Sumanta Kumar Pal, Joanne Mortimer. (2009) Adjuvant systemic therapy for older adults with early-stage breast cancer. Women's Health 5:3, 251-262
CrossRef581
Michael Z. Gilcrease, Wendy A. Woodward, Marlo M. Nicolas, Lynda J. Corley, Gregory N. Fuller, Francisco J. Esteva, Susan L. Tucker, Thomas A. Buchholz. (2009) Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer. The American Journal of Surgical Pathology 33:5, 759-767
CrossRef582
Ann H. Partridge, A. C. Wolff, P. K. Marcom, P. A. Kaufman, L. Zhang, R. Gelman, C. Moore, D. Lake, G. F. Fleming, H. S. Rugo, J. Atkins, E. Sampson, D. Collyar, E. P. Winer. (2009) The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast Cancer Research and Treatment 115:1, 123-129
CrossRef583
Sumithra J. Mandrekar, Daniel J. Sargent. (2009) Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All. Journal of Biopharmaceutical Statistics 19:3, 530-542
CrossRef584
Daniel J. Sargent, Jeremy M. G. Taylor. (2009) Current Issues in Oncology Drug Development, with a Focus on Phase II Trials. Journal of Biopharmaceutical Statistics 19:3, 556-562
CrossRef585
Christoph A. Klein. (2009) Parallel progression of primary tumours and metastases. Nature Reviews Cancer 9:4, 302-312
CrossRef586
Oumar Camara, Cornelia Jörke, Ulrike Hammer, Anne Egbe, Carola Rabenstein, Ingo B. Runnebaum, Klaus Hoeffken, Katharina Pachmann. (2009) Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment. Journal of Cancer Research and Clinical Oncology 135:4, 643-647
CrossRef587
Laura Pentassuglia, Michael Graf, Heidi Lane, Yukio Kuramochi, Gregory Cote, Francesco Timolati, Douglas B. Sawyer, Christian Zuppinger, Thomas M. Suter. (2009) Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Experimental Cell Research 315:7, 1302-1312
CrossRef588
M. Katherine Hoy, Barbara L. Winters, Rowan T. Chlebowski, Constantina Papoutsakis, Alice Shapiro, Michele P. Lubin, Cynthia A. Thomson, Mary B. Grosvenor, Trisha Copeland, Elyse Falk, Kristina Day, George L. Blackburn. (2009) Implementing a Low-Fat Eating Plan in the Women's Intervention Nutrition Study. Journal of the American Dietetic Association 109:4, 688-696
CrossRef589
Heather-Jane Au, Kamran Golmohammadi, Tallal Younis, Shailendra Verma, Stephen Chia, Konrad Fassbender, Philip Jacobs. (2009) Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. Breast Cancer Research and Treatment 114:3, 579-587
CrossRef590
Tianqian Zhang, Dorothee Herlyn. (2009) Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunology, Immunotherapy 58:4, 475-492
CrossRef591
John R Benson, Ismail Jatoi, Martin Keisch, Francisco J Esteva, Andreas Makris, V Craig Jordan. (2009) Early breast cancer. The Lancet 373:9673, 1463-1479
CrossRef592
Dorte Lisbet Nielsen, Michael Andersson, Claus Kamby. (2009) HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treatment Reviews 35:2, 121-136
CrossRef593
Wenjin Yin, Genhong Di, Liheng Zhou, Jinsong Lu, Guangyu Liu, Jiong Wu, Kunwei Shen, Qixia Han, Zhenzhou Shen, Zhimin Shao. (2009) Time-varying pattern of recurrence risk for Chinese breast cancer patients. Breast Cancer Research and Treatment 114:3, 527-535
CrossRef594
Davinder S. Jassal, Song-Yee Han, Cecilia Hans, Anita Sharma, Tielan Fang, Roien Ahmadie, Matthew Lytwyn, Jonathan R. Walker, Raveen S. Bhalla, Andrew Czarnecki, Tarek Moussa, Pawan K. Singal. (2009) Utility of Tissue Doppler and Strain Rate Imaging in the Early Detection of Trastuzumab and Anthracycline Mediated Cardiomyopathy. Journal of the American Society of Echocardiography 22:4, 418-424
CrossRef595
Hagop M. Kantarjian. (2009) Introduction: Targeting Different Pathways to Prevent Tumor Cell Development. Seminars in Oncology 36, S1-S5
CrossRef596
Noor Al-Dasooqi, Joanne M. Bowen, Rachel J. Gibson, Thomas Sullivan, Jude Lees, Dorothy M. Keefe. (2009) Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Investigational New Drugs 27:2, 173-178
CrossRef597
Vivien H. C. Bramwell, Gordon S. Doig, Alan B. Tuck, Sylvia M. Wilson, Katia S. Tonkin, Anna Tomiak, Francisco Perera, Theodore A. Vandenberg, Ann F. Chambers. (2009) Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Research and Treatment 114:3, 503-511
CrossRef598
Vladimir Tolmachev, Eskender Mume, Stefan Sjöberg, Fredrik Y. Frejd, Anna Orlova. (2009) Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. European Journal of Nuclear Medicine and Molecular Imaging 36:4, 692-701
CrossRef599
Dimitrios H Roukos. (2009) Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Review of Molecular Diagnostics 9:3, 217-221
CrossRef600
Maysa M. Abu-Khalaf, Lyndsay Harris. (2009) The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer. Breast Cancer Research and Treatment 114:3, 513-515
CrossRef601
John Mackey, Deanna McLeod, Joseph Ragaz, Karen Gelmon, Sunil Verma, Kathleen Pritchard, Kara Laing, Louise Provencher, Lauren F. Charbonneau. (2009) Adjuvant targeted therapy in early breast cancer. Cancer 115:6, 1154-1168
CrossRef602
A L Jones, M Barlow, P J Barrett-Lee, P A Canney, I M Gilmour, S D Robb, C J Plummer, A M Wardley, M W Verrill. (2009) Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. British Journal of Cancer 100:5, 684-692
CrossRef603
S M Tovey, S Brown, J C Doughty, E A Mallon, T G Cooke, S Grant. (2009) Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. British Journal of Cancer 100:5, 680-683
CrossRef604
D. Fischer, K. Röder, C. Dittmer, K. Diedrich, M. Thill. (2009) „Targeted therapy“ des Mammakarzinoms. Der Gynäkologe
CrossRef605
Dana Faratian, Ashley Graham, Frances Rae, Jeremy Thomas. (2009) Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service. Histopathology 54:4, 428-432
CrossRef606
János Fodor. (2009) Evidenciák a korai invazív emlőrák sugárkezelésében: hagyományos klinikai jellemzők és biomarkerek. Magyar Onkológia 53:1, 7-14
CrossRef607
F.C. Geyer, T. Decker, J.S. Reis-Filho. (2009) Genomweite Expressionsprofile als klinische Entscheidungshilfe. Der Pathologe 30:2, 141-146
CrossRef608
Bushra Haq, Charles E Geyer. (2009) Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer. Women's Health 5:2, 135-147
CrossRef609
Costanza De Rossi, Antonella Brunello, Giuseppe Jirillo, Antonio Jirillo. (2009) When an interim analysis of randomized trial changes the practice in oncology: the lesson of adjuvant Trastuzumab and the HERA trial. Immunopharmacology and Immunotoxicology 31:1, 30-31
CrossRef610
Ayuko A. Iverson, Cheryl Gillett, Paul Cane, Christopher D. Santini, Thomas M. Vess, Lauren Kam-Morgan, Alice Wang, Marcia Eisenberg, Charles M. Rowland, Janice J. Hessling, Samuel E. Broder, John J. Sninsky, Andrew Tutt, Steven Anderson, Sheng-Yung P. Chang. (2009) A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens. The Journal of Molecular Diagnostics 11:2, 117-130
CrossRef611
Christine Desmedt, Jeff Sperinde, Fanny Piette, Weidong Huang, Xueguang Jin, Yuping Tan, Virginie Durbecq, Denis Larsimont, Rosa Giuliani, Colombe Chappey, Marc Buyse, John Winslow, Martine Piccart, Christos Sotiriou, Christos Petropoulos, Michael Bates. (2009) Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH. Diagnostic Molecular Pathology 18:1, 22-29
CrossRef612
Louis M Weiner, Madhav V Dhodapkar, Soldano Ferrone. (2009) Monoclonal antibodies for cancer immunotherapy. The Lancet 373:9668, 1033-1040
CrossRef613
Heather McArthur. (2009) An overview of HER-targeted therapy with lapatinib in breast cancer. Advances in Therapy 26:3, 263-271
CrossRef614
Kevin Kalinsky, Alice Ho, Christopher A. Barker, Andrew Seidman. (2009) Concurrent use of chemotherapy or novel agents in combination with radiation in breast cancer. Current Breast Cancer Reports 1:1, 29-41
CrossRef615
M Scaltriti, C Verma, M Guzman, J Jimenez, J L Parra, K Pedersen, D J Smith, S Landolfi, S Ramon y Cajal, J Arribas, J Baselga. (2009) Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28:6, 803-814
CrossRef616
J D Barros-Silva, D Leitão, L Afonso, J Vieira, M Dinis-Ribeiro, M Fragoso, M J Bento, L Santos, P Ferreira, S Rêgo, C Brandão, F Carneiro, C Lopes, F Schmitt, M R Teixeira. (2009) Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. British Journal of Cancer 100:3, 487-493
CrossRef617
Cecilia Nisticò, Emilio Bria, Vanja Vaccaro, Federica Cuppone, Monica Fornier, Isabella Sperduti, Armando Carpino, Fiorentino Izzo, Francesco Tropea, Francesco Cognetti, Edmondo Terzoli. (2009) Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity. Anti-Cancer Drugs 20:2, 109-114
CrossRef618
Gabriella Mariani, Angelica Fasolo, Elena De Benedictis, Luca Gianni. (2009) Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nature Clinical Practice Oncology 6:2, 93-104
CrossRef619
Makiko Ono, Masashi Ando, Mayu Yunokawa, Eriko Nakano, Kan Yonemori, Koji Matsumoto, Tsutomu Kouno, Chikako Shimizu, Kenji Tamura, Noriyuki Katsumata, Yasuhiro Fujiwara. (2009) Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. International Journal of Clinical Oncology 14:1, 48-52
CrossRef620
Melissa C. Hulvat, Nora M. Hansen, Jacqueline S. Jeruss. (2009) Multidisciplinary Care for Patients with Breast Cancer. Surgical Clinics of North America 89:1, 133-176
CrossRef621
Lee B. Riley, Darius C. Desai. (2009) The Molecular Basis of Cancer and the Development of Targeted Therapy. Surgical Clinics of North America 89:1, 1-15
CrossRef622
Oreste Gentilini, Edoardo Botteri, Nicole Rotmensz, Luciana Lima, Mujgan Caliskan, Carlos A. Garcia-Etienne, Irina Sosnovskikh, Mattia Intra, Giovanni Mazzarol, Simona Musmeci, Paolo Veronesi, Viviana Galimberti, Alberto Luini, Giuseppe Viale, Aron Goldhirsch, Umberto Veronesi. (2009) Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Research and Treatment 113:3, 577-583
CrossRef623
M. J. Pepels, K. A. Boomars, R. Kimmenade, P. S. Hupperets. (2009) Life-threatening interstitial lung disease associated with trastuzumab: case report. Breast Cancer Research and Treatment 113:3, 609-612
CrossRef624
Alejandro Forner, Carmen Ayuso, María Isabel Real, Javier Sastre, Ricardo Robles, Bruno Sangro, María Varela, Manuel de la Mata, María Buti, Luís Martí-Bonmatí, Concepció Bru, Josep Tabernero, Josep M Llovet, Jordi Bruix. (2009) Diagnóstico y tratamiento del carcinoma hepatocelular. Medicina Clínica 132:7, 272-287
CrossRef625
Patrick G Morris, Monica N Fornier. (2009) Novel anti-tubulin cytotoxic agents for breast cancer. Expert Review of Anticancer Therapy 9:2, 175-185
CrossRef626
G E Konecny, L Santos, B Winterhoff, M Hatmal, G L Keeney, A Mariani, M Jones, C Neuper, B Thomas, L Muderspach, D Riehle, H-J Wang, S Dowdy, K C Podratz, M F Press. (2009) HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. British Journal of Cancer 100:1, 89-95
CrossRef627
Sungwoo Park, Kyung-min Lee, Ji-hyun Ju, Jaeyoon Kim, Dong-Young Noh, Taehoon Lee, Incheol Shin. (2009) Protein expression profiling of primary mammary epithelial cells derived from MMTV- neu mice revealed that HER2/NEU-driven changes in protein expression are functionally clustered. IUBMB LifeNA-NA
CrossRef628
Mary Jo Lund, Katrina F. Trivers, Peggy L. Porter, Ralph J. Coates, Brian Leyland-Jones, Otis W. Brawley, Elaine W. Flagg, Ruth M. O’Regan, Sheryl G. A. Gabram, J. William Eley. (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Research and Treatment 113:2, 357-370
CrossRef629
Michelle E Melisko, Michael Glantz, Hope S Rugo. (2009) New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nature Clinical Practice Oncology 6:1, 25-33
CrossRef630
Yeon Hee Park. (2009) Drug Therapy for Breast Cancer. Journal of the Korean Medical Association 52:10, 963
CrossRef631
Michael S. Sabel. 2009. Principles of Adjuvant Chemotherapy for Breast Cancer. , 247-266.
CrossRef632
Ian E. Krop, Eric P. Winer. (2009) Ten years of HER2-directed therapy: still questions after all these years. Breast Cancer Research and Treatment 113:2, 207-209
CrossRef633
K.E. Hoffman, J.R. Harris. (2009) Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. Breast Diseases: A Year Book Quarterly 20:2, 172-174
CrossRef634
Sergio Szvalb, Moshe Stein, Anthony Gershuny, Eli Gez, Amram Hadary, Jamal Zidan. (2009) Lack of HER-2 gene amplification in non-Hodgkin lymphoma using chromogenic in situ hybridisation test. Leukemia & Lymphoma 50:5, 736-740
CrossRef635
Carolyn Straehle, Fatima Cardoso, Evandro Azambuja, Stella Dolci, Livia Meirsman, Kris Vantongelen, Michalis Ignatiadis, Christos Sotiriou, Martine J. Piccart-Gebhart. (2009) Better translation from bench to bedside: Breakthroughs in the individualized treatment of cancer. Critical Care Medicine 37:Supplement, S22-S29
CrossRef636
Patrick Tan. (2009) Divide and Conquer: Progress in the Molecular Stratification of Cancer. Yonsei Medical Journal 50:4, 464
CrossRef637
Philip Savage, Justin Stebbing, Mark Bower, Tim Crook. (2009) Why does cytotoxic chemotherapy cure only some cancers?. Nature Clinical Practice Oncology 6:1, 43-52
CrossRef638
Elyse E. Lower, Eleanor Glass, Robbin Blau, Stacy Harman. (2009) HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Research and Treatment 113:2, 301-306
CrossRef639
Caroline Chung, David Stuart, Mira Keyes. (2009) Radiation Recall Reaction Induced by Adjuvant Trastuzumab (Herceptin). Case Reports in Medicine 2009, 1-3
CrossRef640
Mariella Mannino, John R. Yarnold. (2009) Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: Can radiotherapy ever be safely withheld?. Radiotherapy and Oncology 90:1, 14-22
CrossRef641
C.T. Dang. (2009) Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials. Breast Diseases: A Year Book Quarterly 20:4, 424-426
CrossRef642
David G. Hicks. 2009. Molecular Pathology of Breast Cancer. , 360-378.
CrossRef643
M. Arroyo Yustos, R. Molina Villaverde, J.L. López González, M. Álvarez-Mon Soto. (2009) Cáncer de mama (II). Tratamiento sistémico. Medicine - Programa de Formación Médica Continuada Acreditado 10:24, 1583-1590
CrossRef644
Richard Shaffer, Scott Tyldesley, Martin Rolles, Stephen Chia, Islam Mohamed. (2009) Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: A retrospective single-institution study. Radiotherapy and Oncology 90:1, 122-126
CrossRef645
Amir Harandi, Aisha S. Zaidi, Abigail M. Stocker, Damian A. Laber. (2009) Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. Journal of Oncology 2009, 1-14
CrossRef646
W. F. Anderson, S. Luo, N. Chatterjee, P. S. Rosenberg, R. K. Matsuno, M. T. Goodman, B. Y. Hernandez, M. Reichman, M. P. Dolled-Filhart, R. M. O’Regan, M. Garcia-Closas, C. M. Perou, I. Jatoi, R. W. Cartun, M. E. Sherman. (2009) Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Research and Treatment 113:1, 189-196
CrossRef647
Daphne W Bell. (2009) Our changing view of the genomic landscape of cancer. The Journal of Pathologyn/a-n/a
CrossRef648
S Shousha, D Peston, B Amo-Takyi, M Morgan, B Jasani. (2009) Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology 54:2, 248-253
CrossRef649
Peter S. Hall, David A. Cameron. (2009) Current perspective – Trastuzumab. European Journal of Cancer 45:1, 12-18
CrossRef650
Heather McArthur. (2009) An overview of HER-targeted therapy with lapatinib in breast cancer. Advances in Therapy 26:3, 263
CrossRef651
Richard J. Santen. 2009. Breast Cancer. , 659-686.
CrossRef652
2009. BIBLIOGRAPHIE. , 176-189.
CrossRef653
C Marchiò, R Natrajan, KK Shiu, MBK Lambros, SM Rodriguez-Pinilla, DSP Tan, CJ Lord, D Hungermann, K Fenwick, N Tamber, A Mackay, J Palacios, A Sapino, H Buerger, A Ashworth, JS Reis-Filho. (2008) The genomic profile of HER2 -amplified breast cancers: the influence of ER status. The Journal of Pathology 216:4, 399-407
CrossRef654
Serena Di Cosimo, José Baselga. (2008) Targeted therapies in breast cancer: Where are we now?. European Journal of Cancer 44:18, 2781-2790
CrossRef655
Emilio Bria, Federica Cuppone, Michele Milella, Sunil Verma, Paolo Carlini, Cecilia Nisticò, Vanja Vaccaro, Antonio Rossi, Giuseppe Tonini, Francesco Cognetti, Edmondo Terzoli. (2008) Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opinion on Biological Therapy 8:12, 1963-1971
CrossRef656
&NA;. (2008) Trastuzumab: a guide to its use in early breast cancer. Drugs & Therapy Perspectives 24:12, 4-7
CrossRef657
Hyoungsuk Ko, Hyesil Seol, Wook Youn Kim, Seock-Ah Im, Wonshik Han, Dong-Young Noh, Yoon Kyung Jeon, In Ae Park. (2008) Ongoing debates in the assessment of the HER2 status in breast cancer: A comparative analysis by immunohistochemistry and FISH using original FDA and ASCO/CAP guidelines. Basic and Applied Pathology 1:4, 182-188
CrossRef658
A.-C. Hoffmann, M. Schuler. (2008) Biomarker in der Onkologie. best practice onkologie 3:6, 48-58
CrossRef659
Asna Amin, Linda C. Benavides, Jarrod P. Holmes, Jeremy D. Gates, Mark G. Carmichael, Matthew T. Hueman, Elizabeth A. Mittendorf, Catherine E. Storrer, Yusuf H. Jama, Dianna Craig, Alex Stojadinovic, Sathibalan Ponniah, George E. Peoples. (2008) Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunology, Immunotherapy 57:12, 1817-1825
CrossRef660
Alicia Tosoni, Enrico Franceschi, Alba A. Brandes. (2008) Chemotherapy in breast cancer patients with brain metastases: Have new chemotherapic agents changed the clinical outcome?. Critical Reviews in Oncology/Hematology 68:3, 212-221
CrossRef661
Christian F. Singer, Wolfgang J. Köstler, Gernot Hudelist. (2008) Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1786:2, 105-113
CrossRef662
C. C. Zielinski. (2008) Treatment of metastatic breast cancer: a historical perspective. memo - Magazine of European Medical Oncology 1:4, 227-234
CrossRef663
David Cameron, Michelle Casey, Michael Press, Deborah Lindquist, Tadeusz Pienkowski, C. Gilles Romieu, Stephen Chan, Agnieszka Jagiello-Gruszfeld, Bella Kaufman, John Crown, Arlene Chan, Mario Campone, Patrice Viens, Neville Davidson, Vera Gorbounova, Johannes Isaac Raats, Dimosthenis Skarlos, Beth Newstat, Debasish Roychowdhury, Paolo Paoletti, Cristina Oliva, Stephen Rubin, Steven Stein, Charles E. Geyer. (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Research and Treatment 112:3, 533-543
CrossRef664
Dimosthenis Ziogas, Eleftheria Ignatiadou, Dimitrios Roukos, Efstathios Lykoudis. (2008) HER2 and Trastuzumab: Impact of a New Standard Agent on Local Control and Surgery for Breast Cancer. Annals of Surgical Oncology 15:12, 3614-3615
CrossRef665
K. C. Jensen, D. A. Turbin, S. Leung, M. A. Miller, K. Johnson, B. Norris, T. Hastie, S. McKinney, T. O. Nielsen, D. G. Huntsman, C. B. Gilks, R. B. West. (2008) New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Research and Treatment 112:3, 453-459
CrossRef666
Windy Dean-Colomb, Francisco J. Esteva. (2008) Her2-positive breast cancer: Herceptin and beyond. European Journal of Cancer 44:18, 2806-2812
CrossRef667
Sandro Barni, Mary Cabiddu, F Petrelli. (2008) Toxicity of targeted therapies in elderly patients. Expert Review of Anticancer Therapy 8:12, 1965-1976
CrossRef668
Don S Dizon, Sharmila Makhija. (2008) HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology. Expert Opinion on Drug Discovery 3:11, 1363-1369
CrossRef669
Phuong Dinh, Evandro de Azambuja, Fatima Cardoso, Martine J Piccart-Gebhart. (2008) Facts and controversies in the use of trastuzumab in the adjuvant setting. Nature Clinical Practice Oncology 5:11, 645-654
CrossRef670
H. B. Muss. (2008) Adjuvant chemotherapy for older women with breast cancer. Breast Cancer Online 11:11,
CrossRef671
Aarif Y Khakoo, Edward TH Yeh. (2008) Therapy Insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nature Clinical Practice Oncology 5:11, 655-667
CrossRef672
Wei-Zen Wei, Jennifer Jacob, Olga Radkevich-Brown, Paula Whittington, Yi-chi M. Kong. (2008) The “A, B and C” of Her-2 DNA vaccine development. Cancer Immunology, Immunotherapy 57:11, 1711-1717
CrossRef673
Fátima Carneiro, Carla Oliveira, Marina Leite, Raquel Seruca. (2008) Molecular targets and biological modifiers in gastric cancer. Seminars in Diagnostic Pathology 25:4, 274-287
CrossRef674
Guru Sonpavde. (2008) Neoadjuvant therapy as a paradigm to develop systemic cancer therapy. Drug Development Research 69:7, 388-397
CrossRef675
P. SINGH, C.L. SMITH, G. CHEETHAM, T.J. DODD, M.L.J. DAVY. (2008) Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation. International Journal of Gynecological Cancer 18:6, 1344-1351
CrossRef676
Hiroo Nakajima, Ikuya Fujiwara, Naruhiko Mizuta, Koichi Sakaguchi, Yasushi Hachimine, Eiichi Konishi, Akio Yanagisawa, Junji Magae. (2008) Prognosis of Japanese Breast Cancer Based on Hormone Receptor and HER2 Expression Determined by Immunohistochemical Staining. World Journal of Surgery 32:11, 2477-2482
CrossRef677
Federico Rojo, Joan Albanell, Ana Rovira, Josep Maria Corominas, Felix Manzarbeitia. (2008) Targeted therapies in breast cancer. Seminars in Diagnostic Pathology 25:4, 245-261
CrossRef678
Vera Levina, Yunyun Su, Brian Nolen, Xiaoning Liu, Yuri Gordin, Melissa Lee, Anna Lokshin, Elieser Gorelik. (2008) Chemotherapeutic drugs and human tumor cells cytokine network. International Journal of Cancer 123:9, 2031-2040
CrossRef679
J. Stagg, J. Sharkey, S. Pommey, R. Young, K. Takeda, H. Yagita, R. W. Johnstone, M. J. Smyth. (2008) Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proceedings of the National Academy of Sciences 105:42, 16254-16259
CrossRef680
A. Anton, A. Ruiz, M. A. Segui, L. Calvo, M. Munoz, J. Lao, F. Sancho, L. Fernandez. (2008) Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Annals of Oncology 20:3, 454-459
CrossRef681
Philipp Kiewe, Eckhard Thiel. (2008) Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opinion on Investigational Drugs 17:10, 1553-1558
CrossRef682
Josep M. Llovet, Jordi Bruix. (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:4, 1312-1327
CrossRef683
Axel Grothey, Alex A. Adjei, Steve R. Alberts, Edith A. Perez, Kurt A. Jaeckle, Charles L. Loprinzi, Daniel J. Sargent, Jeff A. Sloan, Jan C. Buckner. (2008) North Central Cancer Treatment Group—Achievements and Perspectives. Seminars in Oncology 35:5, 530-544
CrossRef684
Allen M Gown, Lynn C Goldstein, Todd S Barry, Steven J Kussick, Patricia L Kandalaft, Patricia M Kim, Christopher C Tse. (2008) High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Modern Pathology 21:10, 1271-1277
CrossRef685
Rupert Bartsch, Catharina Wenzel, Simon P. Gampenrieder, Ursula Pluschnig, Gabriela Altorjai, Margaretha Rudas, Robert M. Mader, Peter Dubsky, Andrea Rottenfusser, Michael Gnant, Christoph C. Zielinski, Guenther G. Steger. (2008) Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology 62:5, 903-910
CrossRef686
Ian J. Bristol, Wendy A. Woodward, Eric A. Strom, Massimo Cristofanilli, Delora Domain, S. Eva Singletary, George H. Perkins, Julia L. Oh, Tse-Kuan Yu, Welela Terrefe, Aysegul A. Sahin, Kelly K. Hunt, Gabriel N. Hortobagyi, Thomas A. Buchholz. (2008) Locoregional Treatment Outcomes After Multimodality Management of Inflammatory Breast Cancer. International Journal of Radiation Oncology*Biology*Physics 72:2, 474-484
CrossRef687
Alfonso Sánchez-Muñoz, Ana María García-Tapiador, Esther Martínez-Ortega, Rosario Dueñas-García, Ana Jaén-Morago, Ana Laura Ortega-Granados, Mónica Fernández-Navarro, Capilla Torre-Cabrera, Basilio Dueñas, Ana Isabel Rueda, Francisco Morales, César Ramírez-Torosa, María Dolores Martín-Salvago, Pedro Sánchez-Rovira. (2008) Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clinical and Translational Oncology 10:10, 646-653
CrossRef688
Yolanda Madarnas, Maureen Trudeau, Jacob A. Franek, David McCready, Kathleen I. Pritchard, Hans Messersmith. (2008) Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review. Cancer Treatment Reviews 34:6, 539-557
CrossRef689
D. Lawrence Wickerham, Michael J. O'Connell, Joseph P. Costantino, Walter M. Cronin, Soonmyung Paik, Charles E. Geyer, Patricia A. Ganz, Nicholas Petrelli, Eleftherios P. Mamounas, Thomas B. Julian, Norman Wolmark. (2008) The Half Century of Clinical Trials of the National Surgical Adjuvant Breast and Bowel Project. Seminars in Oncology 35:5, 522-529
CrossRef690
Shun’e Yang, Bing Zhao. (2008) Research progress in the use of drugs for breast cancer targeted therapy. Chinese Journal of Clinical Oncology 5:5, 320-325
CrossRef691
Grace K. Dy, Alex A. Adjei. (2008) Systemic cancer therapy: Evolution over the last 60 years. Cancer 113:S7, 1857-1887
CrossRef692
Tallal Younis, Chris Skedgel. (2008) Is trastuzumab a cost-effective treatment for breast cancer?. Expert Review of Pharmacoeconomics & Outcomes Research 8:5, 433-442
CrossRef693
M. A. Pantaleo, S. Fanti, M. Nannini, S. Boschi, C. Nanni, A. Maleddu, D. Rubello, G. Biasco. (2008) What oncologists need and require from nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging 35:10, 1761-1765
CrossRef694
Peng H Tan, Amrit S Lota. (2008) Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics. Expert Opinion on Pharmacotherapy 9:15, 2639-2660
CrossRef695
A Leary, I E Smith. (2008) Survival from breast cancer in England and Wales up to 2001. British Journal of Cancer 99, S56-S58
CrossRef696
Andrew Z. Wang, Vaishali Bagalkot, Christophoros C. Vasilliou, Frank Gu, Frank Alexis, Liangfang Zhang, Mariam Shaikh, Kai Yuet, Michael J. Cima, Robert Langer, Philip W. Kantoff, Neil H. Bander, Sangyong Jon, Omid C. Farokhzad. (2008) Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy. ChemMedChem 3:9, 1311-1315
CrossRef697
Josep Maria del Campo, Aleix Prat, Antonio Gil-Moreno, José Pérez, Marta Parera. (2008) Update on novel therapeutic agents for cervical cancer. Gynecologic Oncology 110:3, S72-S76
CrossRef698
Juan Haba-Rodriguez, Emilio Alba, Agustí Barnadas, Eloisa Bayo, Antonio Llombart, Ana Lluch, Miguel Martín, José Andrés Moreno-Nogueira, Gumersindo Pérez Manga, Álvaro Rodríguez-Lescure, Enrique Aranda. (2008) Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007. Clinical and Translational Oncology 10:9, 552-559
CrossRef699
Dimitrios H Roukos. (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Review of Molecular Diagnostics 8:5, 587-597
CrossRef700
Robert M. Sharkey, David M. Goldenberg. (2008) Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Advanced Drug Delivery Reviews 60:12, 1407-1420
CrossRef701
Henry G. Kaplan, Judith A. Malmgren. (2008) Impact of Triple Negative Phenotype on Breast Cancer Prognosis. The Breast Journal 14:5, 456-463
CrossRef702
Kai-Keen Shiu, David SP Tan, Jorge S Reis-Filho. (2008) Development of therapeutic approaches to ‘triple negative’ phenotype breast cancer. Expert Opinion on Therapeutic Targets 12:9, 1123-1137
CrossRef703
David A Cameron, Steven Stein. (2008) Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer. Nature Clinical Practice Oncology 5:9, 512-520
CrossRef704
Claudia D’Alessandro, Silvia Dellapasqua, Laura Orlando, Luigi Santoro, Patrick Maisonneuve, Rosalba Torrisi, Alessandra Balduzzi, Eloise Scarano, Raffaella Ghisini, Giulia Peruzzotti, Aron Goldhirsch, Marco Colleoni. (2008) Role of Endocrine Responsiveness and HER2/neu Overexpression in Inflammatory Breast Cancer Treated with Multimodality Preoperative Therapy. The Breast Journal 14:5, 435-441
CrossRef705
Thomas Force, Risto Kerkelä. (2008) Cardiotoxicity of the new cancer therapeutics – mechanisms of, and approaches to, the problem. Drug Discovery Today 13:17-18, 778-784
CrossRef706
Aleix Prat, José Baselga. (2008) The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nature Clinical Practice Oncology 5:9, 531-542
CrossRef707
Angela L.W. Meisner, M. Houman Fekrazad, Melanie E. Royce. (2008) Breast Disease: Benign and Malignant. Medical Clinics of North America 92:5, 1115-1141
CrossRef708
Dhara M. MacDermed, Ralph R. Weichselbaum, Joseph K. Salama. (2008) A rationale for the targeted treatment of oligometastases with radiotherapy. Journal of Surgical Oncology 98:3, 202-206
CrossRef709
C Osipo, P Patel, P Rizzo, A G Clementz, L Hao, T E Golde, L Miele. (2008) ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor. Oncogene 27:37, 5019-5032
CrossRef710
B. Gril, D. Palmieri, J. L. Bronder, J. M. Herring, E. Vega-Valle, L. Feigenbaum, D. J. Liewehr, S. M. Steinberg, M. J. Merino, S. D. Rubin, P. S. Steeg. (2008) Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain. JNCI Journal of the National Cancer Institute 100:15, 1092-1103
CrossRef711
Shailendra Verma, Susan Dent, Benjamin J.W. Chow, Daniel Rayson, Tamar Safra. (2008) Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treatment Reviews 34:5, 391-406
CrossRef712
Nawaz Walji, Lubna Bhatt, Sindy Dhallu, Indrajit N. Fernando. (2008) Prolonged trastuzumab therapy in a patient with recurrent breast cancer and anthracycline-induced cardiac failure. The Breast 17:4, 423-425
CrossRef713
John C. Mansour, Roderich E. Schwarz. (2008) Molecular Mechanisms for Individualized Cancer Care. Journal of the American College of Surgeons 207:2, 250-258
CrossRef714
Andrew Z Wang, Frank Gu, Liangfang Zhang, Juliana M Chan, Aleksander Radovic-Moreno, Mariam R Shaikh, Omid C Farokhzad. (2008) Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opinion on Biological Therapy 8:8, 1063-1070
CrossRef715
Monica Morrow. (2008) Margins in breast-conserving therapy: have we lost sight of the big picture?. Expert Review of Anticancer Therapy 8:8, 1193-1196
CrossRef716
Mary Jo B. Lund, Ebonee N. Butler, Harvey L. Bumpers, Joel Okoli, Monica Rizzo, Nadjo Hatchett, Victoria L. Green, Otis W. Brawley, Gabriela M. Oprea-Ilies, Sheryl G. A. Gabram. (2008) High prevalence of triple-negative tumors in an urban cancer center. Cancer 113:3, 608-615
CrossRef717
F. Peintinger, A. U. Buzdar, H. M. Kuerer, J. A. Mejia, C. Hatzis, A. M. Gonzalez-Angulo, L. Pusztai, F. J. Esteva, S. S. Dawood, M. C. Green, G. N. Hortobagyi, W. F. Symmans. (2008) Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Annals of Oncology 19:12, 2020-2025
CrossRef718
Lee, Thomas H., Emanuel, Ezekiel J., . (2008) Tier 4 Drugs and the Fraying of the Social Compact. New England Journal of Medicine 359:4, 333-335
Full Text719
Melissa L James, Margot Lehman, Phil N Hider, Mark Jeffery, Daniel P Francis, Brigid E Hickey, Brigid E Hickey. 2008. Fraction size in radiation treatment for breast conservation in early breast cancer. .
CrossRef720
Rachel Rosenthal, Carsten T. Viehl, Ulrich Guller, Walter P. Weber, Michel Adamina, Giulio C. Spagnoli, Michael Heberer, Markus Zuber. (2008) Active Specific Immunotherapy Phase III Trials for Malignant Melanoma: Systematic Analysis and Critical Appraisal. Journal of the American College of Surgeons 207:1, 95-105
CrossRef721
Fernanda Milanezi, Silvia Carvalho, Fernando C Schmitt. (2008) EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Review of Molecular Diagnostics 8:4, 417-434
CrossRef722
T. FEHM, V. MUELLER, R. MARCHES, G. KLEIN, B. GUECKEL, H. NEUBAUER, E. SOLOMAYER, S. BECKER. (2008) Tumor cell dormancy: implications for the biology and treatment of breast cancer . APMIS 116:7-8, 742-753
CrossRef723
Ivo M. Hennig, Chris Twelves. (2008) Loading doses for costly cancer biologicals: A cause for concern or tilting at windmills?. European Journal of Cancer 44:11, 1493-1496
CrossRef724
Bruce G. Haffty, Qifeng Yang, Meena S. Moran, Antoinette R. Tan, Michael Reiss. (2008) Estrogen-Dependent Prognostic Significance of Cyclooxygenase-2 Expression in Early-Stage Invasive Breast Cancers Treated With Breast-Conserving Surgery and Radiation. International Journal of Radiation Oncology*Biology*Physics 71:4, 1006-1013
CrossRef725
Reinhard Meier, Morand Piert, Guido Piontek, Martina Rudelius, Robert A. Oostendorp, Reingard Senekowitsch-Schmidtke, Tobias D. Henning, Winfried S. Wels, Christoph Uherek, Ernst J. Rummeny, Heike E. Daldrup-Link. (2008) Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors. Nuclear Medicine and Biology 35:5, 579-588
CrossRef726
Barrett W. Newsome, Marc S. Ernstoff. (2008) The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?. British Journal of Clinical Pharmacology 66:1, 6-19
CrossRef727
Z Cai, G Zhang, Z Zhou, K Bembas, J A Drebin, M I Greene, H Zhang. (2008) Differential binding patterns of monoclonal antibody 2C4 to the ErbB3–p185her2/neu and the EGFR–p185her2/neu complexes. Oncogene 27:27, 3870-3874
CrossRef728
C. Hudis, C. Dang. (2008) The Taxane Limbo: How Low Can We Go?. JNCI Journal of the National Cancer Institute 100:11, 761-763
CrossRef729
R. S. Mehta, T. Schubbert, K. Kong. (2008) Trastuzumab in inflammatory breast cancer. Annals of Oncology 19:10, 1815-1817
CrossRef730
S. Menard, A. Balsari, E. Tagliabue, T. Camerini, P. Casalini, R. Bufalino, F. Castiglioni, M. L. Carcangiu, A. Gloghini, S. Scalone, P. Querzoli, M. Lunardi, A. Molino, M. Mandara, M. Mottolese, F. Marandino, M. Venturini, C. Bighin, G. Cancello, E. Montagna, F. Perrone, A. De Matteis, A. Sapino, M. Donadio, N. Battelli, A. Santinelli, L. Pavesi, A. Lanza, F. A. Zito, A. Labriola, R. A. Aiello, M. Caruso, F. Zanconati, G. Mustacchi, M. Barbareschi, M. Frisinghelli, R. Russo, G. Carrillo, . (2008) Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Annals of Oncology 19:10, 1706-1712
CrossRef731
Helen M. Coley. (2008) Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treatment Reviews 34:4, 378-390
CrossRef732
Maya Guglin, Raymond Cutro, Joseph D. Mishkin. (2008) Trastuzumab-Induced Cardiomyopathy. Journal of Cardiac Failure 14:5, 437-444
CrossRef733
Swati Kulkarni, David G. Hicks. (2008) HER2-Positive Early Breast Cancer and Trastuzumab: A Surgeon’s Perspective. Annals of Surgical Oncology 15:6, 1677-1688
CrossRef734
R. Bartsch, G. G. Steger. (2008) Adjuvant chemotherapy in breast cancer. memo - Magazine of European Medical Oncology 1:2, 91-98
CrossRef735
Julia R. White, Francine E. Halberg, Rachel Rabinovitch, Sheryl Green, Bruce G. Haffty, Lawrence J. Solin, Eric A. Strom, Marie E. Taylor, Stephen B. Edge. (2008) American College of Radiology Appropriateness Criteria® on Conservative Surgery and Radiation: Stages I and II Breast Carcinoma. Journal of the American College of Radiology 5:6, 701-713
CrossRef736
M Hofmann, O Stoss, D Shi, R Büttner, M van de Vijver, W Kim, A Ochiai, J Rüschoff, T Henkel. (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:7, 797-805
CrossRef737
Leisha A Emens. (2008) Cancer vaccines: on the threshold of success. Expert Opinion on Emerging Drugs 13:2, 295-308
CrossRef738
David F. Stern. (2008) ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer. Journal of Mammary Gland Biology and Neoplasia 13:2, 215-223
CrossRef739
K. N. Syrigos, A. Zalonis, E. Kotteas, Muhammad Wasif Saif. (2008) Targeted therapy for oesophageal cancer: an overview. Cancer and Metastasis Reviews 27:2, 273-288
CrossRef740
Takeru Shiroiwa, Takashi Fukuda, Kojiro Shimozuma, Yasuo Ohashi, Kiichiro Tsutani. (2008) The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Research and Treatment 109:3, 559-566
CrossRef741
Feng Guo, Stephen P. Letrent, Pamela N. Munster, Carolyn D. Britten, Karen Gelmon, Anthony W. Tolcher, Amarnath Sharma. (2008) Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety. Cancer Chemotherapy and Pharmacology 62:1, 97-109
CrossRef742
Scott C. Mayer, Annette L. Banker, Frank Boschelli, Li Di, Mark Johnson, Cynthia Hess Kenny, Girija Krishnamurthy, Kristina Kutterer, Franklin Moy, Susan Petusky, Malini Ravi, Diane Tkach, Hwei-Ru Tsou, Weixin Xu. (2008) Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment. Bioorganic & Medicinal Chemistry Letters 18:12, 3641-3645
CrossRef743
Edith A. Perez, Maria Koehler, Julie Byrne, Alaknanda J. Preston, Erica Rappold, Michael S. Ewer. (2008) Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials. Mayo Clinic Proceedings 83:6, 679-686
CrossRef744
E. A. Perez, M. Koehler, J. Byrne, A. J. Preston, E. Rappold, M. S. Ewer. (2008) Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials. Mayo Clinic Proceedings 83:6, 679-686
CrossRef745
D. Rayson, D. Richel, S. Chia, C. Jackisch, S. van der Vegt, T. Suter. (2008) Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Annals of Oncology 19:9, 1530-1539
CrossRef746
S. L. Hines, L. A. Vallow, W. W. Tan, R. B. McNeil, E. A. Perez, A. Jain. (2008) Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Annals of Oncology 19:9, 1561-1565
CrossRef747
M Hermes, W Schormann, M Brulport, K Uhlemann, F Lupatsch, L C Horn, A Schumann, C Allgaier, M Weishaupt, K Engeland, G A Müller, J Mössner, A Bauer, I B Schiffer, S Gebhard, M Schmidt, E Lausch, D Prawitt, C Wilhelm, J G Hengstler. (2008) Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. British Journal of Cancer 98:9, 1525-1532
CrossRef748
C.N.A.M. Oldenhuis, S.F. Oosting, J.A. Gietema, E.G.E. de Vries. (2008) Prognostic versus predictive value of biomarkers in oncology. European Journal of Cancer 44:7, 946-953
CrossRef749
Emilio Bria, Federica Cuppone, Monica Fornier, Cecilia Nisticò, Paolo Carlini, Michele Milella, Isabella Sperduti, Edmondo Terzoli, Francesco Cognetti, Diana Giannarelli. (2008) Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Research and Treatment 109:2, 231-239
CrossRef750
C. Thomssen, J. Huober. (2008) Primäre und adjuvante Systemtherapie des operablen Mammakarzinoms. Der Onkologe 14:5, 504-513
CrossRef751
Scott Metcalfe, Carl Burgess, George Laking, Jackie Evans, Susan Wells, Steffan Crausaz. (2008) Trastuzumab: possible publication bias. The Lancet 371:9625, 1646-1648
CrossRef752
C. Wilhelm, A. Neubauer. (2008) Molekulare Tumortherapie. Der Internist 49:5, 581-592
CrossRef753
Klaus Pantel, Ruud H. Brakenhoff, Burkhard Brandt. (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature Reviews Cancer 8:5, 329-340
CrossRef754
Bindi Dhesy-Thind, Kathleen I. Pritchard, Hans Messersmith, Frances O’Malley, Leela Elavathil, Maureen Trudeau. (2008) HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Research and Treatment 109:2, 209-229
CrossRef755
N. V. Zhukov, S. A. Tjulandin. (2008) Targeted therapy in the treatment of solid tumors: Practice contradicts theory. Biochemistry (Moscow) 73:5, 605-618
CrossRef756
Li Yan, Karl Hsu, Robert A. Beckman. (2008) Antibody-Based Therapy for Solid Tumors. The Cancer Journal 14:3, 178-183
CrossRef757
Edurne Arriola, Caterina Marchio, David SP Tan, Suzanne C Drury, Maryou B Lambros, Rachael Natrajan, Socorro Maria Rodriguez-Pinilla, Alan Mackay, Narinder Tamber, Kerry Fenwick, Chris Jones, Mitch Dowsett, Alan Ashworth, Jorge S Reis-Filho. (2008) Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Laboratory Investigation 88:5, 491-503
CrossRef758
Shaheenah Dawood, Kristine Broglio, Yun Gong, Wei-Tse Yang, Massimo Cristofanilli, Shu-Wan Kau, Funda Meric-Bernstam, Thomas A. Buchholz, Gabriel N Hortobagyi, Ana M. Gonzalez-Angulo, . (2008) Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 112:9, 1905-1911
CrossRef759
Allen M Gown. (2008) Current issues in ER and HER2 testing by IHC in breast cancer. Modern Pathology 21, S8-S15
CrossRef760
Minetta C. Liu, George D. Demetri, Donald A. Berry, Larry Norton, Gloria Broadwater, Nicholas J. Robert, David Duggan, Daniel F. Hayes, I. Craig Henderson, Alan Lyss, Judith Hopkins, Peter A. Kaufman, P. Kelly Marcom, Jerry Younger, Nancy Lin, Katherine Tkaczuk, Eric P. Winer, Clifford A. Hudis. (2008) Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treatment Reviews 34:3, 223-230
CrossRef761
Andreana L. Rivera, Christopher E. Pelloski, Erik Sulman, Ken Aldape. (2008) Prognostic and Predictive Markers in Glioma and Other Neuroepithelial Tumors. Current Problems in Cancer 32:3, 97-123
CrossRef762
Jair Bar, Amir Onn. (2008) Combined anti-proliferative and anti-angiogenic strategies for cancer. Expert Opinion on Pharmacotherapy 9:5, 701-715
CrossRef763
Grant Sellar, John D Alvarez, Frank Loganzo, Richat Abbas, Fred Immermann, Maha Karnoub, Giora Z Feuerstein, Michael E Burczynski, Christina M Coughlin. (2008) Opportunities posed by novel patient selection biomarker approaches in oncology drug development: going beyond the cytotoxics. Biomarkers in Medicine 2:2, 147-153
CrossRef764
Quyen D. Chu, Neal Holm, Kerry Byrnes, Benjamin D. Li. (2008) Translational Research in Breast Cancer. Surgical Oncology Clinics of North America 17:2, 421-438
CrossRef765
Amer H. Zureikat, Mark D. McKee. (2008) Targeted Therapy for Solid Tumors: Current Status. Surgical Oncology Clinics of North America 17:2, 279-301
CrossRef766
Michelle Shayne, Lodovico Balducci. 2008. Supportive Care for Older Cancer Patients. , 1-34.
CrossRef767
Søren M. Bentzen. (2008) From Cellular to High-Throughput Predictive Assays in Radiation Oncology: Challenges and Opportunities. Seminars in Radiation Oncology 18:2, 75-88
CrossRef768
Olivera J. Finn. (2008) Tumor immunology top 10 list. Immunological Reviews 222:1, 5-8
CrossRef769
Barbara T. McGrogan, Breege Gilmartin, Desmond N. Carney, Amanda McCann. (2008) Taxanes, microtubules and chemoresistant breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1785:2, 96-132
CrossRef770
Constantin N Baxevanis. (2008) Antibody-based cancer therapy. Expert Opinion on Drug Discovery 3:4, 441-452
CrossRef771
Chikako Shimizu, Yasuhiro Fujiwara. (2008) Personalized systemic treatment for breast cancer patients: is it a reality?. Breast Cancer 15:2, 141-144
CrossRef772
Patricia S Steeg, Dan Theodorescu. (2008) Metastasis: a therapeutic target for cancer. Nature Clinical Practice Oncology 5:4, 206-219
CrossRef773
Gerald M. Higa. (2008) Targeting HER 1 and 2 in breast cancer with lapatinib. Oncology Reviews 2:1, 21-28
CrossRef774
Paik, Soonmyung, Kim, Chungyeul, Wolmark, Norman, . (2008) HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer. New England Journal of Medicine 358:13, 1409-1411
Full Text775
Sanjay Popat, Ian E Smith. (2008) Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects. Nature Clinical Practice Oncology
CrossRef776
G E Konecny, N Venkatesan, G Yang, J Dering, C Ginther, R Finn, M Rahmeh, M Schoenberg Fejzo, D Toft, S-W Jiang, D J Slamon, K C Podratz. (2008) Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. British Journal of Cancer 98:6, 1076-1084
CrossRef777
F. Trotta, G. Apolone, S. Garattini, G. Tafuri. (2008) Stopping a trial early in oncology: for patients or for industry?. Annals of Oncology 19:7, 1347-1353
CrossRef778
J. King, J. Waxman, H. Stauss. (2008) Advances in tumour immunotherapy. QJM 101:9, 675-683
CrossRef779
Alfredo Santinelli, Eleonora Pisa, Daniela Stramazzotti, Guidalberto Fabris. (2008) HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. International Journal of Cancer 122:5, 999-1004
CrossRef780
Sandip Basu, Wengen Chen, Julia Tchou, Ayse Mavi, Tevfik Cermik, Brian Czerniecki, Mitchell Schnall, Abass Alavi. (2008) Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters. Cancer 112:5, 995-1000
CrossRef781
Primož Drev, Snježana Frković Grazio, Matej Bračko. (2008) Tissue Microarrays for Routine Diagnostic Assessment of HER2 Status in Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 16:2, 179-184
CrossRef782
Tait D. Shanafelt, Susan M. Geyer, Nancy D. Bone, Renee C. Tschumper, Tom E. Witzig, Greg S. Nowakowski, Clive S. Zent, Tim G. Call, Betsy LaPlant, Gordon W. Dewald, Diane F. Jelinek, Neil E. Kay. (2008) CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. British Journal of Haematology 140:5, 537-546
CrossRef783
K D Awadelkarim, C Arizzi, E O M Elamin, H M A Hamad, P De Blasio, S O Mekki, I Osman, I Biunno, N E Elwali, R Mariani-Costantini, M C Barberis. (2008) Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa. Histopathology 52:4, 445-456
CrossRef784
Michael E. Stokes, David Thompson, Eduardo L. Montoya, Milton C. Weinstein, Eric P. Winer, Craig C. Earle. (2008) Ten-Year Survival and Cost Following Breast Cancer Recurrence: Estimates from SEER-Medicare Data. Value in Health 11:2, 213-220
CrossRef785
Paul Wheatley-Price, Frances A Shepherd. (2008) Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Current Opinion in Oncology 20:2, 162-175
CrossRef786
M. Anderssona, A. Awadab, P. Barrett-Leec, P. Ellisd, P. Hupperetse, C. Jackischf, E. Kubistag, H.-J. Lückh, C. Monnerati, U. Nitzj, M. Untchl. (2008) European oncologists' preferences for the management of breast cancer: case presentations and expert commentary. The Breast 17, S1-S12
CrossRef787
M. Brian Hemphill, Julia A. Lawrence. (2008) Current Therapeutic Options for Breast Cancer Central Nervous System Metastases. Current Treatment Options in Oncology 9:1, 41-50
CrossRef788
Márk Barok, Margit Balázs, Péter Nagy, Zsuzsa Rákosy, Andrea Treszl, Enikő Tóth, István Juhász, John W. Park, Jorma Isola, György Vereb, János Szöllősi. (2008) Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Letters 260:1-2, 198-208
CrossRef789
Ian N Olver. (2008) Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when. Future Oncology 4:1, 125-131
CrossRef790
Shaheenah Dawood, Naoto T. Ueno, Massimo Cristofanilli. (2008) The Medical Treatment of Inflammatory Breast Cancer. Seminars in Oncology 35:1, 64-71
CrossRef791
L.S. Kilburn. (2008) ‘Triple Negative’ Breast Cancer: a New Area for Phase III Breast Cancer Clinical Trials. Clinical Oncology 20:1, 35-39
CrossRef792
Isabelle Soerjomataram, Marieke W. J. Louwman, Jacques G. Ribot, Jan A. Roukema, Jan Willem W. Coebergh. (2008) An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Research and Treatment 107:3, 309-330
CrossRef793
Daniela D. Rosa, Gustavo Ismael, Lissandra Dal Lago, Ahmad Awada. (2008) Molecular-targeted therapies: Lessons from years of clinical development. Cancer Treatment Reviews 34:1, 61-80
CrossRef794
T.K. Yau, I.S. Soong, K. Chan, A. Chang, H. Sze, M.W. Yeung, R. Tung, S. Lau, A. Lee. (2008) Evaluation of the prognostic value of 2005 St Gallen risk categories for operated breast cancers in Hong Kong. The Breast 17:1, 58-63
CrossRef795
Partho P. Sengupta, Donald W. Northfelt, Federico Gentile, Jose L. Zamorano, Bijoy K. Khandheria. (2008) Trastuzumab-Induced Cardiotoxicity: Heart Failure at the Crossroads. Mayo Clinic Proceedings 83:2, 197-203
CrossRef796
P. P. Sengupta, D. W. Northfelt, F. Gentile, J. L. Zamorano, B. K. Khandheria. (2008) Trastuzumab-Induced Cardiotoxicity: Heart Failure at the Crossroads. Mayo Clinic Proceedings 83:2, 197-203
CrossRef797
(2008) HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. New England Journal of Medicine 358:2, 197-199
Full Text798
S. Paik, Y. Taniyama, C. E. Geyer. (2008) Anthracyclines in the Treatment of HER2-Negative Breast Cancer. JNCI Journal of the National Cancer Institute 100:1, 2-4
CrossRef799
Wolfgang Janni, Gunter von Minckwitz, Volker Möbus, Ulrike Nitz. (2008) Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer. Breast Care 3:1, 17-20
CrossRef800
Reiki Nishimura, Yasuhiro Okumura, Nobuyuki Arima. (2008) Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Breast Cancer 15:1, 57-64
CrossRef801
Gabriel N. Hortobagyi. (2008) The Future of Breast Cancer Management: Teamwork and Team Science. Breast Diseases: A Year Book Quarterly 18:4, 331-332
CrossRef802
S J L Payne, R L Bowen, J L Jones, C A Wells. (2008) Predictive markers in breast cancer - the present. Histopathology 52:1, 82-90
CrossRef803
David Murdoch, Jason Sager. (2008) Will targeted therapy hold its promise? An evidence-based review. Current Opinion in Oncology 20:1, 104-111
CrossRef804
Yong-Seok Kim, Yong Sung Won, Kyung Shin Park, Byung Joo Song, Jeong Soo Kim, Se Jeong Oh, Hae Myung Jeon, Sang Seol Jung, Woo-Chan Park. (2008) Prognostic Significance of HER2 Gene Amplification According to Stage of Breast Cancer. Journal of Korean Medical Science 23:3, 414
CrossRef805
Dimitrios Chatsiproios, Renate Haidinger, Thomas Suter. (2008) Practical Management Recommendations for Anti-ErbB2 Therapy with Lapatinib. Breast Care 3:1, 13-16
CrossRef806
T.A. Grushko, V.L. Filiaci, A.J. Mundt, K. Ridderstråle, O.I. Olopade, G.F. Fleming. (2008) An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group study. Gynecologic Oncology 108:1, 3-9
CrossRef807
Nancy U. Lin. (2008) Treatment of HER2-Positive Breast Cancer: New Approaches, New Opportunities. Breast Diseases: A Year Book Quarterly 18:4, 336-338
CrossRef808
J. Peppercorn. (2008) Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Breast Diseases: A Year Book Quarterly 19:3, 279-280
CrossRef809
Bryan Hennessy, Robert C. Bast, Ana Maria Gonzalez-Angulo, Gordon B. Mills. 2008. Early Detection of Cancer. , 335-347.
CrossRef810
Danielle M. Doyle, Kathy D. Miller. (2008) Development of new targeted therapies for breast cancer. Breast Cancer 15:1, 49-56
CrossRef811
A. Rab Razzak, Nancy U. Lin, Eric P. Winer. (2008) Heterogeneity of breast cancer and implications of adjuvant chemotherapy. Breast Cancer 15:1, 31-34
CrossRef812
Jan Trøst Jørgensen. (2008) From blockbuster medicine to personalized medicine. Personalized Medicine 5:1, 55-63
CrossRef813
V. Craig Jordan. (2008) Tamoxifen: Catalyst for the change to targeted therapy. European Journal of Cancer 44:1, 30-38
CrossRef814
Kate McKeage, Katherine A Lyseng-Williamson. (2008) Trastuzumab. PharmacoEconomics 26:8, 699-719
CrossRef815
William N. Hait, Eric Rubin, Joseph R. Bertino. 2008. Cancer Therapeutics. , 571-581.
CrossRef816
Franklin L. Chen, Andrew J. Armstrong, Daniel J. George. (2008) Cell Signaling Modifiers in Prostate Cancer. The Cancer Journal 14:1, 40-45
CrossRef817
Steven M Ewer, Michael S Ewer. (2008) Cardiotoxicity Profile of Trastuzumab. Drug Safety 31:6, 459-467
CrossRef818
S Moulder, GN Hortobagyi. (2008) Advances in the Treatment of Breast Cancer. Clinical Pharmacology & Therapeutics 83:1, 26-36
CrossRef819
Juan Gonzales Posada, Arthur E. Frankel. 2008. Monoclonal Antibody Therapy of Cancer. , 671-678.
CrossRef820
Sharon Marsh, Michael S Phillips. (2008) Integrating pharmacogenomics into oncology clinical practice. Expert Review of Clinical Pharmacology 1:1, 73-80
CrossRef821
Shafaat A. Rabbani, Andrew P. Mazar. (2007) Evaluating distant metastases in breast cancer: from biology to outcomes. Cancer and Metastasis Reviews 26:3-4, 663-674
CrossRef822
Michael S. Gee, Rabi Upadhyay, Henry Bergquist, Ralph Weissleder, Lee Josephson, Umar Mahmood. (2007) Multiparameter noninvasive assessment of treatment susceptibility, drug target inhibition and tumor response guides cancer treatment. International Journal of Cancer 121:11, 2492-2500
CrossRef823
Patrick J Perik, Maarten Alexander de Korte, Dirk J van Veldhuisen, Jourik A Gietema, Dirk T Sleijfer, Elisabeth GE de Vries. (2007) Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Expert Review of Anticancer Therapy 7:12, 1763-1771
CrossRef824
Farbod Shojaei, Napoleone Ferrara. (2007) Antiangiogenic Therapy for Cancer: An Update. The Cancer Journal 13:6, 345-348
CrossRef825
Zeina Nahleh, Azadeh Namakydoust, Rania Bakkar, John Bishop. (2007) Trastuzumab not for ductal carcinoma in situ?. Anti-Cancer Drugs 18:10, 1231-1235
CrossRef826
Catherine Alix-Panabières, Volkmar Müller, Klaus Pantel. (2007) Current status in human breast cancer micrometastasis. Current Opinion in Oncology 19:6, 558-563
CrossRef827
C Ginestier, J Adélaïde, A Gonçalvès, L Repellini, F Sircoulomb, A Letessier, P Finetti, J Geneix, E Charafe-Jauffret, F Bertucci, J Jacquemier, P Viens, D Birnbaum. (2007) ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 26:50, 7163-7169
CrossRef828
María Moreno, Hetty J. Bontkes, Rik J. Scheper, Peter Kenemans, René H.M. Verheijen, Silvia von Mensdorff-Pouilly. (2007) High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Letters 257:1, 47-55
CrossRef829
Ashwani K. Sood, Rakhee Saxena, Jeff Groth, Mohamed M. Desouki, Chalong Cheewakriangkrai, Kerry J. Rodabaugh, Chitta S. Kasyapa, Joseph Geradts. (2007) Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Human Pathology 38:11, 1628-1638
CrossRef830
Cynthia Frankel. (2007) Choosing the Appropriate Breast Cancer Therapy for Today's Breast Cancer Patient. Seminars in Oncology Nursing 23, S3-S9
CrossRef831
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Winer, Eric P., Harris, Jay R., Smith, Barbara L., D'Alessandro, Helen Anne, Brachtel, Elena F., . (2007) Case 32-2007. New England Journal of Medicine 357:16, 1640-1648
Full Text832
Bharat B. Aggarwal, Gautam Sethi, Veera Baladandayuthapani, Sunil Krishnan, Shishir Shishodia. (2007) Targeting cell signaling pathways for drug discovery: An old lock needs a new key. Journal of Cellular Biochemistry 102:3, 580-592
CrossRef833
Neal S. Goldstein, David Decker, Dawn Severson, Scott Schell, Frank Vicini, Jeffrey Margolis, Nayana S. Dekhne. (2007) Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 110:8, 1687-1696
CrossRef834
M M Moasser. (2007) Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26:46, 6577-6592
CrossRef835
Hayes, Daniel F., Thor, Ann D., Dressler, Lynn G., Weaver, Donald, Edgerton, Susan, Cowan, David, Broadwater, Gloria, Goldstein, Lori J., Martino, Silvana, Ingle, James N., Henderson, I. Craig, Norton, Larry, Winer, Eric P., Hudis, Clifford A., Ellis, Matthew J., Berry, Donald A., . (2007) HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. New England Journal of Medicine 357:15, 1496-1506
Full Text836
Moore, Anne, . (2007) Breast-Cancer Therapy — Looking Back to the Future. New England Journal of Medicine 357:15, 1547-1549
Full Text837
Sumanta Kumar Pal, Mark Pegram. (2007) HER2 targeted therapy in breast cancer...beyond Herceptin. Reviews in Endocrine and Metabolic Disorders 8:3, 269-277
CrossRef838
Ann E. Vernon, Suzanne J. Bakewell, Lewis A. Chodosh. (2007) Deciphering the molecular basis of breast cancer metastasis with mouse models. Reviews in Endocrine and Metabolic Disorders 8:3, 199-213
CrossRef839
Andrea Madrigrano, Lynn Westphal, Irene Wapnir. (2007) Egg retrieval with cryopreservation does not delay breast cancer treatment. The American Journal of Surgery 194:4, 477-481
CrossRef840
Sanraj K. Basi, John R. Mackey. (2007) Anastrozole Plus Trastuzumab Prolongs Progression-Free Survival in Postmenopausal Patients with HER2-Positive and Hormone Receptor–Positive Metastatic Breast Cancer: A Review of the TAnDEM Study. Breast Diseases: A Year Book Quarterly 18:3, 236-237
CrossRef841
Tristin Abair, Zachary Moore, Joyce A. O'Shaughnessy. (2007) 2007 Highlights from: The 2007 American Society of Clinical Oncology Breast Cancer Symposium; San Francisco, CA; September 7–8, 2007. Clinical Breast Cancer 7:10, 734-738
CrossRef842
Arash Naeim, Rishi Sawhney, Catherine H. MacLean, Homayoon Sanati. (2007) Quality Indicators for the Care of Breast Cancer in Vulnerable Elders. Journal of the American Geriatrics Society 55, S258-S269
CrossRef843
Daphne R. Friedman, Amy P. Abernethy. (2007) <I>REVIEW</I>. Progress in Palliative Care 15:5, 225-232
CrossRef844
Ben Ho Park, Nancy E. Davidson. (2007) PI3 Kinase Activation and Response to Trastuzumab Therapy: What's neu with Herceptin Resistance?. Cancer Cell 12:4, 297-299
CrossRef845
Lee W. Jones, Mark J. Haykowsky, Jonas J. Swartz, Pamela S. Douglas, John R. Mackey. (2007) Early Breast Cancer Therapy and Cardiovascular Injury. Journal of the American College of Cardiology 50:15, 1435-1441
CrossRef846
T. Mieghem, K. Leunen, N. Pochet, B. Moor, F. Smet, F. Amant, P. Berteloot, D. Timmerman, I. Vanden Bempt, R. Drijkoningen, H. Wildiers, R. Paridaens, A. Smeets, W. Hendrickx, E. Limbergen, M. R. Christiaens, I. Vergote, P. Neven. (2007) Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. Breast Cancer Research and Treatment 106:1, 127-133
CrossRef847
Richard S. Finn, Judy Dering, Charles Ginther, Cindy A. Wilson, Padraic Glaspy, Nishan Tchekmedyian, Dennis J. Slamon. (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Research and Treatment 105:3, 319-326
CrossRef848
Chukwuemeka U. Ihemelandu, LaSalle D. Leffall, Robert L. Dewitty, Tammey J. Naab, Haile M. Mezghebe, Kepher H. Makambi, Lucile Adams-Campbell, Wayne A. Frederick. (2007) Molecular Breast Cancer Subtypes in Premenopausal African-American Women, Tumor Biologic Factors and Clinical Outcome. Annals of Surgical Oncology 14:10, 2994-3003
CrossRef849
Shaheenah Dawood, Ana M. Gonzalez-Angulo, Florentia Peintinger, Kristine Broglio, William F. Symmans, Shu-Wan Kau, Rabiul Islam, Gabriel N. Hortobagyi, Aman U. Buzdar. (2007) Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin. Cancer 110:6, 1195-1200
CrossRef850
Feng Guo, Stephen P. Letrent, Amarnath Sharma. (2007) Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors. Cancer Chemotherapy and Pharmacology 60:6, 799-809
CrossRef851
Hervé Bonnefoi. (2007) To bury TNM classification in breast cancer or to praise it?. European Journal of Cancer Supplements 5:5, 23-29
CrossRef852
Gerald M Higa, Jame Abraham. (2007) Lapatinib in the treatment of breast cancer. Expert Review of Anticancer Therapy 7:9, 1183-1192
CrossRef853
Alain Beck, Christine Klinguer-Hamour, Marie-Claire Bussat, Thierry Champion, Jean-François Haeuw, Liliane Goetsch, Thierry Wurch, Masae Sugawara, Alain Milon, Alain Van Dorsselaer, Thien Nguyen, Nathalie CorvaÏa. (2007) Peptides as tools and drugs for immunotherapies. Journal of Peptide Science 13:9, 588-602
CrossRef854
Gaston Demonty. (2007) Docetaxel plus trastuzumab as treatment for HER-2 positive metastatic breast cancer: review of the existing evidence. Women's Health 3:5, 523-528
CrossRef855
Wenfang Shi, Cunye Qu, Qijun Qian. (2007) Trends in therapeutic monoclonal antibodies of cancer. Expert Opinion on Therapeutic Patents 17:9, 1047-1059
CrossRef856
M.A. de Korte, E.G.E. de Vries, M.N. Lub-de Hooge, P.L. Jager, J.A. Gietema, W.T.A. van der Graaf, W.J. Sluiter, D.J. van Veldhuisen, T.M. Suter, D.T. Sleijfer, P.J. Perik. (2007) 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. European Journal of Cancer 43:14, 2046-2051
CrossRef857
Min A Kim, Eun Ji Jung, Hye Seung Lee, Hee Eun Lee, Yoon Kyung Jeon, Han-Kwang Yang, Woo Ho Kim. (2007) Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Human Pathology 38:9, 1386-1393
CrossRef858
S. Savic, L. Bubendorf. (2007) Fluoreszenz-in-situ-Hybridisierung. Der Pathologe 28:5, 384-392
CrossRef859
Erika Matos, Tanja Čufer. (2007) Adjuvant treatment of breast cancer patients with trastuzumab. Radiology and Oncology 41:3, 115-122
CrossRef860
Susanne Briest, Antonio C Wolff. (2007) Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer. Expert Review of Anticancer Therapy 7:9, 1243-1253
CrossRef861
D.A. Cameron. (2007) Herceptin – from bedside to bench to clinic?. European Journal of Cancer Supplements 5:5, 372-374
CrossRef862
Piyush K Agarwal, Peter C Black, David J McConkey, Colin PN Dinney. (2007) Emerging drugs for targeted therapy of bladder cancer. Expert Opinion on Emerging Drugs 12:3, 435-448
CrossRef863
M. Mimeault, R. Hauke, P. P. Mehta, S. K. Batra. (2007) Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. Journal of Cellular and Molecular Medicine 11:5, 981-1011
CrossRef864
S. Pruthi, J. C. Boughey, K. R. Brandt, A. C. Degnim, G. K. Dy, M. P. Goetz, E. A. Perez, C. A. Reynolds, P. J. Schomberg, J. N. Ingle. (2007) A Multidisciplinary Approach to the Management of Breast Cancer, Part 2: Therapeutic Considerations. Mayo Clinic Proceedings 82:9, 1131-1140
CrossRef865
John Mathers. 2007. Toward Personalized Nutrition for the Prevention and Treatment of Cancer. , 75-87.
CrossRef866
Jean-Philippe Theurillat, Ursina Zürrer-Härdi, Zsuzsanna Varga, Martina Storz, Nicole M. Probst-Hensch, Burkhardt Seifert, Mathias K. Fehr, Daniel Fink, Soldano Ferrone, Bernhard Pestalozzi, Achim A. Jungbluth, Yao-Tseng Chen, Dirk Jäger, Alexander Knuth, Holger Moch. (2007) NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunology, Immunotherapy 56:11, 1723-1731
CrossRef867
Hongtao Zhang, Alan Berezov, Qiang Wang, Geng Zhang, Jeffrey Drebin, Ramachandran Murali, Mark I. Greene. (2007) ErbB receptors: from oncogenes to targeted cancer therapies. Journal of Clinical Investigation 117:8, 2051-2058
CrossRef868
Daniela Matei. (2007) Novel agents in ovarian cancer. Expert Opinion on Investigational Drugs 16:8, 1227-1239
CrossRef869
Louis P. Garrison, Deborah Lubeck, Deepa Lalla, Virginia Paton, Amylou Dueck, Edith A. Perez. (2007) Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 110:3, 489-498
CrossRef870
Per E. Lønning, Jürgen Geisler. (2007) Aromatase inhibitors—Socioeconomical issues. The Journal of Steroid Biochemistry and Molecular Biology 106:1-5, 55-61
CrossRef871
Debu Tripathy, Debu Tripathy. (2007) 2007 Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL, June 2007. Clinical Breast Cancer 7:9, 660-669
CrossRef872
Richard D. Powell, James D. Pettay, William C. Powell, Patrick C. Roche, Thomas M. Grogan, James F. Hainfeld, Raymond R. Tubbs. (2007) Metallographic in situ hybridization. Human Pathology 38:8, 1145-1159
CrossRef873
Maryou B.K. Lambros, Rachael Natrajan, Jorge S. Reis-Filho. (2007) Chromogenic and fluorescent in situ hybridization in breast cancer. Human Pathology 38:8, 1105-1122
CrossRef874
P. Harter, A. Bois. (2007) Supportivmaßnahmen in der gynäkologischen Onkologie. Der Gynäkologe 40:8, 629-641
CrossRef875
Hudis, Clifford A., . (2007) Trastuzumab — Mechanism of Action and Use in Clinical Practice. New England Journal of Medicine 357:1, 39-51
Full Text876
McArthur, Heather L., , Chia, Stephen, . (2007) Cardiotoxicity of Trastuzumab in Clinical Practice. New England Journal of Medicine 357:1, 94-95
Full Text877
Philip Poortmans. (2007) Evidence based radiation oncology: Breast cancer. Radiotherapy and Oncology 84:1, 84-101
CrossRef878
I Craig Henderson, Vinona Bhatia. (2007) Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Review of Anticancer Therapy 7:7, 919-943
CrossRef879
Christian Widakowich, Evandro de Azambuja, Thierry Gil, Fatima Cardoso, Phuong Dinh, Ahmad Awada, Martine Piccart-Gebhart. (2007) Molecular targeted therapies in breast cancer: Where are we now?. The International Journal of Biochemistry & Cell Biology 39:7-8, 1375-1387
CrossRef880
Luca Gianni, Emanuela Salvatorelli, Giorgio Minotti. (2007) Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovascular Toxicology 7:2, 67-71
CrossRef881
Jean-Philippe Theurillat, Fabienne Ingold, Claudia Frei, Alfred Zippelius, Zsuzsanna Varga, Burkhardt Seifert, Yao-Tseng Chen, Dirk Jäger, Alexander Knuth, Holger Moch. (2007) NY-ESO-1 protein expression in primary breast carcinoma and metastases—correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. International Journal of Cancer 120:11, 2411-2417
CrossRef882
Beverly Moy, Peter Kirkpatrick, Santwana Kar, Paul Goss. (2007) Lapatinib. Nature Reviews Drug Discovery 6:6, 431-432
CrossRef883
A M Feldman, W J Koch, T L Force. (2007) Developing Strategies to Link Basic Cardiovascular Sciences with Clinical Drug Development: Another Opportunity for Translational Sciences. Clinical Pharmacology & Therapeutics 81:6, 887-892
CrossRef884
Frank X. Gu, Rohit Karnik, Andrew Z. Wang, Frank Alexis, Etgar Levy-Nissenbaum, Seungpyo Hong, Robert S. Langer, Omid C. Farokhzad. (2007) Targeted nanoparticles for cancer therapy. Nano Today 2:3, 14-21
CrossRef885
Patricia A. Fetsch, Andrea Abati. (2007) The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature. Diagnostic Cytopathology 35:6, 319-328
CrossRef886
Aleix Prat, Josep Baselga. (2007) Bioterapia: aplicaciones actuales y futuras en oncología. Medicina Clínica 129:5, 184-193
CrossRef887
Eiji Suzuki, Masakazu Toi. (2007) Improving the efficacy of trastuzumab in breast cancer. Cancer Science 98:6, 767-771
CrossRef888
Elly Barry, Jorge A Alvarez, Rebecca E Scully, Tracie L Miller, Steven E Lipshultz. (2007) Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opinion on Pharmacotherapy 8:8, 1039-1058
CrossRef889
Tsipi Ben-Kasus, Bilha Schechter, Michael Sela, Yosef Yarden. (2007) Cancer therapeutic antibodies come of age: Targeting minimal residual disease. Molecular Oncology 1:1, 42-54
CrossRef890
G. Sauer, N. Schneiderhan-Marra, C. Kurzeder, R. Kreienberg, T. Joos, H. Deissler. (2007) Molekulares Staging und Vorhersage von Therapieansprechen beim Mammakarzinom. Der Gynäkologe 40:6, 424-430
CrossRef891
L. G. Estévez, M. Martín, E. Alba, R. Colomer, F. Lobo, A. Lluch, E. Adrover, J. Albanell, A. Barnadas, J. García-Mata, A. Llombart, M. Muñoz, C. Rodríguez, P. Sánchez-Rovira, M. A. Seguí, I. Tusquets. (2007) Current controversies in the management of early breast cancer. Clinical and Translational Oncology 9:6, 375-384
CrossRef892
S. R. D. Johnston. (2007) Successes and failures: an overview of lessons learnt in the creation of targeted therapy strategies for breast cancer. Breast Cancer Online 10:06,
CrossRef893
R Nahta, F J Esteva. (2007) Trastuzumab: triumphs and tribulations. Oncogene 26:25, 3637-3643
CrossRef894
Filippo Montemurro, Laura Martincich, Ivana Sarotto, Ilaria Bertotto, Riccardo Ponzone, Lisa Cellini, Stefania Redana, Piero Sismondi, Massimo Aglietta, Daniele Regge. (2007) Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. European Radiology 17:6, 1490-1497
CrossRef895
Barbara S. Craft, Gabriel N. Hortobagyi, Stacy L. Moulder. (2007) Adjuvant Biologic Therapy for Breast Cancer. The Cancer Journal 13:3, 156-161
CrossRef896
Josie Ursini-Siegel, Babette Schade, Robert D. Cardiff, William J. Muller. (2007) Insights from transgenic mouse models of ERBB2-induced breast cancer. Nature Reviews Cancer 7:5, 389-397
CrossRef897
Susanne Briest, Vered Stearns. (2007) Advances in the adjuvant and neoadjuvant treatment of breast cancer. Women's Health 3:3, 325-339
CrossRef898
Michael J. Duffy. (2007) Role of tumor markers in patients with solid cancers: A critical review. European Journal of Internal Medicine 18:3, 175-184
CrossRef899
Suzanne A Eccles, Danny R Welch. (2007) Metastasis: recent discoveries and novel treatment strategies. The Lancet 369:9574, 1742-1757
CrossRef900
Thomas Force, Daniela S. Krause, Richard A. Van Etten. (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews Cancer 7:5, 332-344
CrossRef901
Raymond Ng, Michael D Green. (2007) Managing cardiotoxicity in anthracycline-treated breast cancers. Expert Opinion on Drug Safety 6:3, 315-321
CrossRef902
Heather L. McArthur, Clifford A. Hudis. (2007) Breast Cancer Chemotherapy. The Cancer Journal 13:3, 141-147
CrossRef903
T Macarulla, J Tabernero. 2007. Safety of targeted therapies. , 141-155.
CrossRef904
Brian P Rubin, Michael C Heinrich, Christopher L Corless. (2007) Gastrointestinal stromal tumour. The Lancet 369:9574, 1731-1741
CrossRef905
M. Scaltriti, F. Rojo, A. Ocana, J. Anido, M. Guzman, J. Cortes, S. Di Cosimo, X. Matias-Guiu, S. Ramon y Cajal, J. Arribas, J. Baselga. (2007) Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. JNCI Journal of the National Cancer Institute 99:8, 628-638
CrossRef906
Simon Chowdhury, Lisa M. Pickering, Paul A. Ellis. (2007) Lapatinib: a novel dual tyrosine kinase inhibitor. Targeted Oncology 2:2, 107-112
CrossRef907
Heather L. McArthur, Clifford A. Hudis. (2007) Adjuvant Chemotherapy for Early-Stage Breast Cancer. Hematology/Oncology Clinics of North America 21:2, 207-222
CrossRef908
Laura Biganzoli, Wederson M. Claudino, Marta Pestrin, Daniele Pozzessere, Angelo Di Leo. (2007) Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: Where do we stand?. Critical Reviews in Oncology/Hematology 62:1, 1-8
CrossRef909
Gustavo Ismael, Daniela Dornelles Rosa, Evandro de Azambuja, Sofia Braga, Martine Piccart-Gebhart. (2007) Trastuzumab (Herceptin) for Early-Stage Breast Cancer. Hematology/Oncology Clinics of North America 21:2, 239-256
CrossRef910
Marie Catherine Lee, Lisa A. Newman. (2007) Management of Patients with Locally Advanced Breast Cancer. Surgical Clinics of North America 87:2, 379-398
CrossRef911
Hiroji Iwata. (2007) Perspective of trastuzumab treatment. Breast Cancer 14:2, 150-155
CrossRef912
Yoshinori Ito, Nahomi Tokudome, Tsutomu Sugihara, Shunji Takahashi, Kiyohiko Hatake. (2007) Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?. Breast Cancer 14:2, 156-162
CrossRef913
Lisa A. Newman, S. Eva Singletary. (2007) Overview of Adjuvant Systemic Therapy in Early Stage Breast Cancer. Surgical Clinics of North America 87:2, 499-509
CrossRef914
Henry T Lynch, Ramon M Fusaro, Jane F Lynch. (2007) Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control. Future Oncology 3:2, 169-181
CrossRef915
Jennifer Klem, Zachary Moore, Susan Peck, Debu Tripathy, Joyce O'Shaughnessy. (2007) 2007 Highlights from: The 29th Annual San Antonio Breast Cancer Symposium; San Antonio, TX, December 2006. Clinical Breast Cancer 7:7, 535-542
CrossRef916
Thomas A. Buchholz. (2007) Integrating Trastuzumab and Radiation into the Adjuvant Treatments of Breast Cancer. Breast Diseases: A Year Book Quarterly 18:1, 18-20
CrossRef917
Hannah M Simonds, David Miles. (2007) Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor. Expert Opinion on Biological Therapy 7:4, 487-491
CrossRef918
Jane Bayani, Jeremy A. Squire. (2007) Application and interpretation of FISH in biomarker studies. Cancer Letters 249:1, 97-109
CrossRef919
Thomas W. Flaig, Steven K. Nordeen, M. Scott Lucia, Gail S. Harrison, L. Michael Glodé. (2007) Conference Report and Review: Current Status of Biomarkers Potentially Associated With Prostate Cancer Outcomes. The Journal of Urology 177:4, 1229-1237
CrossRef920
Lisa A. Newman, Eleftherios P. Mamounas. (2007) Review of Breast Cancer Clinical Trials Conducted by the National Surgical Adjuvant Breast Project. Surgical Clinics of North America 87:2, 279-305
CrossRef921
V. C. Jordan. (2007) SERMs: Meeting the Promise of Multifunctional Medicines. JNCI Journal of the National Cancer Institute 99:5, 350-356
CrossRef922
William C. Powell, David G. Hicks, Nichole Prescott, Shannon M. Tarr, Simas Laniauskas, Tristin Williams, Sarah Short, James Pettay, Raymond B. Nagle, David J. Dabbs, Katherine M. Scott, Richard W. Brown, Thomas Grogan, Patrick C. Roche, Raymond R. Tubbs. (2007) A New Rabbit Monoclonal Antibody (4B5) for the Immunohistochemical (IHC) Determination of the HER2 Status in Breast Cancer: Comparison With CB11, Fluorescence In Situ Hybridization (FISH), and Interlaboratory Reproducibility. Applied Immunohistochemistry & Molecular Morphology 15:1, 94-102
CrossRef923
Esther MEW Heijnen, Marinus JC Eijkemans, Cora De Klerk, Suzanne Polinder, Nicole GM Beckers, Ellen R Klinkert, Frank J Broekmans, Jan Passchier, Egbert R Te Velde, Nick S Macklon, Bart CJM Fauser. (2007) A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. The Lancet 369:9563, 743-749
CrossRef924
Anthony S.-Y. Leong, Zenobia Haffajee, Megan Clarke. (2007) Microwave Enhancement of CISH for HER2 Oncogene. Applied Immunohistochemistry & Molecular Morphology 15:1, 88-93
CrossRef925
Rebecca L. Olin, Shashank S. Desai, Kevin Fox, Rebecca Davidson. (2007) Non-Myopathic Cardiac Events in Two Patients Treated with Trastuzumab. The Breast Journal 13:2, 211-212
CrossRef926
J. M. Liu, L. S. Wang, M. H. Huang, W. H. Hsu, S. H. Yen, C. Y. Shiau, A. F. Y. Li, C. M. Tiu, S. W. Tseng, B. S. Huang. (2007) Topoisomerase 2α plays a pivotal role in the tumor biology of stage IV thymic neoplasia. Cancer 109:3, 502-509
CrossRef927
Howard Safran, Thomas DiPetrillo, Paul Akerman, Thomas Ng, Devon Evans, Margaret Steinhoff, David Benton, John Purviance, Lisa Goldstein, Umadevi Tantravahi, Teresa Kennedy. (2007) Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics 67:2, 405-409
CrossRef928
Aarati Ranganathan, Zachary Moore, Joyce A. O'Shaughnessy. (2007) 2007 Highlights from: The 29th Annual San Antonio Breast Cancer Symposium San Antonio, TX, December 2006. Clinical Breast Cancer 7:6, 445-454
CrossRef929
Max S. Mano, Daniela D. Rosa, Evandro De Azambuja, Gustavo F.V. Ismael, Virginie Durbecq. (2007) The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours. Cancer Treatment Reviews 33:1, 64-77
CrossRef930
S. M. Lagarde, F. J. W. ten Kate, D. J. Richel, G. J. A. Offerhaus, J. J. B. van Lanschot. (2007) Molecular Prognostic Factors in Adenocarcinoma of the Esophagus and Gastroesophageal Junction. Annals of Surgical Oncology 14:2, 977-991
CrossRef931
Gianluigi Ferretti, Alessandra Felici, Paola Papaldo, Alessandra Fabi, Francesco Cognetti. (2007) HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Current Opinion in Obstetrics and Gynecology 19:1, 56-62
CrossRef932
Shannon M MacDonald, Alphonse G Taghian. (2007) Partial–breast irradiation: towards a replacement for whole–breast irradiation?. Expert Review of Anticancer Therapy 7:2, 123-134
CrossRef933
Filippo Montemurro, Giorgio Valabrega, Massimo Aglietta. (2007) Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opinion on Biological Therapy 7:2, 257-268
CrossRef934
Gurusher Singh Panjrath, Diwakar Jain. (2007) Trastuzumab-induced cardiac dysfunction. Nuclear Medicine Communications 28:2, 69-73
CrossRef935
Frances M. Palmieri, Edith A. Perez. (2007) Managing High-Risk Breast Cancer. Seminars in Oncology Nursing 23:1, 29-36
CrossRef936
Daniel Hind, Hazel Pilgrim, Sue Ward. (2007) Questions about adjuvant trastuzumab still remain. The Lancet 369:9555, 3-5
CrossRef937
Markus Joerger, Alwin D R Huitema, Dick J Richel, Christian Dittrich, Nikolas Pavlidis, Evangelos Briasoulis, Jan B Vermorken, Elena Strocchi, Andrea Martoni, Roberto Sorio, Henk P Sleeboom, Miguel A Izquierdo, Duncan I Jodrell, Régine Féty, Ernst de Bruijn, Georg Hempel, Mats Karlsson, Brigitte Tranchand, Ad H G J Schrijvers, Chris Twelves, Jos H Beijnen, Jan H M Schellens. (2007) Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients. Clinical Pharmacokinetics 46:12, 1051-1068
CrossRef938
Zsuzsanna Kahán. (2007) Emlőműtéttől a HER2-státuszig, avagy a sebész szerepe a molekulárisan célzott terápiában. Magyar Sebészet (Hungarian Journal of Surgery) 60:1, 506-509
CrossRef939
Steven Simoens. (2007) Economic Evaluation and Decision Making. PharmacoEconomics 25:3, 181-185
CrossRef940
Sara M. Tolaney, Eric P. Winer. (2007) Follow-up care of patients with breast cancer. The Breast 16, 45-50
CrossRef941
Stefan Aebi, Olivia Pagani. (2007) Treatment of Premenopausal Women with Early Breast Cancer. Drugs 67:10, 1393-1401
CrossRef942
Sean O. Ryan, Kira R. Gantt, Olivera J. Finn. (2007) Tumor Antigen-Based Immunotherapy and Immunoprevention of Cancer. International Archives of Allergy and Immunology 142:3, 179-189
CrossRef943
H.B. Muss. (2007) Adjuvant treatment of elderly breast cancer patients. The Breast 16, 159-165
CrossRef944
Richard Theriault, Karin Hahn. (2007) Management of breast cancer in pregnancy. Current Oncology Reports 9:1, 17-21
CrossRef945
Rupert Bartsch, Catharina Wenzel, Christoph C Zielinski, Guenther G Steger. (2007) HER-2-Positive Breast Cancer. BioDrugs 21:2, 69-77
CrossRef946
Peter H. Johnson, Francisco J. Esteva. (2007) The use of HER2 modulation in the adjuvant setting. Current Oncology Reports 9:1, 9-16
CrossRef947
Vera J. Suman, Amylou Dueck, Daniel J. Sargent. 2007. Clinical Trials of Novel and Targeted Therapies: Endpoints, Trial Design, and Analysis. , 1-10.
CrossRef948
J Alasdair Millar, Michael J Millward. (2007) Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer. PharmacoEconomics 25:5, 429-442
CrossRef949
Ian Smith, Marion Procter, Richard D Gelber, Sébastien Guillaume, Andrea Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, Jose Baselga, Manfred Kaufmann, David Cameron, Richard Bell, Jonas Bergh, Robert Coleman, Andrew Wardley, Nadia Harbeck, Roberto I Lopez, Peter Mallmann, Karen Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez Rovira, Martine J Piccart-Gebhart. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet 369:9555, 29-36
CrossRef950
Meredith M. Regan, Richard D. Gelber. (2007) Using clinical trial data to tailor adjuvant treatments for individual patients. The Breast 16, 98-104
CrossRef951
Hiroo NAKAJIMA, Naruhiko MIZUTA, Ikuya FUJIWARA, Koichi SAKAGUCHI, Katsuhiko NAKATSUKASA, Aya KOBAYASHI. (2007) Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) 32:4, 643-647
CrossRef952
Keisei TAKU, Narikazu BOKU. (2007) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 38:6, 393-400
CrossRef953
Alison K. Conlin, Andrew D. Seidman. (2007) Taxanes in breast cancer: An update. Current Oncology Reports 9:1, 22-30
CrossRef954
Michail Ignatiadis, Christine Desmedt. (2007) Predicting risk of breast cancer recurrence using gene-expression profiling. Pharmacogenomics 8:1, 101-111
CrossRef955
Beat Thuerlimann, Dieter Koeberle, Hans-Joerg Senn. (2007) Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: Past, present and future recommendations. European Journal of Cancer 43:1, 46-52
CrossRef956
Joyce O'Shaughnessy. (2007) Developments in the systemic therapy of early-stage breast cancer. European Journal of Cancer Supplements 5:1, 3-10
CrossRef957
Damien Downing. (2007) Herceptin madness. Journal of Nutritional and Environmental Medicine 16:1, 1-9
CrossRef958
Christian Jackisch, Michael Untch. (2007) Trastuzumab in the Treatment of Breast Cancer – New Developments. Breast Care 2:2, 90-93
CrossRef959
Hiroo NAKAJIMA, Ikuya FUJIWARA, Naruhiko MIZUTA, Koichi SAKAGUCHI, Yasushi HACHIMINE, Katsuhiko NAKATSUKASA, Miho ICHIDA, Eiichi KONISHI, Akio YANAGISAWA. (2007) INVESTIGATION OF THE PROGNOSIS OF BREAST CANCER FROM THE VIEW POINT OF PRESENTATION OF ESTROGEN RECEPTOR AND HER2 IN IMMUNOHISTOCHEMICAL STAINING. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 68:9, 2171-2177
CrossRef960
Stephan Braun, Florian D. Vogl, Alois Schneitter, Daniel Egle, Doris Auer, Margarete Lang, Christian Marth. (2007) Disseminated tumor cells: Are they ready for clinical use?. The Breast 16, 51-54
CrossRef961
Edith A. Perez, Mansoina. Baweja. 2007. HER2-Positive Breast Cancer: Current Treatment Strategies. , 189-202.
CrossRef962
Kathleen I. Pritchard. (2007) Adjuvant therapy of the very young woman. The Breast 16, 136-146
CrossRef963
Phuong Dinh, Christos Sotiriou, Martine J. Piccart. (2007) The evolution of treatment strategies: Aiming at the target. The Breast 16, 10-16
CrossRef964
B.C. John Cho, David R. McCready. (2007) Oncologic Principles in Breast Reconstruction. Clinics in Plastic Surgery 34:1, 1-13
CrossRef965
Czene Kamila, Bergqvist Jenny, Hall Per, Bergh Jonas. (2007) How to treat male breast cancer. The Breast 16, 147-154
CrossRef966
Muss, Hyman B., . (2006) Targeted Therapy for Metastatic Breast Cancer. New England Journal of Medicine 355:26, 2783-2785
Full Text967
Geyer, Charles E., Forster, John, Lindquist, Deborah, Chan, Stephen, Romieu, C. Gilles, Pienkowski, Tadeusz, Jagiello-Gruszfeld, Agnieszka, Crown, John, Chan, Arlene, Kaufman, Bella, Skarlos, Dimosthenis, Campone, Mario, Davidson, Neville, Berger, Mark, Oliva, Cristina, Rubin, Stephen D., Stein, Steven, Cameron, David, . (2006) Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine 355:26, 2733-2743
Full Text968
R. T. Chlebowski, G. L. Blackburn, C. A. Thomson, D. W. Nixon, A. Shapiro, M. K. Hoy, M. T. Goodman, A. E. Giuliano, N. Karanja, P. McAndrew, C. Hudis, J. Butler, D. Merkel, A. Kristal, B. Caan, R. Michaelson, V. Vinciguerra, S. Del Prete, M. Winkler, R. Hall, M. Simon, B. L. Winters, R. M. Elashoff. (2006) Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition Study. JNCI Journal of the National Cancer Institute 98:24, 1767-1776
CrossRef969
Anthony S-Y Leong, Mark Formby, Zenobia Haffajee, Megan Clarke, Adrienne Morey. (2006) Refinement of Immunohistologic Parameters for Her2/neu Scoring Validation by FISH and CISH. Applied Immunohistochemistry & Molecular Morphology 14:4, 384-389
CrossRef970
Katherine Stemke-Hale, Bryan Hennessy, Gordon B. Mills, Rahul Mitra. (2006) Molecular screening for breast cancer prevention, early detection, and treatment planning: Combining biomarkers from DNA, RNA, and protein. Current Oncology Reports 8:6, 484-491
CrossRef971
L. Michael Glodé. (2006) The Case for Adjuvant Therapy for Prostate Cancer. The Journal of Urology 176:6, S30-S33
CrossRef972
Debajit K. Biswas, J. Dirk Iglehart. (2006) Linkage between EGFR family receptors and nuclear factor kappaB (NF-κB) signaling in breast cancer. Journal of Cellular Physiology 209:3, 645-652
CrossRef973
Markus Müller. (2006) Grenzen der ökonomischen Bewertung von Arzneimitteln aus klinischpharmakologischer Sicht. Wiener Medizinische Wochenschrift 156:23-24, 619-621
CrossRef974
J. Eucker, A. Emde, K. Possinger. (2006) Therapie des Mammakarzinoms. Der Internist 47:12, 1223-1228
CrossRef975
F. Stenner-Liewen, A. Zippelius, B. C. Pestalozzi, A. Knuth. (2006) Molekular zielgerichtete Therapie. Der Chirurg 77:12, 1118-1125
CrossRef976
B. You, V. Trillet-Lenoir. (2006) Thérapeutiques anticancéreuses ciblées. La Revue de Médecine Interne 27, S285-S288
CrossRef977
Stefan Aebi. (2006) Chemotherapy - overview and future perspectives. The Breast 15, S11-S14
CrossRef978
Joseph P. Crowe, Rebecca J. Patrick, Lisa A. Rybicki, Pedro F. Escobar, David Weng, G. Thomas Budd, Raymond R. Tubbs, Gary W. Procop, David G. Hicks. (2006) A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. The Breast 15:6, 728-735
CrossRef979
M SABEL, A ARORA, G SU, A CHANG. (2006) Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor
. Cryobiology 53:3, 360-366
CrossRef980
E Myers, A D K Hill, G Kelly, E W McDermott, N J O'Higgins, L S Young. (2006) A positive role for PEA3 in HER2-mediated breast tumour progression. British Journal of Cancer 95:10, 1404-1409
CrossRef981
Christina Richard, Jonathan Yau, John P. H. Th’ng, Wilhelmina C. M. Duivenvoorden. (2006) Naturally occurring resistance of bone marrow mononuclear and metastatic cancer cells to anticancer agents. Clinical & Experimental Metastasis 23:5-6, 249-258
CrossRef982
Axel Schulenburg, Herbert Ulrich-Pur, Dietmar Thurnher, Boban Erovic, Stefan Florian, Wolfgang R. Sperr, Peter Kalhs, Brigitte Marian, Friedrich Wrba, Christoph C. Zielinski, Peter Valent. (2006) Neoplastic stem cells: A novel therapeutic target in clinical oncology. Cancer 107:10, 2512-2520
CrossRef983
Levine, Mark N., Whelan, Timothy, . (2006) Adjuvant Chemotherapy for Breast Cancer — 30 Years Later. New England Journal of Medicine 355:18, 1920-1922
Full Text984
Andrea Rocca, Giulia Peruzzotti, Raffaella Ghisini, Giuseppe Viale, Paolo Veronesi, Alberto Luini, Mattia Intra, Elisabetta Pietri, Giuseppe Curigliano, Filippo Giovanardi, Patrick Maisonneuve, Aron Goldhirsch, Marco Colleoni. (2006) A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. Anti-Cancer Drugs 17:10, 1201-1209
CrossRef985
Mitsuo Satoh, Shigeru Iida, Kenya Shitara. (2006) Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opinion on Biological Therapy 6:11, 1161-1173
CrossRef986
Vered Stearns, Bryan Schneider, N. Lynn Henry, Daniel F. Hayes, David A. Flockhart. (2006) Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nature Reviews Cancer 6:11, 886-893
CrossRef987
Jeffrey S Ross, W Fraser Symmans, Lajos Pusztai, Gabriel N Hortobagyi. (2006) Personalized medicine for breast cancer: moving forward and going back. Personalized Medicine 3:4, 363-370
CrossRef988
SM Tovey, JR Reeves, P Stanton, BW Ozanne, JMS Bartlett, TG Cooke. (2006) Low expression of HER2 protein in breast cancer is biologically significant. The Journal of Pathology 210:3, 358-362
CrossRef989
Michael Davies, Bryan Hennessy, Gordon B Mills. (2006) Point mutations of protein kinases and individualised cancer therapy. Expert Opinion on Pharmacotherapy 7:16, 2243-2261
CrossRef990
S. Arif, P.J. Barrett-Lee, C. Jordan. (2006) The Incidence and Treatment Outcome after Radiotherapy for Brain Metastases in HER-2-positive Metastatic Breast Cancer Patients Treated with Trastuzumab. Clinical Oncology 18:9, 719-720
CrossRef991
G Frasci, G D'Aiuto, P Comella, R Thomas, G Botti, M Di Bonito, V De Rosa, G Iodice, M R Rubulotta, G Comella. (2006) Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study. British Journal of Cancer 95:8, 1005-1012
CrossRef992
Lorenzo Moja, Cinzia Brambilla, Anna Compagnoni, Vanna Pistotti, Lorenzo Moja. 2006. Trastuzumab containing regimens for early breast cancer. .
CrossRef993
M. Namer, J. Gligorov, E. Luporsi, D. Serin, . (2006) Breast cancer clinical practice recommendations from Saint-Paul-de-Vence: excerpts concerning targeted therapies. Targeted Oncology 1:4, 228-238
CrossRef994
J M Cummins, V E Velculescu. (2006) Implications of micro-RNA profiling for cancer diagnosis. Oncogene 25:46, 6220-6227
CrossRef995
Neil J. Freedman, Geoffrey S. Ginsburg. (2006) Novel—and “Neu”—Therapeutic Possibilities for Heart Failure
CrossRef996
Karen Lisa Smith, Chau Dang, Andrew D Seidman. (2006) Cardiac dysfunction associated with trastuzumab. Expert Opinion on Drug Safety 5:5, 619-629
CrossRef997
Elisa Rossi, Vincenzo Villanacci, Gabrio Bassotti, Domenico Della Casa, Guido Missale, Luigi Minelli, Renzo Cestari. (2006) HER-2/neu in Barrett Esophagus. Diagnostic Molecular Pathology 15:3, 125-130
CrossRef998
Trishe Y.-M. Leong, Anthony S.-Y. Leong. (2006) Controversies in the Assessment of HER-2. Advances in Anatomic Pathology 13:5, 263-269
CrossRef999
Markus Müller. (2006) Biological therapies: concepts and challenges. Wiener klinische Wochenschrift 118:17-18, 508-512
CrossRef1000
Michael C Cox, Tu D Dan, Sandra M Swain. (2006) Emerging drugs to replace current leaders in first-line therapy for breast cancer. Expert Opinion on Emerging Drugs 11:3, 489-501
CrossRef1001
Eleanor E. R. Harris, Wei-Ting Hwang, Eric A. Lee, Keith A. Cengel, Michael D. Feldman, Angela DeMichele, Gary Kao, Lawrence J. Solin. (2006) The Impact of HER-2 Status on Local Recurrence in Women with Stage I?II Breast Cancer Treated with Breast-Conserving Therapy. The Breast Journal 12:5, 431-436
CrossRef1002
Andrea H. Bild, Anil Potti, Joseph R. Nevins. (2006) Linking oncogenic pathways with therapeutic opportunities. Nature Reviews Cancer 6:9, 735-741
CrossRef1003
Robin L Jones, Michael S Ewer. (2006) Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Review of Anticancer Therapy 6:9, 1249-1269
CrossRef1004
Kadri Altundag, Mauricio Z. Baptista. (2006) Why Adjuvant Trastuzumab Led to Better Outcomes in Women with High-Risk HER-2-Positive Breast Cancer. The Breast Journal 12:5, 497-498
CrossRef1005
M Laakso, M Tanner, J Isola. (2006) Dual-colour chromogenicin situ hybridization for testing ofHER-2 oncogene amplification in archival breast tumours. The Journal of Pathology 210:1, 3-9
CrossRef1006
Bobbak VAHID, Anita MEHROTRA. (2006) Trastuzumab (Herceptin)-associated lung injury. Respirology 11:5, 655-658
CrossRef1007
Ranee Mehra, Barbara Burtness. (2006) Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. Expert Opinion on Biological Therapy 6:9, 951-962
CrossRef1008
O'Shaughnessy, Joyce A., . (2006) Molecular Signatures Predict Outcomes of Breast Cancer. New England Journal of Medicine 355:6, 615-617
Full Text1009
Patricia S Steeg. (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nature Medicine 12:8, 895-904
CrossRef1010
Andrew I. Minchinton, Ian F. Tannock. (2006) Drug penetration in solid tumours. Nature Reviews Cancer 6:8, 583-592
CrossRef1011
Risto Kerkelä, Luanda Grazette, Rinat Yacobi, Cezar Iliescu, Richard Patten, Cara Beahm, Brian Walters, Sergei Shevtsov, Stéphanie Pesant, Fred J Clubb, Anthony Rosenzweig, Robert N Salomon, Richard A Van Etten, Joseph Alroy, Jean-Bernard Durand, Thomas Force. (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine 12:8, 908-916
CrossRef1012
Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein. (2006) The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nature Biotechnology 24:8, 985-995
CrossRef1013
D K Wilkins, A Mayer. (2006) Development of antibodies for cancer therapy. Expert Opinion on Biological Therapy 6:8, 787-796
CrossRef1014
Sabeeha Muneer, Joyce A. O'Shaughnessy. (2006) 2006 Highlights from: the 42nd Annual Meeting of the American Society of Clinical Oncology; Atlanta, GA, June 2006. Clinical Breast Cancer 7:3, 215-220
CrossRef1015
A. G. Dalgleish, M. A. Whelan. (2006) Cancer vaccines as a therapeutic modality: the long trek. Cancer Immunology, Immunotherapy 55:8, 1025-1032
CrossRef1016
Sofia Braga, Lissandra dal Lago, Chantal Bernard, Fátima Cardoso, Martine Piccart. (2006) Use of trastuzumab for the treatment of early stage breast cancer. Expert Review of Anticancer Therapy 6:8, 1153-1164
CrossRef1017
Jan Norum. (2006) The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer. Expert Opinion on Pharmacotherapy 7:12, 1617-1625
CrossRef1018
M. Kaufmann, S. Loibl, A. Rody, G. Minckwitz. (2006) Stadienadaptierte Therapie des Mammakarzinoms. Der Gynäkologe 39:8, 618-626
CrossRef1019
Mark Pegram, Debbie Ngo. (2006) Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin®): A case study. Advanced Drug Delivery Reviews 58:5-6, 723-734
CrossRef1020
Eriko Tokunaga, Eiji Oki, Kojiro Nishida, Tadashi Koga, Akinori Egashira, Masaru Morita, Yoshihiro Kakeji, Yoshihiko Maehara. (2006) Trastuzumab and breast cancer: developments and current status. International Journal of Clinical Oncology 11:3, 199-208
CrossRef1021
Niklaus G Schaefer, Bernhard C Pestalozzi, Alexander Knuth, Christoph Renner. (2006) Potential use of humanized antibodies in the treatment of breast cancer. Expert Review of Anticancer Therapy 6:7, 1065-1074
CrossRef1022
Melinda Epstein, Yanling Ma, Michael F. Press. (2006) Herceptin (Trastuzumab) in the Adjuvant Setting: The Need for Accurate HER-2 Testing in Breast Cancer. Advances in Anatomic Pathology 13:4, 200-201
CrossRef1023
Hitoshi Tsuda. (2006) HER-2 (c-erbB-2) test update: Present status and problems. Breast Cancer 13:3, 236-248
CrossRef1024
Miguel Martin. (2006) Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer. Women's Health 2:4, 527-537
CrossRef1025
Alan Eastman, Raymond P. Perez. (2006) New targets and challenges in the molecular therapeutics of cancer. British Journal of Clinical Pharmacology 62:1, 5-14
CrossRef1026
Tiffany H. Svahn, Robert W. Carlson. (2006) Modest benefits of adjuvant chemotherapy in hormone receptor-positive breast cancer. Breast Cancer Online 9:07,
CrossRef1027
Cappuzzo, Federico, , Bemis, Lynne, Varella-Garcia, Marileila, . (2006) HER2 Mutation and Response to Trastuzumab Therapy in Non–Small-Cell Lung Cancer. New England Journal of Medicine 354:24, 2619-2621
Full Text1028
Karin Schreiber, Donald A. Rowley, Gert Riethmüller, Hans Schreiber. (2006) Cancer Immunotherapy and Preclinical Studies: Why We Are Not Wasting Our Time with Animal Experiments. Hematology/Oncology Clinics of North America 20:3, 567-584
CrossRef1029
M Myat Moe, T Pwint Pwint, RCF Leonard. (2006) Treatment options for older woman with early breast cancer. Expert Review of Anticancer Therapy 6:6, 941-950
CrossRef1030
Emilio Bria, Cecilia Nistico, Federica Cuppone, Paolo Carlini, Mariangela Ciccarese, Michele Milella, Guido Natoli, Edmondo Terzoli, Francesco Cognetti, Diana Giannarelli. (2006) Benefit of taxanes as adjuvant chemotherapy for early breast cancer. Cancer 106:11, 2337-2344
CrossRef1031
Chunfai Lai, Xin Jiang, Xianqiang Li. (2006) Development of Luciferase Reporter-Based Cell Assays. ASSAY and Drug Development Technologies 4:3, 307-315
CrossRef1032
Ryan P. Million. (2006) Impact of genetic diagnostics on drug development strategy. Nature Reviews Cancer 5:6, 459-462
CrossRef1033
Emer O. Hanrahan, Kristine Broglio, Deborah Frye, Aman U. Buzdar, Richard L. Theriault, Vicente Valero, Daniel J. Booser, Sonja E. Singletary, Eric A. Strom, James L. Gajewski, Richard E. Champlin, Gabriel N. Hortobagyi. (2006) Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma. Cancer 106:11, 2327-2336
CrossRef1034
Benny Vittrup Jensen. (2006) Cardiotoxic Consequences of Anthracycline-Containing Therapy in Patients With Breast Cancer. Seminars in Oncology 33, 15-21
CrossRef1035
(2006) Trastuzumab Treatment in Breast Cancer. New England Journal of Medicine 354:20, 2186-2186
Full Text1036
Thomas Ng, Thomas Dipetrillo, John Purviance, Howard Safran. (2006) Multimodality treatment of esophageal cancer: A review of the current status and future directions. Current Oncology Reports 8:3, 174-182
CrossRef1037
Rita Nahta, Dihua Yu, Mien-Chie Hung, Gabriel N Hortobagyi, Francisco J Esteva. (2006) Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice Oncology 3:5, 269-280
CrossRef1038
M.-O. Grimm, F. H. Hartmann, R. Ackermann. (2006) Zukunft der Chemotherapie. Der Urologe 45:5, 567-571
CrossRef1039
Heidi A. Lane, David Lebwohl. (2006) Future Directions in the Treatment of Hormone-Sensitive Advanced Breast Cancer: The RAD001 (Everolimus)-Letrozole Clinical Program. Seminars in Oncology 33, 18-25
CrossRef1040
Sheila A Doggrell. (2006) ‘Simply stunning’ – trastuzumab in HER2-positive breast cancer. Expert Opinion on Pharmacotherapy 7:5, 631-634
CrossRef1041
Rebecca Dent, Mark Clemons. (2006) Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence. Cancer Treatment Reviews 32:2, 144-148
CrossRef1042
Ryan H Engel, Virginia G Kaklamani. (2006) Role of efaproxiral in metastatic brain tumors. Expert Review of Anticancer Therapy 6:4, 477-485
CrossRef1043
Simon Chowdhury, Peter G. Harper. (2006) Aims and difficulties of targeting. Targeted Oncology 1:2, 69-70
CrossRef1044
Daniel D. Von Hoff. (2006) What's new in pancreatic cancer treatment pipeline?. Best Practice & Research Clinical Gastroenterology 20:2, 315-326
CrossRef1045
T. B. Y. Liem. (2006) Trastuzumab in combinatie met en na adjuvante chemotherapie bij borstkanker. MFM 44:4, 107-109
CrossRef1046
Andrew D Seidman. (2006) Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?. Nature Clinical Practice Oncology 3:4, 178-179
CrossRef1047
Joanne E Mortimer, Sarah L Blair. (2006) Management of early stage breast cancer in the elderly. Aging Health 2:2, 245-251
CrossRef1048
Masakazu Toi, Yuichi lino. (2006) Who benefits from hormone therapy?. Breast Cancer 13:2, 117-122
CrossRef1049
Ahmad Al-Hajj, Ruth O’Regan. (2006) Selection of optimal adjuvant endocrine therapy for early-stage breast cancer. Current Treatment Options in Oncology 7:2, 153-165
CrossRef1050
(2006) Scientific surgery. British Journal of Surgery 93:3, 378-378
CrossRef1051
Howard Fingert, Mary Varterasian. (2006) Safety biomarkers and the clinical development of oncology therapeutics: Considerations for cardiovascular safety and risk management. The AAPS Journal 8:1, E89-E94
CrossRef1052
Dale Chenoweth. (2006) Can single-patient investigational new drug studies hurry slow trains to the fast track?. Drug Discovery Today 11:5-6, 185-186
CrossRef1053
Steven Khoo, Sathibalan Ponniah, George E Peoples. (2006) HER2/neu vaccines in breast cancer. Women's Health 2:2, 217-223
CrossRef1054
Koji MATSUMOTO, Chikako SHIMIZU, Yasuhiro FUJIWARA. (2006) The next step to approaching central nervous system metastasis in HER-2-positive metastatic breast cancer patients. Asia-Pacific Journal of Clinical Oncology 2:1, 6-8
CrossRef1055
Chau T Dang. (2006) Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions. Expert Review of Anticancer Therapy 6:3, 427-436
CrossRef1056
D Yee. (2006) Targeting insulin-like growth factor pathways. British Journal of Cancer 94:4, 465-468
CrossRef1057
Joensuu, Heikki, Kellokumpu-Lehtinen, Pirkko-Liisa, Bono, Petri, Alanko, Tuomo, Kataja, Vesa, Asola, Raija, Utriainen, Tapio, Kokko, Riitta, Hemminki, Akseli, Tarkkanen, Maija, Turpeenniemi-Hujanen, Taina, Jyrkkiö, Sirkku, Flander, Martti, Helle, Leena, Ingalsuo, Seija, Johansson, Kaisu, Jääskeläinen, Anna-Stina, Pajunen, Marjo, Rauhala, Mervi, Kaleva-Kerola, Jaana, Salminen, Tapio, Leinonen, Mika, Elomaa, Inkeri, Isola, Jorma, . (2006) Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer. New England Journal of Medicine 354:8, 809-820
Full Text1058
(2006) Trastuzumab in Breast Cancer. New England Journal of Medicine 354:6, 640-644
Full Text1059
David Lane. (2006) Designer combination therapy for cancer. Nature Biotechnology 24:2, 163-164
CrossRef1060
Sabeeha Muneer, Aarati Ranganathan, Susan Peck, Latha Shivakumar, Joyce A. O'Shaughnessy. (2006) 2005 Highlights From: The 28th Annual San Antonio Breast Cancer Symposium; San Antonio, TX December 2005. Clinical Breast Cancer 6:6, 481-489
CrossRef1061
Tufia Haddad, Douglas Yee. (2006) Targeting the insulin-like growth factor axis as a cancer therapy. Future Oncology 2:1, 101-110
CrossRef1062
Raymond Ng, Nathan Better, Michael D. Green. (2006) Anticancer Agents and Cardiotoxicity. Seminars in Oncology 33:1, 2-14
CrossRef1063
Nina Ditsch, Sandra Rückert, Carolin Kümper, Miriam Lenhard, Steffen Kahlert, Ingo Bauerfeind, Klaus Friese, Michael Untch. (2006) Trastuzumab (Herceptin<sup>®</sup>): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation. Breast Care 1:2, 78-84
CrossRef1064
Joachim Bischoff, Serban-Dan Costa. (2006) Advances in Adjuvant and Primary Systemic Therapy of Early Breast Cancer. Breast Care 1:2, 129-133
CrossRef1065
Ali Badache, Anthony Gonçalves. (2006) The ErbB2 Signaling Network as a Target for Breast Cancer Therapy. Journal of Mammary Gland Biology and Neoplasia 11:1, 13-25
CrossRef1066
Mangesh Thorat. (2006) Trastuzumab for early breast cancer. The Lancet 367:9505, 108
CrossRef1067
Ian E Smith. (2006) Trastuzumab for early breast cancer. The Lancet 367:9505, 107
CrossRef1068
Volker R. Jacobs. (2006) Current Status of Financing and Reimbursement of Trastuzumab (Herceptin<sup>®</sup>) for Adjuvant and Advanced Therapy of Breast Cancer in Germany. Breast Care 1:2, 86-94
CrossRef1069
H SWEETLAND. (2006) Adjuvant therapy for breast cancer. Women's Health Medicine 3:1, 36-39
CrossRef1070
Christian Jackisch, Andreas Schneeweiss. (2006) Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients. Breast Care 1:4, 242-247
CrossRef1071
Alexandra King. (2006) Major developments in adjuvant treatment of early HER2-positive breast cancer. Nature Clinical Practice Oncology 3:1, 10-11
CrossRef1072
Samuel K. Chan, Mark E. Hill, William J. Gullick. (2006) The Role of the Epidermal Growth Factor Receptor in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia 11:1, 3-11
CrossRef1073
N Lynn Henry, Kathleen M Diehl, Daniel F Hayes. (2006) Adjuvant systemic therapy for elderly women with breast cancer. Women's Health 2:1, 75-87
CrossRef1074
Pedram Argani. (2006) Trastuzumab as Adjuvant Therapy for Primary Breast Cancer. Advances in Anatomic Pathology 13:1, 66-67
CrossRef1075
Deepali Sachdev, Douglas Yee. (2006) Inhibitors of Insulin-like Growth Factor Signaling: A Therapeutic Approach for Breast Cancer. Journal of Mammary Gland Biology and Neoplasia 11:1, 27-39
CrossRef1076
Chantal Bernard-Marty, Fabienne Lebrun, Ahmad Awada, Martine J Piccart. (2006) Monoclonal Antibody-Based Targeted Therapy in Breast Cancer. Drugs 66:12, 1577-1591
CrossRef1077
Clifford A Hudis. (2006) Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer. Nature Clinical Practice Oncology 3:1, 12-13
CrossRef1078
Greg L Plosker, Susan J Keam. (2006) Trastuzumab. Drugs 66:4, 449-475
CrossRef1079
Rakesh K Jain, Dan G Duda, Jeffrey W Clark, Jay S Loeffler. (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clinical Practice Oncology 3:1, 24-40
CrossRef1080
Daniele Santini, Bruno Vincenzi, Giuseppe Tonini. (2006) Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?. Women's Health 2:1, 1-3
CrossRef1081
Peter Littlejohns. (2006) Trastuzumab for early breast cancer: evolution or revolution?. The Lancet Oncology 7:1, 22-23
CrossRef1082
Sebastian F. Schoppmann, Raimund Jakesz. (2006) Early-Stage Breast Cancer – Highlights at ASCO 2006. Breast Care 1:4, 265-269
CrossRef1083
G. Des Guetz. (2006) The 41st annual ASCO meeting: targeted therapies, Orlando, Florida. Targeted Oncology 1:1, 59-65
CrossRef1084
Annette Lebeau. (2006) HER2 Testing in Breast Cancer: Opportunities and Challenges. Breast Care 1:2, 69-76
CrossRef1085
Napoleone Ferrara, Robert S. Kerbel. (2005) Angiogenesis as a therapeutic target. Nature 438:7070, 967-974
CrossRef1086
Eliahu Gez. (2005) Postmastectomy radiotherapy in breast cancer with high risk of relapse: current and future approaches. Future Oncology 1:6, 767-769
CrossRef1087
Bryan T Hennessy, Ana Maria Gonzalez-Angulo, Gabriel N Hortobagyi. (2005) Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics. Nature Clinical Practice Oncology 2:12, 598-599
CrossRef1088
(2005) News In Brief. Nature Reviews Drug Discovery 4:12, 948-949
CrossRef1089
Burstein, Harold J., . (2005) The Distinctive Nature of HER2-Positive Breast Cancers. New England Journal of Medicine 353:16, 1652-1654
Full Text1090
Hortobagyi, Gabriel N., . (2005) Trastuzumab in the Treatment of Breast Cancer. New England Journal of Medicine 353:16, 1734-1736
Full Text1091
Piccart-Gebhart, Martine J., Procter, Marion, Leyland-Jones, Brian, Goldhirsch, Aron, Untch, Michael, Smith, Ian, Gianni, Luca, Baselga, Jose, Bell, Richard, Jackisch, Christian, Cameron, David, Dowsett, Mitch, Barrios, Carlos H., Steger, Günther, Huang, Chiun-Shen, Andersson, Michael, Inbar, Moshe, Lichinitser, Mikhail, Láng, István, Nitz, Ulrike, Iwata, Hiroji, Thomssen, Christoph, Lohrisch, Caroline, Suter, Thomas M., Rüschoff, Josef, Sütő, Tamás, Greatorex, Victoria, Ward, Carol, Straehle, Carolyn, McFadden, Eleanor, Dolci, M. StellaGelber, Richard D., . (2005) Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. New England Journal of Medicine 353:16, 1659-1672
Full Text
- Letters
